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Abstract: Epoxide hydrolases (EHs) of the ￿/￿ hydrolase fold enzyme family hydrolyze epoxides to the
corresponding vicinal diols. In mammals, epoxides are mainly formed within the body through epoxi-
dation of xenobiotic or endogenous substrates by cytochrome P450-dependent monooxygenases (CYPs).
Two of the five known mammalian EHs are well characterized. The microsomal epoxide hydrolase (mEH)
is primarily involved in detoxification of carcinogenic epoxides derived from xenobiotic compounds and
the soluble epoxide hydrolase (sEH) primarily regulates endogenous signaling epoxides derived from fatty
acids. Although some substrates are known for the epoxide hydrolase 3 (EH3), its function remains
unclear. For the epoxide hydrolase 4 (EH4) and mesoderm specific transcript (MEST) no substrates are
known, but knockout of MEST in mice leads to growth retardation and a behavioral phenotype. Another
EH with activity in the human body is the CFTR inhibitory factor (Cif), a virulence factor secreted by the
opportunistic pathogen Pseudomonas aeruginosa. Cif reduces the surface expression of the chloride chan-
nel CFTR in human airway endothelial cells, resulting in increased mucus viscosity facilitating bacterial
colonization. The enzyme activity of Cif is crucial for the effect on CFTR but the molecular target re-
mains to be identified. In this project, we aimed to identify the physiologically relevant substrate(s) of the
aforementioned EHs. For the bacterial EH Cif, a substrate screening was performed using recombinantly
expressed enzyme, but kinetic analysis suggested that the found substrates 14,15-epoxyeicosatrienoic acid
(14,15-EET), 17,18-epoxyeicosatetraenoic acid, and 19,20-epoxydocosapentaenoic acid are not relevant in
vivo. To identify relevant substrates in vivo, an unbiased approach was developed that takes advantage
of the characteristic two-step reaction mechanism of ￿/￿ hydrolase fold EHs. By introducing a point mu-
tation, trapping mutants of the six EHs were constructed which are able to nucleophilically attack and
bind their substrates but cannot perform the second hydrolytic step, thus trapping their substrates with
a covalent ester bond. Using adeno-associated viruses (AAVs), these trapping mutants were expressed in
mice, where they should encounter and bind their substrates in a physiologic environment. For expression
in peripheral organs of mice, the serotype AAV-rh10 was used, while the serotype AAV-PHP.B was used
to target the brain after the intravenous injection of the virus into the tail vein. Successful expression in
the liver was confirmed for all trapping EHs except EH3, and in the brain for mEH, sEH and EH4 by
western blot analysis. Mass spectrometry was used to identify the substrates that were trapped by the
enzymes. For this, mouse tissue was lyzed and the virally expressed trapping mutants were enriched using
His-tag affinity chromatography. After digestion with trypsin, the samples were analyzed on a TripleTOF
mass spectrometer using SWATH, a data independent scan mode which provides time-resolved recording
of the fragment ions of all precursors. Since the sequence and therefore the mass of the peptide which
carries the trapped substrate is known, the mass of the substrate can be determined. With mass spec-
trometry we confirmed the presence of virally expressed mEH, sEH, Cif and MEST in the liver and mEH
and sEH in the brain by detecting peptides specific for these enzymes. However, no substrate modified
peptide was detected for any enzyme in any of the tissues. As proof of principle, the peptide-substrate
complex of recombinantly expressed sEH incubated with 14,15-EET was detected in an in vitro trapping
experiment confirming that the ester intermediate is stable enough for detection by mass spectrometry.
Analysis of the sample preparation procedure with synthetic peptides revealed a selective and substantial
loss of the sEH, EH3, and EH4 peptides. This was probably the main problem in the analysis of the sEH
expressing tissue. For mEH and MEST, only the unmodified peptide was detected, indicating that the
trapping mutants were not able to bind their substrates, probably due to protein misfolding. EH3, EH4,
and Cif peptides were likely not detected due to their low tissue concentrations, probably caused by a
shorter half-life of these proteins. Nevertheless, successful trapping and analysis was shown in vitro and
required measures to improve the method were identified. Establishment of the in vivo trapping approach
and identification of EH substrates could bring fundamental insights into the role of EHs in mammalian
physiology and new strategies for therapeutic intervention. Unexpectedly, mice expressing trapping mEH
in the brain developed a striking trembling phenotype which was milder in mEH KO mice and absent
when wild type instead of trapping mEH was expressed. Further analysis is required but preliminary
experiments suggest a loss of dopaminergic cells in the substantia nigra causing a Parkinson’s disease-like
pathology Weniger anzeigen
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PREAMBLE  
The main project entitled “Deciphering the (patho)physiologic role of epoxide hydrolases by ex vivo 
cartography of their substrate landscape” was a joint project conducted by me and Bettina Hew. 
Initially, it was planned that after the establishment of the trapping method in cooperation, I would 
focus on the three enzymes mEH, Cif and MEST and Bettina would focus on sEH, EH3 and EH4. 
Application of the method was not successful and a separation of the project by enzymes was not 
possible. During method development, I had the lead in the mass spectrometry part and Bettina Hew 
in the virus production and application, but the experiments and data analysis was performed with 
equal contribution. In my doctoral thesis I focused on the mass spectrometry analysis but to provide 
complete information about the project, I included the necessary results from virus production, which 
are described in Bettina Hew’s doctoral thesis in detail, as well. For the second project, “Kinetic analysis 
of Cif”, I performed all experiments and data analysis.   
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SUMMARY 
Epoxide hydrolases (EHs) of the α/β hydrolase fold enzyme family hydrolyze epoxides to the 
corresponding vicinal diols. In mammals, epoxides are mainly formed within the body through 
epoxidation of xenobiotic or endogenous substrates by cytochrome P450-dependent monooxygenases 
(CYPs). Two of the five known mammalian EHs are well characterized. The microsomal epoxide 
hydrolase (mEH) is primarily involved in detoxification of carcinogenic epoxides derived from 
xenobiotic compounds and the soluble epoxide hydrolase (sEH) primarily regulates endogenous 
signaling epoxides derived from fatty acids. Although some substrates are known for the epoxide 
hydrolase 3 (EH3), its function remains unclear. For the epoxide hydrolase 4 (EH4) and mesoderm 
specific transcript (MEST) no substrates are known, but knockout of MEST in mice leads to growth 
retardation and a behavioral phenotype. Another EH with activity in the human body is the CFTR 
inhibitory factor (Cif), a virulence factor secreted by the opportunistic pathogen Pseudomonas 
aeruginosa. Cif reduces the surface expression of the chloride channel CFTR in human airway 
endothelial cells, resulting in increased mucus viscosity facilitating bacterial colonization. The enzyme 
activity of Cif is crucial for the effect on CFTR but the molecular target remains to be identified.  
In this project, we aimed to identify the physiologically relevant substrate(s) of the aforementioned 
EHs. For the bacterial EH Cif, a substrate screening was performed using recombinantly expressed 
enzyme, but kinetic analysis suggested that the found substrates 14,15-epoxyeicosatrienoic acid 
(14,15-EET), 17,18-epoxyeicosatetraenoic acid, and 19,20-epoxydocosapentaenoic acid are not 
relevant in vivo. To identify relevant substrates in vivo, an unbiased approach was developed that takes 
advantage of the characteristic two-step reaction mechanism of α/β hydrolase fold EHs. By introducing 
a point mutation, trapping mutants of the six EHs were constructed which are able to nucleophilically 
attack and bind their substrates but cannot perform the second hydrolytic step, thus trapping their 
substrates with a covalent ester bond. Using adeno-associated viruses (AAVs), these trapping mutants 
were expressed in mice, where they should encounter and bind their substrates in a physiologic 
environment. For expression in peripheral organs of mice, the serotype AAV-rh10 was used, while the 
serotype AAV-PHP.B was used to target the brain after the intravenous injection of the virus into the 
tail vein. Successful expression in the liver was confirmed for all trapping EHs except EH3, and in the 
brain for mEH, sEH and EH4 by western blot analysis. 
Mass spectrometry was used to identify the substrates that were trapped by the enzymes. For this, 
mouse tissue was lyzed and the virally expressed trapping mutants were enriched using His-tag affinity 
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chromatography. After digestion with trypsin, the samples were analyzed on a TripleTOF mass 
spectrometer using SWATH, a data independent scan mode which provides time-resolved recording 
of the fragment ions of all precursors. Since the sequence and therefore the mass of the peptide which 
carries the trapped substrate is known, the mass of the substrate can be determined. 
With mass spectrometry we confirmed the presence of virally expressed mEH, sEH, Cif and MEST in 
the liver and mEH and sEH in the brain by detecting peptides specific for these enzymes. However, no 
substrate modified peptide was detected for any enzyme in any of the tissues. As proof of principle, 
the peptide-substrate complex of recombinantly expressed sEH incubated with 14,15-EET was 
detected in an in vitro trapping experiment confirming that the ester intermediate is stable enough for 
detection by mass spectrometry.   
Analysis of the sample preparation procedure with synthetic peptides revealed a selective and 
substantial loss of the sEH, EH3, and EH4 peptides. This was probably the main problem in the analysis 
of the sEH expressing tissue. For mEH and MEST, only the unmodified peptide was detected, indicating 
that the trapping mutants were not able to bind their substrates, probably due to protein misfolding. 
EH3, EH4, and Cif peptides were likely not detected due to their low tissue concentrations, probably 
caused by a shorter half-life of these proteins. Nevertheless, successful trapping and analysis was 
shown in vitro and required measures to improve the method were identified. Establishment of the in 
vivo trapping approach and identification of EH substrates could bring fundamental insights into the 
role of EHs in mammalian physiology and new strategies for therapeutic intervention. 
Unexpectedly, mice expressing trapping mEH in the brain developed a striking trembling phenotype 
which was milder in mEH KO mice and absent when wild type instead of trapping mEH was expressed. 
Further analysis is required but preliminary experiments suggest a loss of dopaminergic cells in the 
substantia nigra causing a Parkinson’s disease-like pathology. 
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ZUSAMMENFASSUNG 
Epoxidhydrolasen (EHs) der α/β hydrolase fold Enzymfamilie hydrolysieren Epoxide zu 
korrespondierenden Diolen. In Säugetieren werden Epoxide hauptsächlich durch Epoxidierung von 
Fremdstoffen oder körpereigenen Stoffen durch Cytochrom P450-abhängige Monooxigenasen (CYPs) 
gebildet. Zwei der fünf bekannten EHs in Säugetieren sind gut untersucht. Die mikrosomale EH (mEH), 
die hauptsächlich für die Entgiftung krebserregender Epoxide verantwortlich ist und die lösliche EH 
(sEH), die vorwiegend Fettsäureepoxide abbaut, die vom Körper als Signalstoffe verwendet werden. 
Von der EH3 kennt man einige Substrate, die Funktion dieses Enzyms ist jedoch noch unklar. Von der 
EH4 und dem mesoderm specific transcript (MEST) sind keine Substrate bekannt, MEST KO Mäuse 
zeigen aber eine verlangsamte Entwicklung und einen Verhaltensphänotyp. Eine weitere für den 
Menschen relevante EH ist der CFTR inhibitoy factor (Cif), ein Virulenzfaktor des opportunistischen 
Krankheitserregers Pseudomonas aeruginosa. Cif reduziert die Menge des Chloridkanals CFTR auf der 
Oberfläche von Lungenepithelzellen des Menschen, was zur Erhöhung der Mukusviskosität führt und 
die Kolonisierung durch Bakterien vereinfacht. Die EH-Aktivität von Cif ist relevant für diesen Effekt 
aber der molekulare Mechanismus ist nicht bekannt.  
Das Ziel dieses Projekts war es, physiologisch relevante Substrate der sechs EHs zu finden. Für die 
bakterielle EH Cif wurde ein Substratscreening mit rekombinant exprimiertem Enzym durchgeführt. 
Kinetische Analysen mit den gefundenen Substraten 14,15-Eepoxyeicosatriensäure (14,15-EET), 17,18-
Epoxyeicosatetraensäure und 19,20-epoxydocosapentaensäure deuten jedoch darauf hin, dass dies 
keine relevanten in vivo Substrate von Cif sind. Um relevante Substrate zu finden, haben wir einen 
unvoreingenommenen Ansatz entwickelt, der auf dem typischen, zweistufigen Reaktionsmechanismus 
von α/β hydrolase fold EHs basiert. Durch eine Punktmutation haben wir die EHs so verändert, dass 
sie ihr Substrat nicht umsetzen, sondern nur einfangen (Trappingmutanten). Die Mutanten können das 
Substrat nukleophil angreifen und binden, aber der zweite Schritt des Reaktionsmechanismus, die 
Hydrolyse und Freisetzung des Produkts, ist unterbunden und das Substrat bleibt durch eine kovalente 
Esterbindung ans Enzym gebunden. Mit Hilfe von Adeno-assoziierten Viren (AAVs) wurden die 
Trappingmutanten in Mäusen exprimiert, wo sie ihr physiologisch relevantes Substrat einfangen 
sollten. Für die Expression in peripheren Organen wurde der Virusserotyp AAV-rh10 benutzt und für 
die Expression im Gehirn der Serotyp AAV-PHP.B. Mit Western Blot Analysen wurde die virale 
Expression von mEH, sEH und EH4 im Gehirn und aller Trapping-EHs ausser EH3 in der Leber bestätigt.  
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Die gebundenen Substrate wurden mit Massenspektrometrie analysiert. Dazu wurde das Mausgewebe 
lysiert und die Trappingmutanten über His-tag Affinitätschromatographie angereichert. Nach 
proteolytischem Verdau mit Trypsin wurden die entstandenen Peptide auf einem TripleTOF 
Massenspektrometer mit SWATH gemessen. SWATH ist ein datenunabhängiger Scanmodus, der alle 
Vorläuferionen und alle Fragmente aufzeichnet. Da die Sequenz und dadurch die Masse des Peptids, 
an die das Substrat gebunden ist, bekannt ist, kann die Masse des gebundenen Substrats bestimmen 
werden.  
Die virale Expression von mEH, sEH, Cif und MEST in der Leber und mEH und sEH im Gehirn konnte mit 
Massenspektrometrie bestätigt werden indem für diese Enzyme spezifische Peptide gemessen 
wurden. Ein eingefangenes Substrat konnte jedoch nicht gefunden werden, in keinem der 
untersuchten Gewebe. Um das Prinzip zu verifizieren, wurde ein in vitro Versuch durgeführt, bei dem 
rekombinant exprimierte sEH mit 14,15-EETs inkubiert wurde und der Peptid-Substrat-Komplex 
identifiziert werden konnte. Dieser Versuch bestätigt, dass der Peptid-Substrat-Komplex für die 
Analyse stabil genug ist. 
Mit synthetischen Peptiden konnte gezeigt werden, dass die Peptide von sEH, EH3 und EH4 während 
der Probenaufarbeitung selektiv und in grossem Umfang verloren gingen. Dies war vermutlich das 
Hauptproblem bei der Analyse von sEH aus dem Gewebe. Die Peptide von mEH und MEST konnten 
gemessen werden, aber sie hatten kein Substrat gebunden. Dies deutet darauf hin, dass die mEH und 
MEST Trappingenzyme das Substrat nicht binden konnten, vermutlich aufgrund von 
Proteinfehlfaltung. Die Peptide von EH3, EH4 und Cif konnten in den Gewebeproben nicht detektiert 
werden, was vermutlich mit ihrer tiefen Konzentration, verursacht durch eine kürzere Halbwertszeit, 
zusammenhängt. Die Etablierung dieser Substrateinfangmethode in vivo und die Identifizierung von 
EH Substraten würde einen fundamentalen Einblick in die Rolle von EHs in der Säugetierphysiologie 
bringen und könnte zur Entwicklung von neuen therapeutischen Strategien führen.   
Die Mäuse, die die Trapping-mEH Mutante im Gehirn exprimiert haben, haben unerwarteterweise 
einen Phänotyp gezeigt. Die Tiere entwickelten ein Zittern am ganzen Körper, welches sich über die 
Zeit verstärkte. Das Phänomen war in mEH KO Mäusen verlangsamt und trat bei Mäusen, bei denen 
das wildtyp mEH Enzym im Gehirn exprimiert wurde, überhaupt nicht auf. Weitere Untersuchungen 
werden benötig, um die Grundlage dieses Phänotyps zu verstehen. Die Daten deuten jedoch darauf 
hin, dass der Phänotyp durch Untergang von dopaminergen Zellen in der Substantia nigra verursacht 
wird, was eine Parkinson-ähnliche Pathologie hervorruft. 
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GLOSSARY 
AA arachidonic acid 
AAV adeno-associated virus 
ABHD α/β-hydrolase domain-containing 
ABHD7  obsolete gene name of EPHX4 
ABHD9  obsolete gene name of EPHX3 
ACN acetonitrile 
AEBS microsomal antiestrogen binding site  
Ala or A alanine 
Arg or R arginine 
Asn or N asparagine 
Asp or D aspartic acid 
AUC  area under the curve 
B[a]P benzo[a]pyrene  
BKCa large conductance calcium-activated potassium channel  
bp base pair(s) 
CA2 region of the hippocampus 
CatNuc  catalytic nucleophile 
CF cystic fibrosis 
CFTR cystic fibrosis transmembrane conductance regulator 
ChEH cholesterol epoxide hydrolase 
CID collision induced dissociation 
Cif cystic fibrosis transmembrane conductance regulator inhibitory factor 
Cif HQ Cif trapping mutant with point mutation H297Q  
COPD chronic obstructive pulmonary disease 
COX cyclooxygenase 
CV coefficient of variation 
CYP cytochrome P450-dependent monooxygenase 
Cys or C cysteine 
DHA docosahexaenoic acid  
DHET  dihydroxyeicosatrienoic acid  
DIA data independent acquisition  
EET epoxyeicosatrienoic acids  
EH epoxide hydrolase 
EH3 epoxide hydrolase 3 
EH3 HQ epoxide hydrolase 3 trapping mutant with point mutation H337Q 
EH3 KO epoxide hydrolase 3 knockout  
EH3k epoxide hydrolase 3 missing the N-terminal membrane anchor 
EH4 epoxide hydrolase 4 
EH4 HQ epoxide hydrolase 4 trapping mutant with point mutation H336Q 
EH4k epoxide hydrolase 4 missing the N-terminal membrane anchor 
ENaC epithelial sodium channel  
eNOS endothelial nitric oxide synthase  
EPA eicosapentaenoic acid 
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EpDPA epoxydocosapentaenoic acid  
EpETEs epoxyeicosatetraenoic acids  
EPI enhanced product ion 
ER endoplasmic reticulum 
ESA epoxystearic acid  
ESI electron spray ionization  
EST expression sequence tag  
FA formic acid 
FASP filter aided sample preparation 
FRET Foerster resonance energy transfer 
G3BP1 Ras-GAP SH3 domain binding protein-1  
GFP green fluorescent protein 
Gln or Q glutamine 
Glu or E glutamic acid 
Gly or G glycine 
HETE hydroxyeicosatetraenoic acids  
His or H histidine 
HPLC high pressure liquid chromatography 
HxA3 hepoxilin A3 
HxB3 hepoxilin B3 
i.v.  intravenous 
IC50 half maximal inhibitory concentration 
IDA information dependent acquisition 
IgA immunoglobulin A  
IHC immunohistochemistry 
IMAC immobilized metal affinity chromatography  
ITR inverted terminal repeat 
kb kilobase 
kcat/Km  catalytic efficiency  
Km Michaelis constant, substrate concentration at which the reaction rate is half maximal 
KO knockout 
LC-MS/MS liquid chromatography tandem mass spectrometry 
LD lipid droplet 
LIT  linear ion trap 
LOX lipoxygenase 
LPLD familial lipoprotein lipase deficiency  
LTA4 leukotriene A4 
LTB4 leukotriene B4 
LXA4 lipoxin A4 
Lys or K lysine 
m/z mass-to-charge ratio  
mEH microsomal epoxide hydrolase 
mEH HQ microsomal epoxide hydrolase trapping mutant with point mutation H431Q 
mEH KO microsomal epoxide hydrolase knockout  
MEST mesoderm specific transcript (also known as peg1) 
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MEST HQ mesoderm specific transcript trapping mutant with point mutation H314Q 
MEST KO mesoderm specific transcript knockout  
MOI multiplicity of infection 
MPTP 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine, neurotoxin 
MRM multiple reaction monitoring, also called selected reaction monitoring (SRM) 
mRNA messenger RNA 
MS mass spectrometer/mass spectrometry 
OMV outer membrane vesicle 
ORF open reading frame 
PCR polymerase chain reaction 
Peg1 paternally expressed gene 1, see MEST 
PPARγ peroxisome proliferator-activated receptor gamma 
PUFA poly-unsaturated fatty acid  
Q1, Q2, Q3 quadrupole mass filter 1, 2, 3 
Qtrap triple quadrupole linear ion trap  
RPLC reversed phase liquid chromatography 
RT-PCR  reverse transcription polymerase chain reaction 
SAR scaffold attachment region 
SDS-PAGE sodium dodecyl sulfate polyacrylamide gel electrophoresis 
sEH soluble epoxide hydrolase 
sEH HQ soluble epoxide hydrolase trapping mutant with point mutation H524Q 
sEH KO soluble epoxide hydrolase knockout 
Ser or S serine 
SNP single-nucleotide polymorphism 
SPE solid phase extraction 
SRM selected reaction monitoring, alternative name for MRM 
SWATH  sequential window acquisition of all theoretical spectra 
TFA trifluoroacetic acid 
TOF time-of-flight  
Tyr or T tyrosine 
USP10  ubiquitin specific peptidase-10  
Val or V valine 
VEGF  vascular endothelial growth factor 
vg viral genomes 
Vmax maximal rate of enzyme catalyzed reaction 
WB western blot 
WT wild type 
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1. INTRODUCTION 
1.1. Epoxides in the human body 
An epoxide is a three-membered ring of one oxygen and two carbon atoms. Due to the 
electronegativity of the oxygen atom and tension in the ring, the carbon atoms possess electrophilic 
reactivity. Epoxide hydrolases (EHs) hydrolyze epoxides to their corresponding vicinal diol by the 
addition of a water molecule (Figure 1).  
 
Figure 1: Epoxide hydrolysis to vicinal diol by epoxide hydrolase (EH). 
In mammals, epoxides can be taken up from the environment as such but most often they are formed 
within the body during xenobiotic (foreign compound) metabolism, mainly in the liver. In phase I of 
xenobiotic metabolism, the compounds are functionalized. Different enzymes oxidize, reduce or 
hydrolyze xenobiotics which can then be conjugated in phase II to hydrophilic endogenous molecules 
such as glutathione, sulfate, glycine, or glucuronic acid, creating more hydrophilic compounds that can 
be excreted. The functionalization in phase I can lead to reactive intermediates, for example the 
epoxidation of aromatic ring systems or alkenes by cytochrome P450-dependent monooxygenases 
(CYPs). The generated epoxides are electrophilically reactive and potentially react with proteins and 
DNA bases leading to toxic or carcinogenic effects. EHs generally protect the body by hydrolyzing these 
epoxides to the less reactive and more water-soluble diols. 
Besides xenobiotic epoxides, the body produces epoxides with important signaling function. These 
signaling molecules are mainly derived from fatty acids and have little genotoxic potential. A well 
characterized group of signaling epoxides are the epoxyeicosatrienoic acids (EETs), which are 
generated in the arachidonic acid cascade. (For further details about their functions see chapter 
1.2.2.2.) Hydrolysis of these epoxides to the corresponding diol typically leads to the termination of 
the signaling function. Other endogenous epoxides found in the body are hepoxilin A3 and B3 
(chemoattractants involved in neutrophil recruitment (Mrsny et al., 2004)), leukotoxin and 
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isoleukotoxin (9,10-epoxide and 12,13-epoxide of linoleic acid generated by neutrophils during 
oxidative burst (Kosaka et al., 1994)), leukotriene A4 (precursor of the chemoattractant leukotriene B4), 
cholesterol-5,6-epoxide, cholesterol-24,25-epoxide, and epoxides generated from eicosapentaenoic 
acid (EPA) and docosahexaenoic acid (DHA).  
1.2. Mammalian epoxide hydrolases 
In mammals, five epoxide hydrolases have been described: microsomal EH (mEH), soluble EH (sEH), 
epoxide hydrolase 3 (EH3), cholesterol EH (ChEH), and the leukotriene A4 (LTA4) hydrolase. Structural 
analysis further proposed that epoxide hydrolase 4 (EH4) and mesoderm-specific transcript (MEST, 
also known as paternally expressed gene 1 (Peg1)) also act as epoxide hydrolases but no substrate has 
been found to proof their activity (Kaneko-Ishino et al., 1995; Decker et al., 2012). Previously, it had 
been reported that hepoxilins were hydrolyzed by the hepoxilin hydrolase but it was shown that this 
turnover is performed by sEH and not by a distinct hepoxilin hydrolase (Cronin et al., 2011). Among 
the mammalian EHs, mEH and sEH have been studied intensively over the last decades. mEH is mainly 
involved in xenobiotic metabolism protecting the body from reactive epoxide whereas sEH is the key 
player in the metabolism of signaling fatty acid-epoxides but it also complements the detoxification 
selectivity of mEH.  
 mEH, sEH, EH3, EH4, and MEST belong to the same enzyme superfamily, the α/β hydrolase fold 
enzymes (Arand et al., 1994; Decker et al., 2012). In contrast, LTA4 hydrolase and ChEH do not belong 
to this enzyme superfamily. The LTA4 hydrolase, which converts LTA4 to LTB4, is a member of the 
superfamily of zinc metallohydrolases, and epoxide hydrolysis does not result in the formation of a 
vicinal diol but in two hydroxyl groups that are separated by eight carbon atoms. This enzyme shows 
besides its epoxide hydrolase activity also zinc-dependent aminopeptidase activity (Vo et al., 2018). 
The identity of ChEH was unknown for a long time and comparison of ChEH and mEH concerning 
substrate turnover and reaction mechanism suggested that ChEH belongs to a different enzyme family 
(Muller et al., 1997). In 2010, the ChEH was identified when it was shown that ChEH activity is carried 
out by the microsomal antiestrogen binding site (AEBS). The enzyme is fully inhibited by AEBS ligands 
including tamoxifen (de Medina et al., 2010).  
The enzymes from the family of the α/β hydrolase fold enzymes have diverged from a common 
ancestor and share structural similarities along with a typical catalytic triad (Ollis et al., 1992). The core 
of these enzymes consists of eight central β-strands connected by several α-helices (Figure 2). This α/β 
hydrolase fold is covered by a variable lid domain that is inserted between strand β6 and β7. The 
substrate binding pocket is located between the core domain and the lid domain and harbors the 
common catalytic triad which consists of a catalytic nucleophile (Ser, Cys or Asp), a base (His) and an 
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acid (Asp or Glu). In the primary sequence, these three residues are separated by a variable number of 
amino acids but are always in the order nucleophile – acid – histidine and in the tertiary structure they 
lie in close proximity (Ollis et al., 1992). 
 
Figure 2: Secondary structure of the α/β- hydrolase fold. α-Helices are represented by white cylinders 
and β-strands by grey arrow. The location of the residues forming the catalytic triad is indicated by 
black dots. Dashed lines indicate the location of possible insertions. Figure adapted from (Nardini & 
Dijkstra, 1999).  
The nucleophile is located in a sharp turn, the nucleophile elbow, making it accessible for the substrate. 
The histidine is the only residue that is absolutely conserved among the family members (Nardini & 
Dijkstra, 1999). Further Insertions of a few amino acid residues or even complete extra domains in the 
α/β hydrolase fold are possible while maintaining a conserved catalytic machinery, shaping the 
substrate binding site for the respective substrates (Nardini & Dijkstra, 1999). 
Enzymes with different functions and very different substrates belong to the α/β hydrolase fold 
enzyme family, including esterases, lipases, proteases, haloalkane dehalogenases and EHs. EHs 
invariably use an aspartic acid as catalytic nucleophile. The feature that distinguishes EHs from other 
members of the α/β hydrolase fold enzyme family are two conserved tyrosine residues located in the 
lid domain which are important for the epoxide activation and orientation in the catalytic pocket 
(Nardini et al., 1999). The following reaction mechanism depicted in Figure 3, which all EHs from the 
α/β hydrolase fold enzyme family have in common, was first proposed based on similarities to the 
bacterial haloalkane dehalogenase (Arand et al., 1994). The two tyrosine residues from the lid domain 
position the epoxide in the catalytic pocket via hydrogen bonds which increases electron withdrawal 
from the carbon atoms adjacent to the oxygen, thus increasing their reactivity. In the first catalytic 
step, the oxygen of the aspartic acid attacks one of the electrophilic carbons of the epoxide and forms 
an ester bond resulting in opening of the ring structure. In the second catalytic step, this ester 
intermediate is hydrolyzed by a water molecule which is activated through proton abstraction by the 
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His-Asp/Glu charge relay system. This releases the diol product and the transfer of the proton from the 
catalytic nucleophile to the tyrosine reconstitutes the enzyme.  
 
 
Figure 3: Enzymatic mechanism of α/β hydrolase fold epoxide hydrolases. Detailed description in the 
text. Figure adapted from (Arand et al., 2005).  
Lacourciere and Armstrong could proof the formation of the covalent enzyme-substrate intermediate 
with a mEH turnover experiment in H218O. In a single-step reaction, the labelled oxygen of water would 
be incorporated into the product but in the mEH turnover, 18O was incorporated into the protein 
(Lacourciere & Armstrong, 1993). Further studies showed that the first step, the formation of the ester 
intermediate, proceeds by several orders of magnitude faster than the second, hydrolyzing step which 
therefore is the rate-limiting step (Laughlin et al., 1998). 
1.2.1. Microsomal epoxide hydrolase 
mEH, encoded by the gene EPHX1, is an endoplasmic reticulum (ER) resident enzyme consisting of 455 
amino acids. The catalytic triad is formed by Asp226, Glu404, and His431 and the two tyrosine residues 
involved in catalysis are Tyr299 and Tyr374 (Saenz-Mendez et al., 2017). Its N-terminal membrane 
anchor spans the ER membrane and its catalytic domain is located on the cytoplasmic side of the ER 
(Friedberg et al., 1994; Holler et al., 1997). Crystallization of a mammalian mEH has not been 
successful, however, a crystal structure of the related Aspergillus niger EH is available (Arand et al., 
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1999b; Zou et al., 2000). mEH is widely expressed in different organs with highest expression in the 
liver, mainly in hepatocytes, followed by the pancreas and other glands (Coller et al., 2001). The 
expression in the brain was studied in more detail in the mouse and was found in vascular cells, in the 
choroid plexus epithelial cells and in some specific neuronal populations of the hippocampus, striatum, 
amygdala, and cerebellum, as well as in a fraction of astrocytes (Marowsky et al., 2009a). 
1.2.1.1. Role in xenobiotic metabolism 
mEH is regarded as the major player in xenobiotic metabolism and the detoxification of reactive and 
potentially genotoxic epoxides. Its high expression in the liver and its broad substrate selectivity of cis-
substituted epoxides of various sizes are supporting its position as a detoxifying enzyme. mEH 
hydrolyses epoxides derived from chemicals, for example styrene (Oesch, 1974; Herrero et al., 1997), 
1,3-butadiene (Wickliffe et al., 2003), benzene (Snyder et al., 1993), or polycyclic aromatic 
hydrocarbons (PAHs) (Shimada, 2006) and epoxides derived from pharmaceuticals such as 
carbamazepine (Bellucci et al., 1987) or oprozomib (Wang et al., 2017). This broad substrate specificity 
is combined with a comparatively low hydrolysis rate, for most of its substrates smaller than 1 s-1. 
However, mEH is still a rapid detoxifier due to its two-step reaction mechanism. The first step, the 
formation of the ester intermediate, is sufficient to abolish the reactive potential of a toxic epoxide 
and thus detoxify it. Due to the up to three orders of magnitude higher rate constant of the first step 
compared to the second step, the consumption of the substrate is much faster than the formation of 
the diol product. If mEH is in excess over toxic epoxides, which can be expected from the high mEH 
expression in the liver, the substrate is eliminated quickly in the first step resulting in rapid 
detoxification (Oesch et al., 2004). 
In certain cases, mEH metabolism increases the carcinogenic potential of xenobiotics instead of 
reducing it. One example is the activation of benzo[a]pyrene (B[a]P), a compound produced by 
incomplete combustion of organic matter (Figure 4). CYPs epoxidize B[a]P which is subsequently 
hydrolyzed by mEH. The resulting dihydrodiol is still a substrate of CYPs and is either conjugated by 
phase II enzyme or epoxidized again. If the first epoxidation and subsequent hydrolysis takes place at 
position 7,8 and this compound is epoxidized again, B[a]P-7,8-dihydrdiol-9,10-epoxide is produced. 
This reactive bay region dihydrodiol epoxide is no longer a substrate of mEH due to steric hindrance 
and can only be detoxified by phase II metabolism (Shimada, 2006), which is insufficient to protect the 
body from its potent mutagenic effects.  
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Figure 4: Selected pathways of benzo[a]pyrene metabolism. Formation of the benzo[a]pyrene 7,8-
diol and subsequent epoxidation leads to an epoxide, benzo[a]pyrene 7,8-diol 9,10-epoxide, which is 
no substrate of mEH and possesses reactivity towards DNA. Epoxidation at other sites leads to 
metabolites that are rapidly turned over by mEH and can be conjugated and excreted.  
The role of mEH in detoxification and toxification was also studied with mEH knockout (KO) mice. mEH 
deficient mice showed reduced carcinogenicity of 7,12-dimethylbenz[a]anthracene versus control 
animals in a skin tumorigenicity model (Miyata et al., 1999) and also the toxicity of naphthalene was 
decreased in mEH KO mice in some locations of the lung compared to wild type (WT) mice (Carratt et 
al., 2016). A protective effect of mEH was shown for example for 1,3-butadien. mEH deficient mice had 
signiﬁcantly higher mutation frequencies in the Hprt reporter gene than exposed WT mice of the same 
strain (Wickliffe et al., 2003). In general, mEH can activate some carcinogenic compounds, but it is 
predominantly a detoxifying enzyme.  
1.2.1.2. Role in physiology 
The role of mEH in xenobiotic metabolism has been studied in detail but its role in the turnover of 
endogenous epoxides is not yet fully understood. Endogenous substrates for mEH are some steroid 
epoxides, such as estroxide or androstene oxide, and epoxy-fatty acids, particularly arachidonic acid 
derived EETs. However, kinetic analysis showed that mEH hydrolyzes EETs less efficient than sEH, 
suggesting that sEH is the relevant enzyme in EETs turnover (Morisseau, 2013). 
Targeted depletion of mEH in mice was used to further study the role of mEH in physiology. mEH KO 
mice exhibited no differences in weight, development, fertility, and behavior, and histological 
examination revealed no differences between mEH KO and wild type mice, indicating that mEH is not 
a critical requirement of normal development and physiology (Miyata et al., 1999). In humans, two 
high frequency polymorphisms of mEH are reported at position 113 (either Tyr or His) and at position 
139 (either His or Arg). No effect on enzyme kinetics has been determined but the His113/His139 
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haplotype is reported to have a slightly reduced half-life (Laurenzana et al., 1998). The His113 variant 
has been associated with lower risk and a less severe course of preeclampsia (Groten et al., 2014) and 
with a protective effect for COPD in smokers and former smokers (Brogger et al., 2006). The cause of 
these effects is not known but a role in signaling cascades cannot be excluded (Sari et al., 2017). 
Recent studies support the hypothesis that mEH plays a significant role in the turnover of endogenous 
signaling epoxides. sEH was generally shown to hydrolyze EETs faster than mEH but they have different 
region-preference profiles concerning Vmax. Fastest hydrolysis with sEH is obtained with 14,15-EET 
whereas mEH prefers 11,12-EET (Decker et al., 2012). Analysis with plasma from mEH KO mice showed 
that mEH contributes substantially to the turnover of 8,9-EET and leukotoxin (Marowsky et al., 2017). 
In addition, mEH and sEH differ in their expression pattern and subcellular localization. In the liver of 
mice, mEH but not sEH was detected in Kupffer cells and endothelial cells (Marowsky et al., 2017). In 
the brain, mEH is present in specific neuronal populations in different regions and sEH is almost 
exclusively expressed in astrocytes (Marowsky et al., 2009b). Furthermore, mEH is ER resident and very 
recent reports suggest a physical interaction of mEH with the epoxide forming CYP enzymes leading to 
substrate channeling between these two enzymes (Orjuela Leon et al., 2017). Taken together, these 
results suggest distinctive roles of both mEH and sEH in the turnover in the endogenous fatty acid 
epoxides.   
1.2.2. Soluble epoxide hydrolase 
sEH, encoded by the gene EPHX2, consists of 554 amino acids and is present in the cell cytosol and, in 
some tissues such as hepatocytes and renal proximal tubules, as well in peroxisomes (Arand et al., 
1991; Enayetallah et al., 2006). The catalytic triad consists of Asp333, His524 and Asp495 and is 
supported in substrate turnover by the tyrosines Tyr381 and Tyr465. A crystal structure of human sEH 
is available (Gomez et al., 2004). In contrast to the other mammalian EHs, sEH is a bi-functional enzyme 
with two catalytic domains. The C-terminal domain harbors the epoxide hydrolase activity, whereas 
the N-terminal domain shows phosphatase activity (Cronin et al., 2003). The two domains are linked 
by a proline-rich linker (Figure 5). The enzyme forms a homodimer where the N-terminal domain 
interacts with the C-terminal domain of the other monomer (Argiriadi et al., 1999). 
sEH is widely expressed in many different organs including liver, kidneys, heart, brain and lungs with 
highest activity in the liver followed by the kidneys (Pacifici et al., 1988; Enayetallah et al., 2004). In 
the mouse brain, sEH is primarily expressed in astrocytes in all areas of the brain, particularly in the 
cortex, hippocampus, amygdala and striatum. Neuronal expression was only found in the central 
amygdala (Marowsky et al., 2009b). 
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Figure 5: Three-dimensional structure of a human sEH monomer. The N-terminal phosphatase 
domain is shown in blue, the C-terminal EH domain in green, and the linker in red.  
1.2.2.1. Role in xenobiotic metabolism 
The EH that is mainly associated with xenobiotic metabolism is the mEH. However, sEH complements 
the substrate specificity of mEH as it is able to hydrolyze trans-substituted epoxides that are not too 
bulky. Examples are trans-stilbene oxide or trans-ethyl styrene oxide (Arand et al., 2003c).  
1.2.2.2. Role in physiology 
It has been well established that the major function of sEH is the metabolism and control of fatty acid 
derived epoxides. Substrates of sEH are all regioisomeres of EET, epoxides of other PUFAs, leukotoxin, 
LTA4 and hepoxilin A3 and B3 (Newman et al., 2005; Cronin et al., 2011). Early reports show clinical 
relevance of sEH in the turnover of leukotoxin to leukotoxin-diol which has been reported to be a 
strong mediator of acute respiratory distress syndrome (ARDS) characterized by a widespread 
inflammation in the lungs after severe stress conditions such as extensive body burn (Moghaddam et 
al., 1997). Of major clinical relevance is, however, the hydrolysis of EETs. EETs are produced from 
arachidonic acid (AA) which is released from membrane phospholipids by phospholipase A2 upon 
different stimuli, such as growth factors, hormones or cytokines. AA is the precursor for three main 
metabolic pathways, the cyclooxygenase (COX) pathway producing prostaglandins, the lipoxygenase 
(LOX) pathway producing leukotriene, lipoxins and hydroxyeicosatetraenoic acids (HETEs), and the CYP 
pathway producing EETs and HETEs (Harizi et al., 2008). The CYP pathway is perhaps the least explored 
eicosanoid pathway. Four possible regioisomeres of EET are formed from AA mainly by CYPs of the 
CYP2C and CYP2J subfamily (Figure 6).  
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Figure 6: Synthesis of the four regioisomeres of EET from AA by CYP epoxygenases and hydrolysis by 
epoxide hydrolases. 
The resulting EETs act as local, autocrine, or paracrine mediators and have important physiological 
effects such as anti-inflammation, vasodilation, analgesia, angiogenesis, antithrombotic effects, 
cardioprotection, and antidiabetic effects (Decker et al., 2009; Campbell et al., 2017). The mechanism 
how EETs produce their effects is not understood yet. Multiple EET targets have been identified, for 
example activation of large conductance calcium-activated potassium channel (BKCa) which leads to 
hyperpolarization and relaxation of smooth muscle cells, or inhibition of the epithelial sodium channel 
(ENaC) which results in increased sodium excretion in the kidney. Other targets are the IκB kinase (IKK) 
involved in NF-κB translocation, KCa channels and TRPA1 and TRPV4 (Sisignano et al., 2012; Campbell 
et al., 2017). Some low affinity EET receptors have been proposed, for example peroxisome 
proliferator-activated receptor gamma (PPARγ), however, a high affinity EET receptor has not been 
identified (Liu et al., 2005). Different studies showed that EET actions are GTP-dependent and Gαs 
mediated which suggests a G-protein coupled EET receptor (Campbell et al., 2017). 
EET hydrolysis by sEH (or mEH) to the less active dihydroxyeicosatrienoic acids (DHETs) is thought to 
terminate the mostly beneficial effects. Based on this, sEH was established as a drug target and 
numerous studies tested the effect of sEH inhibition on inflammatory disease, neurodegenerative 
diseases, stroke, cardiovascular diseases, COPD, pain, metabolic syndrome, and diabetes (Morisseau 
& Hammock, 2013; Wagner et al., 2017). For example, sEH inhibitors reduced blood pressure in 
angiotensin II hypertensive rats (Imig 2002) and chronic inhibition of sEH showed cardioprotective 
effects (Neckar et al., 2012). Anti-inflammatory effects of sEH inhibition were shown in a mouse model 
of chronic active inflammatory bowel disease (Zhang et al., 2012) and, in a different study, sEH 
inhibitors reduced tobacco-smoke induced lung inflammation in rats (Smith et al., 2005). However, not 
all effects of EETs are beneficial. Panigrahy et al. analyzed the role of EETs in cancer and showed that 
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EETs promote metastasis by triggering secretion of VEGF by the endothelium at the secondary 
(metastasis) site. Furthermore, sEH inhibition promoted primary tumor growth and metastasis in mice 
which could lead to severe side effects in clinical use of sEH inhibitors (Panigrahy et al., 2012). 
Many sEH inhibitors were generated that usually carry a urea moiety as the pharmacophore. The urea 
was postulated to mimic the reaction intermediate resulting in a high affinity to the active site of sEH. 
Modern compounds show low-nanomolar to picomolar potency and exhibit good pharmacokinetics 
(Morisseau & Hammock, 2013). Different inhibitors went to clinical tests, for example the compound 
GSK2256294 was tested for COPD (Yang et al., 2017) and AR9281 for hypertension and type 2 diabetes 
(Chen et al., 2012). However, no sEH inhibitor has been approved for human applications so far.  
1.2.2.3. sEH polymorphism and knockout mice 
In humans, six sEH polymorphisms have been identified, Lys55Arg, Arg103Cys and Cys154Tyr in the 
phosphatase domain and Arg287Gln, Val422Ala and Glu470Gly in the EH domain. The Arg287Gln and 
Arg103Cys variant showed decreased EH activity and the double mutant had a 10-fold decreased 
catalytic efficiency compared to the WT enzyme combined with a reduced stability (Przybyla-Zawislak 
et al., 2003). The two SNPs also decreased the phosphatase activity whereas Lys55Arg, Cys254Tyr 
increased phosphatase activity in vitro. The Arg287Gln was associated with increased risk for coronary 
artery calcification in African-American but not Caucasian (Fornage et al., 2004), increased risk for 
ischemic stroke in white Europeans (Gschwendtner et al., 2008) and insulin resistance in Japanese type 
2 diabetic patients (Ohtoshi et al., 2005). In patients with IgA nephropathy, Arg287Gln was associated 
with a positive effect on kidney survival (Lee et al., 2011).   
sEH KO mice showed no obvious phenotype and developed and reproduced normally. The first sEH KO 
mouse line produced exhibited reduced systolic blood pressure in male but not female animals (Sinal 
et al., 2000). In contrast, a second sEH KO line did not show a difference in baseline blood pressure 
(Luria et al., 2007). In both studies, the epoxy fatty acid metabolism was impaired in sEH deficient mice. 
1.2.2.4. sEH phosphatase domain 
The role of the sEH phosphatase domain is not fully understood. Substrates are threo-9/10-
phosphonooxy-hydroxy-octadecanoic acid, polyisoprenyl phosphates, sphingosine-1-phosphate and 
lysophosphatidic acid (Kramer & Proschak, 2017). A role in cholesterol metabolism was suggested, as 
in mice cholesterol levels were elevated by the phosphatase domain and lowered by the EH domain of 
sEH (EnayetAllah et al., 2008). Another theory is that sEH phosphatase is involved in the regulation of 
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endothelial nitric oxid synthease (eNOS) activity which is a key regulator of vascular tone (Hou et al., 
2012).   
1.2.3. Epoxide hydrolase 3 and 4 
EH3 and EH4 were discovered by Decker and colleagues through a sequence similarity search with a 
16 amino acid sequence motif that is highly conserved among EHs (Decker et al., 2012). The identified 
genes ABHD9 and ABHD7 were renamed to EPHX3 and EPHX4, respectively. The primary sequence of 
both enzymes predicts an N-terminal membrane anchor. EH3 consists of 360 amino acids and the 
residues involved in catalysis are Asp173, His337, Asp307, Tyr220, and Tyr281. Quantitative RT-PCR 
indicated strongest EH3 expression in mice in lung, skin, and upper gastro-intestinal tract. Substrates 
of EH3 are 9,10-epoxystearic acid, EETs and leukotoxin. EH3 hydrolyses EETs and leukotoxin with higher 
specific activity than sEH or mEH but also higher Km, resulting in a catalytic efficiency in the range of 
sEH (Decker et al., 2012). 
The substrate specificity of EH3 implies a role in signaling molecule processing. However, genetic 
disruption of EPHX3 in mice showed no significant effects on the metabolism of EETs or leukotoxin in 
vivo and no other overt phenotype (Hoopes et al., 2017). A study which predicted disease genes by 
human-mouse conserved co-expression analysis suggested a role of EH3 in ichthyosis (Ala et al., 2008). 
Based on this and the expression pattern of EH3 it was speculated that EH3 plays a role in skin barrier 
formation (Decker et al., 2012). 
EH4 is a 362 residue protein and is mainly expressed in the brain (Lord et al., 2013). The predicted 
catalytic triad is Asp169, His336 and Asp307 and one of the involved tyrosines is likely Tyr281. No 
epoxide substrate is known for EH4 but the high sequence identity of 45% with EH3 highly suggests 
identity as an EH. Recently, EH4 was shown to be associated with lipid droplets (LD) in sebaceous gland 
cells and siRNA-mediated downregulation of EH4 increased LD size (Dahlhoff et al., 2015). 
1.2.4. Mesoderm specific transcript 
Mest is an imprinted gene and only the paternally inherited allele is expressed. The maternally 
inherited gene is silenced by CpG-methylation in the promoter during development and in adult tissue 
(Kobayashi et al., 1997). The MEST protein consists of 335 amino acids and has a predicted N-terminal 
membrane anchor. The catalytic triad consists of Asp147, His314 and Asp284. MEST belongs to the 
α/β-hydrolase fold family and is postulated to be an epoxide hydrolase due to its sequence similarity 
and a proposed conserved epoxide-coordinating tyrosine Tyr254 (Kaneko-Ishino et al., 1995; Decker 
et al., 2012). However, no substrate has been identified so far to proof EH activity.  
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MEST is highly conserved in mammalian species (Sado et al., 1993). For example, the primary sequence 
of human and rat MEST differs in only 5 of the total 335 amino acids. Throughout development it is 
widely expressed, particularly in mesodermal tissue and areas of the developing brain (Kaneko-Ishino 
et al., 1995). There is limited information about the expression in adult tissue. The expression sequence 
tag (EST) profile1 identified high numbers of Mest transcripts in various tissues. MEST protein 
expression was shown in neuron-enriched areas in brain and spinal cord (Lefebvre et al., 1998), 
placenta (Mayer et al., 2000) and adipose tissue (Takahashi et al., 2005). 
Targeted disruption of the Mest gene in mice led to a phenotype. Knockout mice were viable and fertile 
but peri- and postnatal lethality was increased, and pups were smaller at birth and showed growth 
retardation. Furthermore, adult Mest KO females showed abnormal maternal behavior. They were 
unable to care properly for delivered pups and often failed to free them from their extra-embryonic 
tissue in preparation of feeding (Lefebvre et al., 1998).  
More recently, a correlation of MEST with adipose tissue expansion has been established. In mice with 
a positive energy balance, MEST expression in adipose tissue was induced and levels correlated with 
expansion of fat mass (Nikonova et al., 2008). Additionally, when Mest was depleted in adipose tissue 
or globally, fat mass accumulation with high fat diet was reduced compared to WT (Anunciado-Koza et 
al., 2017). 
1.3. The bacterial EH Cif 
Bacteria use EHs for different purposes, for example in catabolism to exploit carbon and energy sources 
(van der Werf et al., 1998), in the defense against toxic epoxides (Chownk et al., 2017) or in the 
synthesis of, for instance, mycolic acids which are found in the cell wall of mycobacteria (Madacki et 
al., 2018).  
One bacterial EH that belongs to the α/β hydrolase fold enzyme family, the cystic fibrosis 
transmembrane conductance regulator (CFTR) inhibitory factor (Cif), is of particular interest because 
it directly affects the human host. Cif is a virulence factor secreted from the opportunistic pathogen 
Pseudomonas aeruginosa (Swiatecka-Urban et al., 2006; MacEachran et al., 2007). The enzyme 
consists of 319 amino acids and the residues Asp129, His297, and Glu153 build the catalytic triad. 
However, the crystal structure of Cif revealed that the enzyme differs in typical EH motifs. Instead of 
two tyrosine residues involved in epoxide positioning, Cif possesses a tyrosine and a histidine, Tyr239 
and His177 (Bahl et al., 2010). Substrates of Cif are epibromohydrin and cis-stilbene oxide as well as 
                                                          
1 https://www.ncbi.nlm.nih.gov/UniGene/ESTProfileViewer.cgi?uglist=Hs.270978, December 14th, 2018 
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endogenous fatty acid-epoxides 14,15-EET, epoxyeicosatetraenoic acids (EpETEs) and 
epoxydocosapentaenoic acid (EpDPAs) (Bahl et al., 2010; Flitter et al., 2016; Hvorecny et al., 2017).  
Cif was first identified in a study where they analyzed why P. aeruginosa is particularly successful at 
colonizing and chronically infecting lungs of patients with cystic fibrosis (CF). CFTR-mediated 
transepithelial Cl- secretion, which is already impaired in CF patients, was reduced by a cell free filtrate 
of P. aeruginosa in polarized human airway epithelial cells (Swiatecka-Urban et al., 2006). Further 
studies identified Cif as the responsible factor and gave more insight in the action on CFTR. Cif is 
secreted by P. aeruginosa in outer membrane vesicles and enters the cytosol of human airway 
epithelial cells upon fusion of the vesicles with the plasma membrane. In the host cell, Cif reduces the 
abundance of CFTR on the apical membrane leading to a reduction of transepithelial Cl- and indirectly 
Na+ and water flux. In consequence, the airway superficial fluid dehydrates, and its viscosity increases 
which impairs mucociliary clearance, the first line of host defense (Hvorecny et al., 2018).  
The molecular mechanism of Cif is only partially understood (Figure 7). In healthy lung epithelial cells, 
CFTR is continuously ubiquitinated and internalized by endocytosis. Most of the CFTR is then 
deubiquitinated by the ubiquitin specific peptidase-10 (USP10) and recycled back to the apical cell 
membrane. Cif inhibits the deubiquitination by stabilizing an inhibitory effect of Ras-GAP SH3 domain 
binding protein-1 (G3BP1) on USP10, thereby inhibiting the recycling of CFTR and redirecting it to the 
lysosome, where it is degraded (Bomberger et al., 2011). The epoxide hydrolase activity of Cif is 
necessary for the reduction of CFTR. Inactive Cif mutants had no effect on the apical membrane 
abundance of CFTR (Bahl et al., 2015). Up to now, the link between EH activity and deubiquitination of 
CFTR remains unknown (Bahl et al., 2015), and no role for an epoxide or diol in the recycling of CFTR 
has been established.  
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Figure 7: Proposed effect of Cif on airway epithelial cells. In healthy lung epithelial cells, CFTR is 
constitutively ubiquitinated, internalized in the endosome, and recycled back to the apical plasma 
membrane. Cif, which is delivered from P. aeruginosa via outer membrane vesicles, blocks the 
deubiquitination by ubiquitin specific peptidase-10 (USP10) and redirects CFTR from the recycling 
pathway to the degradative pathway, decreasing its expression on the apical membrane. It was 
proposed that Cif stabilizes an inhibitory interaction between USP10 and Ras-GAP SH3 domain binding 
protein-1 (G3BP1) but the exact molecular mechanism remains to be determined. The reduced apical 
membrane abundance of CFTR reduces Cl- and indirectly H20 and Na+ flux, leading to dehydration of 
airway superficial fluid and impaired mucociliary clearance.   
This data showed that Cif is a potential drug target for the treatment of P. aeruginosa infections and 
Cif inhibitors were developed. The first identified Cif inhibitor, tiratricol, was not useful for in vivo 
applications due to thyroid hormone-like activity. A series of rationally designed Cif inhibitors displayed 
IC50 in the sub-micromolar range and 27-fold selectivity over sEH and 50-fold selectivity over mEH 
toward Cif. However, the inhibitors showed high plasma protein binding (>99%) and short half-lives of 
5.7-29 min determined with human liver microsomes (Kitamura et al., 2016).  
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More recent studies propose an additional effect of Cif on neutrophilic inflammation in the lung. Cif 
was shown to hydrolyze 14,15-EET produced by airway epithelial cells which decreases the generation 
of pro-resolving 15-epi LXA4 by neutrophils. This contributes to a robust, damaging inflammation which 
is typical for P. aeruginosa infection in cystic fibrosis (Flitter et al., 2016; Hvorecny et al., 2018). Besides 
14,15-EET, Cif can also hydrolyze other fatty acid epoxides including EpDPAs and EpETEs. The highest 
hydrolytic activity was found towards 19,20-EpDPA and 17,18-EpETE when tested individually. 
However, in a mixed substrate approach of EETs, EpETEs, and EpDPAs, which better represents the in 
vivo situation, only EpDPAs and 14,15-EET were hydrolyzed (Hvorecny et al., 2017). Also in this model, 
the highest turnover was achieved with 19,20-EpDPA outperforming the previously described turnover 
of 14,15-EET which has been connected to neutrophilic inflammation in vivo (Flitter et al., 2016). 
Further studies are required to, on one hand, identify the link between Cif’s epoxide hydrolase activity 
and the downregulation of CFTR and, on the other hand, evaluate the role of Cif in the hydrolysis of 
fatty acid epoxides produced by the host.  
1.4. Classical approaches to study enzyme substrates 
An important step to understand the role of an enzyme is to identify its substrate(s). Without this 
information, the role of an enzyme can be studied by structural comparison to related enzymes, by 
pharmacological inhibition or by knockout mouse models but to confirm the results, the molecular 
mechanism including the substrate are required. 
Classical approaches to identify enzyme substrates include substrate screenings and kinetic analysis to 
evaluate the relevance of a found substrate. This is usually done in an in vitro system with purified 
enzyme under standardized conditions. The limitations of these studies are that the substrate selection 
depends on the availability of the compounds and on the choice of the researcher. Furthermore, the 
study conditions might not represent the conditions in vivo, requiring confirmation of the results in 
vivo to avoid false conclusions. For example, with classical approaches, no substrate could have been 
identified for EH4 and MEST yet (Decker et al., 2012). If a substrate screening is negative, it is not clear 
whether the true substrate was not offered, the used enzyme was inactive, or the conditions were not 
appropriate.  
The substrate landscape of mEH and sEH is well established. Kinetic analyses indicated that sEH is the 
main enzyme involved in the turnover of endogenous epoxides, such as EETs. However, even though 
sEH hydrolyzes EETs more efficiently (Zeldin et al., 1993; Decker et al., 2012), there is gaining evidence 
that mEH is also involved in EETs turnover in the body (Marowsky et al., 2009a; Marowsky et al., 2017). 
A possible explanation is the difference in cellular and subcellular distribution of mEH and sEH. A recent 
study showed complex formation between mEH and CYP2J5, one of the enzymes that produces EETs 
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from arachidonic acid (Orjuela Leon et al., 2017). This allows efficient substrate channeling and gives 
mEH an advantage that is lost in kinetic in vitro studies.    
1.5. A novel trapping approach to identify EH substrates 
To identify physiologically relevant substrates of EHs, a novel unbiased approach was developed which 
takes advantage of the two-step reaction mechanism of EHs (Figure 8A). By replacing the catalytic 
histidine (His) by glutamine (Gln, Q) or alanine (Ala, A), enzymes were created that can still perform 
the first catalytic step leading to a covalent intermediate between the enzyme and the substrate but 
cannot perform hydrolysis (Figure 8B). These enzymes are called trapping EHs or EH HQ/HA. 
 
Figure 8: Modification of the EH mechanism to trap the substrate with a covalent ester bond. The 
typical two-step reaction mechanism of EHs of the α/β-hydrolase fold enzyme family shown in (A) was 
modified by site-directed mutagenesis of the catalytic histidine (His, H) which was replaced by 
glutamine (Gln, Q) or alanine (Ala, A) (B). Gln or Ala are not able to activate a water molecule, inhibiting 
the second hydrolytic step. The mutated enzyme, called trapping mutant, nucleophilically attacks its 
substrate but cannot release it, keeping it covalently bound to the catalytic nucleophile of the enzyme.   
The trapping mutants of the different EHs were used to trap their substrates in vivo. With adeno-
associated viruses (AAVs), the trapping enzymes were expressed in the living mouse which provides all 
possible substrate under physiological conditions, including compounds that have not been identified 
yet. To identify the bound substrates, the substrate-enzyme complex was enriched from the tissue by 
His-tag base affinity chromatography and analyzed by liquid chromatography tandem mass 
spectrometry (LC-MS/MS).  
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EH trapping mutants have been successfully used before for different purposes. In a study to identify 
the catalytic triad of the rat mEH, the purified trapping mutant H431Q was incubated with 9,10-
epoxy[14C]stearic acid. After intensive washing, autoradiography revealed covalent substrate binding 
to the mEH mutant (Arand et al., 1999a). The same was shown with a recombinantly expressed H332Q 
mutant of rat sEH with [3H]trans-stilbene oxide (Arand et al., 1996). More recently, a purified Cif E153Q 
trapping mutant was used to trap the substrate epibromohydrin for crystallization to analyze the 
structure of the covalent intermediate (Bahl et al., 2016). Finally, the trapping approach was tested in 
a preliminary experiment in our group. Purified rat sEH trapping mutant was incubated with 
epoxystearic acid (ESA) or 14,15-EET and the predicted modified peptide could be detected with LC-
MS/MS. Additionally, alkaline hydrolysis was used to release the product which could be detected. 
Taken together, these experiments indicate that the substrate-enzyme intermediate obtained with the 
trapping mutants is stable enough for retrieval from the tissue and analysis with LC-MS/MS.   
1.6. Epoxide hydrolase expression patterns and expected 
substrates  
To trap relevant substrates, the trapping EHs have to be expressed in the same organs and cells where 
the wild type enzyme occurs. This is particularly important for mEH and sEH which have overlapping 
substrate specificities and the substrate turnover might be mainly influenced by their localization. For 
the other enzymes, the site of expression is less important as identification of any novel substrate 
would help to understand the role of these enzymes. 
sEH is widely expressed throughout the body with highest expression in the liver in hepatocytes 
followed by kidneys, heart, brain and lungs (Pacifici et al., 1988; Enayetallah et al., 2004). Based on the 
well-established role in signaling molecule metabolism, we expect sEH to trap mainly EETs and other 
fatty acid epoxides (Decker et al., 2009). In the liver, epoxides derived from xenobiotic precursors could 
be trapped as well, especially when animals are challenged with xenobiotic compounds.  
mEH shows highest expression in the liver mainly in hepatocytes, where both metabolism of xenobiotic 
epoxides and endogenous signaling epoxides take place (Coller et al., 2001). Due to its broader 
substrate specificity, mEH might trap many different epoxides derived from xenobiotic compounds but 
also endogenous epoxides. Another organ of interest for mEH is the brain where it is expressed in 
different cell types compared to sEH. mEH expression was reported in vascular cells, choroid plexus 
epithelial cells and neurons whereas sEH is mainly expressed in astrocytes (Marowsky et al., 2009a). In 
the vascular and choroid plexus epithelial cells, a role of mEH in detoxification is expected and thus 
trapping of epoxides derived from xenobiotic compounds. However, in neurons we expect a role in 
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physiological processes probably mediated by EETs. The substrate spectrum trapped by mEH should 
give insight to the extent mEH is occupied with detoxification and what role the enzyme plays in the 
turnover of signaling molecules in different organs. 
Expression of EH3 was found in lung, skin, and upper gastro-intestinal tract (Decker et al., 2012). EH3 
was shown to efficiently hydrolyze EETs and leukotoxin but the function of this turnover is unclear. A 
role of EH3 in skin barrier formation was proposed and trapping of an epoxyalcohol of a skin specific 
linoleate ceramide ester is possible (Yamanashi et al., 2018).  
The orphan enzymes EH4 and MEST are mainly expressed in the brain and in adipose tissue (Lefebvre 
et al., 1998; Takahashi et al., 2005; Lord et al., 2013). For MEST the brain is of high interest as MEST 
KO mice showed a behavioral phenotype (Lefebvre et al., 1998). For both enzymes the identification 
of a substrate would confirm their identity as EH.  
The bacterial EH Cif has been reported to be expressed in airway endothelial cells upon infection by P. 
aeruginosa, therefore the target organ for substrate trapping is the lung. However, we expect every 
cell type expressing CFTR to contain the target epoxide of Cif. We hypothesize that Cif hydrolyzes an 
epoxide linked to CFTR recycling, but no such compound is known so far. 19,20-EpDPA and 14,15-EET 
were proposed to be the primary substrates of Cif (Hvorecny et al., 2017).  
1.7. Adeno-associated viral vectors for gene delivery 
Adeno-associated viruses (AAV) are among the smallest viruses known and require co-infection with 
adenoviruses or other viruses to replicate. No pathologic effect has been associated with AAV 
infections. They have been studied intensively and are a widely used tool for mammalian gene delivery. 
Many AAV vectors have been used in clinical trials and the first AAV based gene therapy, alipogene 
tiparvovec, for the treatment of familial lipoprotein lipase deficiency (LPLD) was approved in Europe 
in 2012 (Scott, 2015; Naso et al., 2017). 
AAVs are non-enveloped, linear, single-stranded DNA viruses. Their genome of approximately 4.7 kb 
size contain rep, cap and aap genes which are flanked by inverted terminal repeats (ITRs). The rep 
genes encode proteins required for genome replication, virus assembly, and site-specific integration 
into the host genome upon infection. The capsid proteins are encoded by the cap genes and aap is 
required for the activation of assembly (Ojala et al., 2015). The ITRs flanking these genes are the only 
cis-acting elements and are required for genome replication and packaging (Wu et al., 2006).  
To use recombinant AAVs as gene delivery tool, the viral genome between the ITRs is replaced by a 
transgene expression cassette containing the gene of interest, a mammalian promoter and a 
terminator. For virus production usually done in HEK cells, the expression cassette flanked by ITRs is 
provided on a plasmid. A second plasmid is used to provide the required rep, cap and aap genes lacking 
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ITRs to avoid packaging of these genes into the AAV capsid. The adenovirus genes necessary for AAV 
replication (E1a, E1b, E2a, E4Orf6, vaRNA) are supplied on a third plasmid or together with the rep, 
cap and aap genes on one single plasmid. Upon co-transfection of HEK cells with the plasmids, viral 
particles are produced and can be purified (Salganik et al., 2015; Naso et al., 2017).  
Infection with the obtained viral particle does not lead to integration of the transgene into the host 
genome due to the lack of the rep genes. The transgene persists as episomes in the nucleus of 
transduced cells and leads to long-lasting expression in both dividing and non-dividing cells (Ojala et 
al., 2015). An additional advantage of AAVs is low immunogenicity probably due to low transduction 
efficiency of antigen-presenting cells such as macrophages and dendritic cells (Salganik et al., 2015).  
Tissue tropism (which cells are infected by an AAV) depends on the virus serotype and the route of 
application. For example, after tail vein injection in mice, almost all the serotypes AAV1-AAV9 
mediated transgene expression in the liver and muscle but only AAV8 and AAV9 could target the brain 
(Zincarelli et al., 2008). A very promising candidate for high transgene expression is the more recently 
discovered serotype rh10. After i.v. injection, this serotype could transduce all organs and showed 
higher expression levels than serotypes AAV1-AAV9 (Hu et al., 2010). A promising candidate to 
efficiently transduce the brain is the serotype PHP.B which was developed by Cre recombination-based 
AAV targeted evolution of AAV9 (Deverman et al., 2016). 
1.8. Liquid chromatography-tandem mass spectrometry 
LC-MS/MS synergistically combines the separation capabilities of high-performance LC (HPLC) with the 
mass analysis potential of MS. For the data acquisition, the compounds are separated by HPLC prior to 
MS detection. The retention time, the time required to elute analytes from the solid stationary phase, 
is the first level of selectivity. The technique used here for LC separation of peptide analytes is reversed 
phase LC (RPLC). In RPLC, peptides are separated on a C18-HPLC column according to their lipophilicity. 
Thus, lipophilic peptides elute later than hydrophilic peptides. Before entering the MS, analytes are 
ionized, and the mobile phase is evaporated in the ionization source at the interface between LC and 
MS.  
In the used LC-MS/MS systems, the ionization is based on electron spray ionization (ESI) (Fenn et al., 
1989). The liquid mobile phase coming from the LC is pumped through a fine metal capillary kept at 
3-5 kV and nebulized at its tip. The fine spray of charged droplets is evaporated usually by heat under 
a stream of dry nitrogen and the resulting charged analytes are drawn into the mass analyzer by 
electrical force. 
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In the mass analyzer, molecules are separated according to their mass-to-charge ratio (m/z). Typical 
mass analyzers use the principles of time-of-flight analysis (TOF) or quadrupole-based separation. The 
MS systems used in this work are a triple quadrupole linear ion trap (QTrap) 4000 and a tripleTOF 6600.  
1.8.1. QTrap 4000 MS technology 
 
Figure 9: Principle of a QTrap MS. Visualization of the arrangement of the different modules in a QTrap 
device. 
The QTrap MS system consists of an ESI source and a hybrid triple quadrupole linear ion trap (LIT). It is 
a tandem MS composed of two quadrupole mass filters (Q1 and Q3) connected via a quadrupole 
collision cell (Q2) (Figure 9). In a typical experiment, the mass filters are set to a certain m/z allowing 
only molecules with this m/z to pass. In Q1, the precursor ion (also called parent ion) is selected which 
then enters the collision cell Q2 where it is fragmented through a collision gas. The fragment ions enter 
the Q3 which either acts as a mass filter again or as a linear ion trap depending on the used scan type. 
In the multiple reaction monitoring (MRM) (also called selected reaction monitoring (SRM)) scan type, 
both quadrupoles act as mass filters selective for the precursor ion in Q1 and for a specific fragment 
of the molecule of interest in Q3. This transition (pair of precursor m/z and fragment m/z) is highly 
specific and allows the discrimination of two molecules that have similar or identical precursor m/z. 
The MS cycles through a series of transitions and records the signal as a function of time (HPLC elution) 
(Figure 10, upper panel). This scan type allows quantitative analysis of molecules in complex samples 
with very high sensitiviy. In the enhanced product ion (EPI) scan type, the Q3 acts as an ion trap 
acquiring a full scan spectrum of all fragments generated by the fragmentation of the precursor ion in 
the collision cell (Figure 10, lower panel). Sensitivity for the fragments is increased, as in the EPI scan 
mode the Q3 operates as a LIT, accumulating fragments before detecting them, thus giving a better 
signal-to-noise ratio for the detected spectra. The obtained fragment spectra contain further 
information about the detected molecules increasing the confindence in positive findings. In contrast 
to MRM, acquisition of EPI spectra takes more time, limiting the number of analytes that can be 
detected per run.  
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Figure 10: MRM EPI scan mode. In a first step, MRM acquisition is performed. If a transition (precursor-
fragment ion pair) exceeds a certain threshold, the EPI acquisition is induced for the respective 
precursor ion and all fragments are trapped in the LIT and transferred to the detector. CID stands for 
collision-induced dissociation and represents Q2. Figure taken from Sciex user guide2. 
Using information dependent acquisition (IDA), these two scan types can be combined (Figure 10). 
MRM is used as the survey scan. Any MRM signal exceeding a certain threshold triggers the acquisition 
of an EPI scan. This combines the selectivity of MRM with the high information content obtained by 
EPI. MRM EPI (IDA) data provides a “fingerprint” of a compound, bearing the possibility to be compared 
to MS/MS mass spectral libraries for better identification (Sciex user guide1).  
1.8.2. TripleTOF 6600 MS technology 
The TripleTOF system combines quadrupole technology front-end with the accelerator TOF analyzer in 
the back. Like the triple quadrupole, it contains a Q1 quadrupole mass filter followed by a Q2 collision 
cell but instead of the Q3 mass filter/LIT, the TripleTOF 6600 has an accelerator TOF analyzer. In TOF 
analyzers, m/z of a fragment is determined by the time the ion takes to fly through a tube with a certain 
length under vacuum (Domon & Aebersold, 2006). 
                                                          
2 https://sciex.com/Documents/brochures/qtrapMRM-EPI-lib-search_10160414.pdf, October 10th, 2018 
Introduction 
 
 
26 
 
 
Figure 11: Principle of a TripleTOF MS. Visualization of the arrangement of the different modules in a 
TripleTOF device. 
TripleTOF systems exhibit higher mass resolution in MS and MS/MS mode compared to QTrap devices. 
In the MS mode, Q1 acts as an ion guide to the accelerated TOF analyzer where the mass analysis takes 
place. In the MS/MS mode, the precursor ions are selected in Q1 and fragmented in the Q2 collision 
cell and the product ions are analyzed in the TOF analyzer. Due to the high resolution, the isotope 
pattern of multiply charged analytes can be resolved. Most elements have more than one stable 
isotope, most importantly, 1.1% of the carbon ions have a weight of 13 Da instead of 12 Da. For 
example, a molecule that contains 100 carbon atoms contains no 13C with a chance of approximately 
34%, one 13C with a chance of 37%, two 13C with a chance of 20% and more than two 13C with a chance 
of 9%. In the mass spectrum, this translates to a typical isotope pattern with multiple peaks where the 
chance is reflected by the relative abundance of every species measured. Since the mass spectrum 
shows m/z and the isotope only affects m, the charge z can be derived from the isotope pattern which 
equals 1 divided by the m/z difference of two isotopes. (For example, if the peaks of different isotopes 
are separated by 0.25 Da then the charge z equals 1/0.25 = 4.) 
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1.8.3. SWATH scan mode 
The TripleTOF 6600 used in this work is able to perform sequential window acquisition of all theoretical 
spectra (SWATH) (Gillet et al., 2012). In contrast to the aforementioned IDA used on the QTrap 4000, 
SWATH is a data independent acquisition (DIA) mode, meaning that all precursor ions are fragmented 
independently of their signal in Q1 (Lambert et al., 2013). In the SWATH scan mode, within 2-4 s cycle 
time, the MS steps through a set of precursor acquisition windows designed to cover 400-1200 m/z as 
a whole mass range. All precursors from the quadrupole isolation window (Q1) are fragmented in Q2 
during each cycle and complete, high accuracy fragment ion spectra are recorded in the accelerated 
TOF analyzer (Figure 12). 
 
Figure 12: Schematic representation of SWATH acquisition. The MS steps through a set of precursor 
acquisition windows designed to cover 400-1200 m/z as a whole mass range within a certain cycle 
time. All precursors from the quadrupole isolation window (Q1) (e.g. 450-475 m/z, for 25 Da wide 
windows) are fragmented in Q2 during each cycle and fragment ion spectra are recorded in the 
accelerated TOF analyzer. The same precursor isolation window is fragmented repeatedly at each cycle 
during the whole chromatographic run. Figure taken from (Gillet et al., 2012). 
The same precursor isolation window is fragmented in every cycle during the whole chromatographic 
run, thus providing a time-resolved recording of the fragment ions of all precursors that enter the MS 
(Gillet et al., 2012). SWATH MS data is therefore highly multiplexed and contains information about all 
analytes present above the detection limit. The data can be analyzed for any analyte in question, also 
post-acquisition, which is not possible with MRM or IDA data (see Figure 13).  
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Figure 13: Data structure of the SWATH (DIA) and MRM acquisition mode. In DIA (left), the complete 
precursor mass range is selected for fragmentation in consecutive and contiguous precursor windows 
(e.g. 25 Da windows, as shown here for region 500–525 m/z) repeatedly during the LC separation. This 
enabels screening of the data for any compound or fragment present above the detection limit. In 
MRM (IDA) (right) only the peptides of interest (here blue and red) are selected for fragmentation 
repeatedly and with a given periodicity during the elution. Recorded data only includes MS/MS spectra 
of the specified transitions (precursor-fragment pairs). No information is recorded for compounds that 
were not included into the acquisiton method. Figures taken from (Gillet et al., 2016). 
1.9. Peptide analysis with mass spectrometry 
Protein analysis typically includes digestion with a protease, with trypsin being the most frequently 
used and thus the one with the most comprehensive data in peptide libraries. The MS/MS spectra of 
the obtained peptides contain structural information about the peptide as they preferentially break at 
certain points along the backbone. Figure 14 shows the typical fragments that are produced from 
peptides. 
 
Figure 14: Nomenclature of fragments occurring during MS/MS analysis of peptides. N-terminal 
fragments are called a, b and c with the number indicating the number of amino acids. C-terminal 
fragments are called x, y and z.  
The fragments will only be detected if they carry at least one charge. Using low energy CID (collision 
induced dissociation) which is the case for QTrap and TripleTOF, y and b fragments are generated 
predominantly. In a series of, for example, y fragments, the mass difference of y(n) to y(n-1) is the 
mass of amino acid n. This can be used for de-novo sequencing of the peptide but requires high quality 
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and complete spectra which are usually not available. Therefore, the obtained spectra are compared 
to databases that contain a limited pool of peptide sequences. The masses and fragments of peptides 
from known proteins are predicted in silico and the peptide sequence that matches the given spectrum 
best, is identified. If several spectra match multiple peptides of the same protein, the confidence that 
this protein is truly present is increased.  
In contrast to classical large-scale proteomic approaches which aim to elucidate the entire content of 
proteins in a cell, organ, or organism, we are interested in one particular peptide of each of the six 
proteins under investigation. Although we know the amino acid sequences, the exact masses are 
unknown because these peptides will be modified by the substrates. However, the fragmentation 
pattern obtained in the MS/MS spectrum is predictable. This fingerprint of the target peptide is used 
to identify the parent mass of the substrate modified peptide. Since the mass of the unmodified 
peptide is known, the mass of the substrate can be calculated. This provides the first lead for further 
structural analyses to identify the caught substrate.  
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1.10. Aim of the study 
The aim of the present project is to identify the preferred in vivo substrates of the six EHs mEH, sEH, 
EH3, EH4, MEST, and Cif to elucidate their physiologic functions. Besides classical substrate screening 
and kinetic analysis we aim to develop and use a novel in vivo substrate trapping approach. The major 
questions addressed are:  
1) Which substrates are preferred in vivo by the well characterized sEH, mEH and EH3 in a tissue and 
treatment-specific manner? 
2) What are the physiologic substrates of the hitherto orphan human EHs EH4 and MEST? 
3) Which substrate is processed by the bacterial EH Cif and does this provide a lead to understand Cif's 
role in the pathophysiology of P. aeruginosa infection? 
Answering these questions would boost the understanding of the role of EHs in mammalian/human 
physiology and thus create new leads for the development of novel therapeutic strategies. The 
development of the substrate trapping method itself would be a major breakthrough in identifying the 
real contribution of enzymes under investigation in the in vivo situation in an unbiased manner.  
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2. MATERIALS AND METHODS 
2.1. Chemicals 
If not indicated otherwise, all chemicals were obtained from Sigma-Aldrich (St. Louis, MO, USA) and 
Roth AG (Karlsruhe, Germany). Fatty acid derived epoxides were purchased from Cayman Chemicals 
(Michigan, USA). 
2.2. Vectors and plasmids 
Table 1: Plasmid constructs 
Abbreviation Full name Purpose 
pRSET  pRSET A Expression of inclusion bodies in E.coli 
pET pET20b(+) Expression of functional EHs in E. coli 
pAM-CAG pAM-CAG-pl-HisC-WPRE AAV production and expression of EHs in HEK cells 
pGEF pGEFII-HisC Expression of active Cif in E. coli 
AAV-PHP.B pUCmini-iCAP-PHP.B AAV production (Deverman et al., 2016) 
AAV-rh10 pAAV2/rh10 AAV production (Gao et al., 2003; Cearley et al., 2008) 
Helper plasmid pBS-E2A-VA-E4 AAV production (Paterna et al., 2000) 
Adapted from Bettina Hew, ETH Diss. No. 25662, (Hew, 2019) 
2.3. Primers 
Table 2: Primers used to insert EHs into pRSET  
Name Sequence Restric. site 
mEHfor BamHI BstBI GATCGGATCCGCCGCCATGTGGCTAGAAATCCTCCTCAC BamHI 
mEHrev BamHI BstBI GATCTTCGAAGCTTGCCGCTCCAGCACCGACAGGAA BstBI 
sEHfor BamHI BstBI GATCGGATCCGCCGCCATGACGCTGCGCGCGG BamHI  
sEHrev BamHI BstBI GATCTTCGAAGCCATCTTTGAGACCACCGG BstBI 
EH3for Cla BstBI GATCATCGATGCGGCCGCGCCGCCATGGCGGAGCTGGTGGTGA ClaI  
EH3rev NotI BstBI GATCTTCGAAGCGTCCAGCAGGTCTTGCAAGAAGG BstBI 
EH4for BamHI BstBI GATCGGATCCGCCGCCATGGCGAGGCTGCGGGATTGCCTG BamHI  
EH4rev BamHIBstBI GATCTTCGAAGCATCTTTTTTTCTTGTTTCTTCTTTTAGAAATGTCCATATCAA BstBI 
Mestfor KpnI BstBI GATCGGTACCGCGGCCGCGCCGCCATGGTGCGCCGAGATCGCCTCC KpnI 
Mestrev NotI BstBI GATCTTCGAAGCGAAGGAGTTGATGAAGCCCAT BstBI 
Ciffor BamHI HindIII GATCGGATCCGCCGCCATGGTCCTCGATAGACTTTGCCG BamHI 
Cifrev BamHI HindIII GATCAAGCTTATCGATGCTAGATCTCCTCCGCGACCGCGG HindIII 
Cursive, non-complementary sequence; underlined, restriction site 
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Table 3: Mutagenesis primer 
Name Sequence 
mEH D226A for  CTACATTCAAGGAGGCGCCTGGGGGTCCCTG 
mEH D226A rev CAGGGACCCCCAGGCGCCTCCTTGAATGTAG 
mEH H431A for GGTTCGTGGGGGCGCCTTTGCGGCCTTTGAGG 
mEH H431A rev CCTCAAAGGCCGCAAAGGCGCCCCCACGAACC 
mEH H431Q for CGTGGTGGCCAGTTTGCGGCCTTTGAGGAG 
mEH H431Q rev CTCCTCAAAGGCCGCAAACTGGCCACCACG 
sEH D335A for  CATTGGCCATGCATGGGGTGGCATGCTGGTG 
sEH D335A rev CACCAGCATGCCACCCCATGCATGGCCAATG 
sEH H524A for GACTGTGGGGCCTGGACACAGATGGAC 
sEH H524A rev GTCCATCTGTGTCCAGGCCCCACAGTC 
sEH H524Q for GGACACATTGAGGACTGTGGGCAGTGGACACAGATGGAC 
sEH H524Q rev GTCCATCTGTGTCCACTGCCCACAGTCCTCAATGTGTCC 
EH3 D173A for GTGGCCCATGCATGGGGTGCCCTCCTTG 
EH3 D173A rev CAAGGAGGGCACCCCATGCATGGGCCAC 
EH3 H337A for GCCAGGCATAGGGGCTTGTATCCCACAGAG 
EH3 H337A rev CTCTGTGGGATACAAGCCCCTATGCCTGGC 
EH3 H337Q for GCCAGGCATAGGGCAGTGTATCCCACAGAG 
EH3 H337Q rev CTCTGTGGGATACACTGCCCTATGCCTGGC 
EH4 D169A for GTTCTTATTGGCCATGCATGGGGGGGCATGATTGCTTGG 
EH4 D169A rev CCAAGCAATCATGCCCCCCCATGCATGGCCAATAAGAAC 
EH4 H336A for GTCAGAAGCCAGTGCTTGGCTGCAGCAAGACCAAC 
EH4 H336A rev GTTGGTCTTGCTGCAGCCAAGCACTGGCTTCTGAC 
EH4 H336Q for GTCAGAAGCCAGTCAGTGGCTGCAGCAAGACCAAC 
EH4 H336Q rev GTTGGTCTTGCTGCAGCCACTGACTGGCTTCTGAC 
Mest D147A for GGATCAACCTTCTTTCTCATGCATATGGAGATATTGTTGCTCAGG 
Mest D147A rev CCTGAGCAACAATATCTCCATATGCATGAGAAAGAAGGTTGATCC 
Mest H314A for  GATGACCACATTAGCGCTTATCCACAGCTAGAGGATCCC 
Mest H314A rev GGGATCCTCTAGCTGTGGATAAGCGCTAATGTGGTCATC 
Mest H314Q for GACCACATTAGCCAATATCCACAGCTGGAGG 
Mest H314Q rev CCTCCAGCTGTGGATATTGGCTAATGTGGTC 
Cif D129A for CTGGTGGCCCACGCGATCGGTATCTG 
Cif D129A rev CAGATACCGATCGCGTGGGCCACCAG 
Cif H297A for GCTGTGGCGCCTGGCTGCCGGAAGAGTG 
Cif H297A rev CACTCTTCCGGCAGCCAGGCGCCACAGC 
Cif H297Q for GCTGTGGCCAATGGCTTCCGGAAGAGTG 
Cif H297Q rev CACTCTTCCGGAAGCCATTGGCCACAGC  
Bold cursive, mutation; underlined, changed codon 
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Table 4: Primers to insert EHs into pAM-CAG vector 
Name Sequence Restric. site 
mEHfor BamHI BstBI GGATCCGCCGCCATGTGGCTAGAAATCCTCCTCAC BamHI 
mEHrev BamHI BstBI GATCTTCGAAGCTTGCCGCTCCAGCACCGACAGGAA BstBI 
sEHfor BamHI BstBI GGATCCGCCGCCATGACGCTGCGCGCGG BamHI 
sEHrev BamHI BstBI GATCTTCGAAGCCATCTTTGAGACCACCGG BstBI 
EH3for NotI BstBI GCGGCCGCGCCGCCATGGCGGAGCTGGTGGTGA NotI 
EH3rev NotI BstBI GATCTTCGAAGCGTCCAGCAGGTCTTGCAAGAAGG BstBI 
EH4for BamHI BstBI GGATCCGCCGCCATGGCGAGGCTGCGGGATTGCCTG BamHI 
EH4rev BamHIBstBI GATCTTCGAAGCATCTTTTTTTCTTGTTTCTTCTTTTAGAAATGTCCATATCAA BstBI 
Mestfor NotI BstBI GCGGCCGCGCCGCCATGGTGCGCCGAGATCGCCTCC NotI 
Mestrev NotI BstBI GATCTTCGAAGCGAAGGAGTTGATGAAGCCCAT BstBI 
Ciffor BglII ClaI AGATCTGCCGCCATGGTCCTCGATAGACTTTGCCG BglII 
Cifrev BglII ClaI ATCGATGCTAGATCTCCTCCGCGACCGCGG ClaI 
Cursive, non-complementary sequence; underlined, restriction site 
 
Table 5: Oligonucleotides 
Name Sequence 
Polylinker pAM-CAG sense1 GATCCGCTAGCGGTACCTTCG 
Polylinker pAM-CAG sense2 AATCGCGAACATCATCATCATCATCATCGCGAGTA 
Polylinker pAM-CAG antisense1 AGCTTACTCGCGATGATGATG 
Polylinker pAM-CAG antisense2 ATGATGATGTTCGCGATTCGAAGGTACCGCTAGCG 
Polylinker pAM-CAG sense3 GATCCGCGGCCGCCTGCAGCTCGAGGAATT 
Polylinker pAM-CAG antisense3 CGAATTCCTCGAGCTGCAGGCGGCCGCG 
 
Table 6: Sequencing primer 
Name Sequence 
AAV8-SAR120514 TGACGTCAATGGAAAGTCCC 
AAV-pl-for GTGGCTGCGTGAAAGCCTTGA 
CAGfor GCCCAGTACATGACCTTA 
VP1.5 GGACTTTCCAAAATGTCG 
XL39 CCACCAGCCTTGTCCTAATA 
2.4. Antibodies  
Table 7: Primary antibodies 
Abbreviation  Supplier information 
Anti-His-tag Anti-6X Histag® antibody-ChIP Grade (ab9108), polyclonal, Abcam 
Anti-GFP GFP Polyclonal Antibody (A6455), polyclonal, Invitrogen 
Anti-human mEH Rabbit 2 Anti-mix mEH, polyclonal, in-house 
Adapted from Bettina Hew, ETH Diss. No. 25662, (Hew, 2019) 
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Table 8: Secondary antibodies 
Abbreviation Supplier information 
Anti-rabbit AP Anti-Rabbit IgG (whole molecule), F(ab′)2 fragment−Alkaline Phosphatase 
antibody produced in goat (A3937), Sigma Aldrich 
Odyssey 680 IRDye® 680RD Donkey anti-Rabbit Antibody (926-68073), polyclonal, Li-Cor 
Odyssey 800 IRDye® 800CW Donkey Anti-Rabbit IgG (H+L) (926-32213), polyclonal, Li-Cor 
Cy3  Cy™3 AffiniPure Donkey Anti-Rabbit IgG (H+L) (711-165-152), polyclonal, 
Jackson Immuno Research 
Adapted from Bettina Hew, ETH Diss. No. 25662, (Hew, 2019) 
2.5. Microbiological methods 
2.5.1. PCR 
DNA fragments of interests were amplified by polymerase chain reaction (PCR) with the PCR reaction 
mix and PCR program summarized in 
 
Table 9 using a Thermal Cycler T100 (Bio-Rad Laboratories, Inc., Hercules, CA, USA). PCR primers were 
obtained from Microsynth (Balgach, Switzerland) and were solubilized in water. 10 x dNTP mix 
contained 2.5 mM dNTPs (Thermo Fischer Scientific, Waltham, MA, USA) and 10 x PCR buffer consisted 
of 200 mM Tris, 100 mM (NH4)2SO4, 100 mM KCl, 20 mM MgSO4, 1% Triton X-100, 1 mg/mL BSA at pH 
7.4. Homemade Pfu DNA polymerase, which can correct wrongly incorporated nucleotides by its 3'→5' 
exonuclease activity, was used. To avoid unspecific primer binding, the Pfu polymerase was added last 
to the PCR reaction mix, after heating up to 95 °C (hot-start PCR).  
 
Table 9: PCR reaction mix and PCR program 
PCR reaction mix    PCR program   
Plasmid DNA 40 ng   95 °C 5’  
Forward primer (25 µM) 0.5 µl   95 °C 30’’  
Reverse primer (25 µM) 0.5 µl   55 - 65 °C* 10’’ 30 cycles 
10 x dNTP mix 5 µl   72 °C 2’  
10 x PCR buffer 5 µl   72 °C 5’  
Pfu polymerase, added last 1 µl      
Water ad 50 µl      
* 3-5 tubes of the same reaction mix were processed in parallel with different annealing temperatures 
between 55-65 °C (gradient PCR)  
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2.5.2. Site-directed mutagenesis PCR 
Site-directed mutagenesis PCR was performed to change up to three nucleotides in a plasmid 
construct. The complete plasmid was amplified by PCR using two complementary primers containing 
the desired mutations flanked by at least 10-15 bases on either side of the mutation(s). The PCR 
reaction mix and PCR program are summarized in Table 10 and a Thermal Cycler T100 (Bio-Rad 
Laboratories, Inc., Hercules, CA, USA) was used. Primers, dNTP mix, PCR buffer and Pfu polymerase 
were used as described in the previous chapter 2.5.1. 
After the PCR, the template plasmid was digested by direct addition of 1 µl of the restriction 
endonuclease DpnI and incubation for 1 h at 37 °C. DpnI cleaves the sequence GATC in the methylated 
template plasmid of bacterial origin but not the amplified, mutated plasmid lacking methylation. After 
digestion, 0.5 - 2 µl of the plasmid solution was transformed into E. coli for amplification and analysis 
(see chapter 2.5.5. and 2.5.6.).   
 
Table 10: Site-directed mutagenesis PCR reaction mix and PCR program 
PCR reaction mix    PCR program   
Plasmid DNA 40 ng   95 °C 3’  
Forward primer (25 µM) 0.3 µl   95 °C 1’  
Reverse primer 0.3 µl   55-65 °C* 1’ 30 cycles 
10 x dNTP mix 3 µl   72 °C 10’  
10 x PCR buffer 3 µl   72 °C 15’  
ATP 0.5 µl      
Pfu polymerase 0.6 µl      
Water ad 30 µl      
* 3-5 tubes of the same reaction mix were processed in parallel with different annealing temperatures 
between 55-65 °C (gradient PCR)  
2.5.3. Cloning 
The plasmid segment of interest was amplified by PCR with primers designed to introduce the required 
endonuclease restriction sites. The amplified DNA insert was purified using the QIAquick PCR 
Purification Kit (Qiagen, Hilden, Germany) according to the manufacturer’s protocol. The insert and up 
to 5 µg of target plasmid backbone were digested with the respective restriction endonucleases (New 
England Biolabs (NEB), Ipswich, MA, USA) using the suggested NEB buffer and, if required, BSA for 1 hr 
at 37 °C. If required, the backbone was dephosphorylated by addition of calf intestinal phosphatase 
(NEB) to the restriction endonuclease digest and incubation for 1 h at 37 °C. Both backbone and insert 
were separated by gel electrophoresis on a preparative 0.7-1% agarose gel and purified using the 
QIAquick Gel Extraction Kit (Qiagen, Hilden, Germany) according to the manufacturer’s protocol. The 
DNA concentration was quantified by Nanodrop.  
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For the ligation, 40-50 ng backbone was incubated with the insert in a molar ratio of 1:3 
(backbone:insert) together with 1 µl of 10 x T4 ligation buffer and 0.2 µl T4 DNA ligase (both Thermo 
Fisher Scientific, Waltham, MA, USA) in a final volume 10 µl for 30 min in the dark. The ligase was 
inactivated by incubation for 10 min at 65 °C before up to 2 µl of the ligated plasmid was transformed 
into TOP10 or MDS42 E. coli. 
2.5.4. Transformation of E. coli 
Electroporation was used to transform electrocompetent E. coli (One Shot TOP10 Electrocomp E. coli; 
Thermo Fisher Scientific, Waltham, MA, USA) with a plasmid of interest. 0.5-2 µl plasmid were added 
to 40 µl thawed electrocompetent bacteria and incubated for 5 min on ice. The bacteria were then 
transferred to a pre-cooled electroporation cuvette with a gap width of 0.1 cm (Bio-Rad Laboratories, 
Inc., Hercules, CA, USA) and electroporated with one pulse of 5 ms at 1.35 kV with a Gene Pulser™ (Bio-
Rad Laboratories). Subsequently, cells were suspended in 500 µl pre-warmed (37 °C) LB medium and 
incubated for 1 h at 37 °C and 220 rpm. 100 µl of the bacteria suspension was plated on LB agar dishes 
containing 0.1 mg/ml ampicillin and incubated overnight at 37 °C.  
2.5.5. Plasmid amplification 
A starter culture of 4 ml of LB medium containing 100 µg/ml ampicillin was inoculated with an E. coli 
colony containing the plasmid of interest and incubated overnight at 37 °C and 220 rpm. The starter 
culture was directly used to isolate the plasmid with QIAprep Spin Miniprep Kit (Qiagen, Hilden, 
Germany). For high plasmid amounts, the starter colony was used to inoculate a larger culture of 150-
250 ml for isolation with the HiSpeed Plasmid Maxi Kit (Qiagen). Isolation was performed according to 
the manufacturer’s protocol. DNA yield was quantified by Nanodrop.  
2.5.6. Plasmid analysis and Sanger sequencing 
200-500 ng plasmid DNA was digested with suitable restriction endonucleases (NEB, Ipswich, MA, USA) 
using the suggested NEB buffer and, if required, BSA for 1 h at 37 °C. The obtained DNA fragments 
were separated on a 1-2% agarose gel by gel electrophoresis and the size was determined by 
comparison to standards (GeneRuler DNA Ladder Mix; Thermo Fisher Scientific, Waltham, MA, USA). 
DNA sequence was determined by Sanger sequencing performed by Microsynth (Balgach, Switzerland) 
using the primers listed in Table 6.   
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2.6. Recombinant protein expression 
pRSET plasmid constructs were used for the expression of inclusion bodies and pET and pGEF 
constructs were used for the expression of functional protein in E. coli. Expression of functional enzyme 
in HEK293T cells after transient transfection with pAM-CAG constructs is described in the doctoral 
thesis of Bettina Hew (Hew, 2019). 
The expression vector was transformed into BL21-AI E. coli which contain an arabinose inducible T7 
RNA polymerase. A starter culture of 4 ml of LB medium containing 100 µg/ml ampicillin was inoculated 
with an E. coli colony and incubated overnight at 37 °C and 220 rpm. The next day, the starter culture 
was centrifuged, and the bacteria were washed twice with LB medium before they were used to 
inoculate 250 ml LB medium containing 100 µg/ml ampicillin which was incubated at 37 °C. At an 
optical density (OD600) of 0.4-0.6, protein expression was induced by the addition of arabinose to a 
final concentration of 10 µM for expression of functional enzyme and 1 mM for expression of inclusion 
bodies. Expression was performed over night at room temperature for functional enzyme and 30 °C 
for inclusion bodies at 220 rpm. Bacteria were harvested by centrifugation (4000 g, 15 min, 4 °C, 
Heraeus Megafuge 1.0R, rotor #2704; Heraeus Instruments GmbH, Hanau, Germany) and the pellet 
was either resuspended in Tris-buffer (20 mM Tris, 100 mM NaCl) for further use or stored at -80 °C.  
2.7. Protein purification  
All recombinantly expressed proteins are fused to a hexa histidine-tag (His-tag) used for purification 
or enrichment from bacterial cultures or mouse tissue homogenates by immobilized metal affinity 
chromatography (IMAC). Functional Cif expressed in E. coli is transferred to the bacterial periplasm 
and was isolated from there by osmotic shock prior IMAC to increase purity.  
2.7.1. French Pressure Cell 
Bacterial cell pellets obtained from 250 ml expression cultures were resuspended in 10 ml Tris-buffer 
(20 mM Tris, 100 mM NaCl). Mechanical lysis of the bacteria was performed using a French® Pressure 
Cell press (Slm Aminco, Thermo Fisher Scientific, Waltham, MA, USA) with a pressure of 30’000 psi. 
Lysis was performed slowly to avoid increase of temperature of the lysate. Bacteria and lysates were 
kept on ice. Inclusion bodies were separated from soluble protein by centrifugation for 20 min at 
4000 g and 4 °C (Heraeus Megafuge 1.0R, rotor #2704, Heraeus Instruments GmbH, Hanau, Germany).  
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2.7.2. Osmotic shock 
Bacterial cell pellets obtained from 250 ml expression culture were resuspended in 30 mM Tris, 20% 
sucrose, pH 8, for 10 min. After centrifugation (4000 g, 15 min, 4 °C, Heraeus Megafuge 1.0R, rotor 
#2704; Heraeus Instruments GmbH, Hanau, Germany), the pellet was resuspended in ice-cold 5 mM 
MgSO4 and stirred slowly on ice for 10 min. During this step, the bacterial outer membrane is disrupted 
by osmotic forces and the periplasmic proteins are released into the buffer. The bacteria were pelleted 
again by centrifugation and the supernatant containing the protein of interest was collected. Mg2+ was 
removed from the protein solution by dialysis against chilled IMAC buffer A (20 mM Tris, 0.5 M NaCl, 
20 mM Imidazole, pH 7.4) overnight prior purification.  
2.7.3. Immobilized metal ion chromatography (IMAC) 
Lysates of bacteria expressing membrane bound enzymes such as mEH were incubated with 0.5% (v/v) 
Genapol X-100 for 1 h on ice to release proteins from the membrane prior centrifugation for 20 min at 
50’000 g (Kendro, Sorvall RC-%C, rotor SS-34; Thermo Fisher Scientific, Waltham, MA, USA) to remove 
insoluble cell debris. Soluble proteins such as sEH were centrifuged without Genapol X-100 treatment 
and Cif isolated from periplasm was used directly for purification.  
Using an ÄKTA Explorer setup (GE Healthcare Life Sciences, Chalfont St Giles, UK) cleared protein 
samples were loaded with a flow rate of 0.5 ml/min on a 1 ml HisTrap FF column (GE Healthcare Life 
Sciences) primed with 100% buffer A (20 mM Tris, 0.5 M NaCl, 20 mM Imidazole, pH 7.4). The column 
was washed with 1 ml/min buffer A until no protein elution was detected anymore with the UV 
detector at 280 nm. Elution was performed with a linear gradient of 1% per 2 min of buffer B (20 mM 
Tris, 0.5 M NaCl, 500 mM Imidazole, pH 7.4) at a flowrate of 0.5 ml/min. The eluted protein was 
collected in 0.5 ml fractions which was monitored by UV. Cif was eluted with a linear two-step gradient 
of buffer B from 4 to 20% B in 8 min and from 20 to 100% B in 8 min and a flow rate of 0.5 ml/min. The 
collected fractions were analyzed by SDS-PAGE and Coomassie staining and western blot.  
2.7.4. Enrichment of His-tagged protein from mouse tissue 
Up to 400 mg of frozen mouse tissue were homogenized in 1 ml of ice-cold homogenization buffer 
(0.125 M KCl, 0.25 M sucrose, 1 mM EDTA, 0.1 M potassium phosphate, pH 7.4) supplied with 0.5% 
(v/v) Genapol X-100 for membrane bound enzymes, in a tissue grinder on ice. The tissue homogenate 
was centrifuged for 15 min at 10’000 g, 4 °C (Eppendorf Centrifuge 5430R, rotor FA-45-30-11, 
Eppendorf AG, Hamburg, Germany) and the cleared supernatant was loaded on a primed 1 ml 
HisTrap FF column using a syringe pump (Harvard Apparatus 11 Plus Syringe Pump, flow 0.5 ml/min). 
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The column was washed with 6 ml buffer A (20 mM Tris, 0.5 M NaCl, 20 mM Imidazole, pH 7.4) and 
the His-tagged protein was subsequently eluted by 3-4 ml of buffer B (20 mM Tris, 0.5 M NaCl, 500 mM 
Imidazole, pH 7.4) whereas the flow through was collected in 0.5-1 ml fractions and analyzed by SDS-
PAGE and Coomassie staining and western blot. 
2.8. Protein analysis and characterization 
2.8.1. Protein quantification by Bradford assay 
BSA stock solution (1 mg/ml) for the calibration curve was stirred for 1 h before use and diluted 
according to the following Table 11 in a 96-well plate: 
 
Table 11: Pipetting scheme for BSA calibration curve for the Bradford assay 
BSA conc. [µg/ml] 0 6.67 13.33 26.67 40.00 53.33 66.67 
BSA stock (1 mg/ml) [µl] 0 2 4 8 12 16 20 
H2O [µl] 100 98 96 92 88 84 80 
Adapted from Bettina Hew, ETH Diss. No. 25662, (Hew, 2019) 
 
The protein sample was diluted to an expected concentration within the BSA standard curve and 100 µl 
were provided in a well of the 96-well plate. For the Bradford working solution, Bradford reagent 
(Roti®-Quant 5x concentrated Bradford Reagent K015; Carl Roth, Karlsruhe, Germany) was diluted 
1:2.33 in water. 200 µl of Bradford working solution were added to each well of the standard curve or 
sample and the absorbance was measured in a plate reader at 595 nm (SpectraMAX GeminiXS 
microplate fluorescence reader; Molecular Devices, San Jose, CA, USA). The standard curve as well as 
the samples were determined in duplicates or triplicates. 
2.8.2. Peptide quantification by Lowry assay 
The performance of protein digestion was tracked by Lowry peptide assay. Solutions A (2% Na2CO3 in 
1 M NaOH) and B (0.5% CuSO4 and 1% potassium sodium tartrate (KNaC4H4O64H2O)) were prepared 
and mixed in a ratio 50:1 to form the Lowry solution. The BSA stock solution (1 mg/ml) for the 
calibration curve was stirred for 1 h before use and diluted according to the following Table 12 in 1.5 ml 
Eppendorf tubes: 
 
Materials and methods 
 
 
40 
 
Table 12: Pipetting scheme of the BSA standards for the Lowry assay 
BSA conc. [µg/ml] 0 10 25 50 75 100 
BSA stock (1mg/ml) [µl] 0 2.5 6.25 12.5 18.75 25 
H2O [µl] 250 247.5 243.75 237.5 231.25 225 
 
The sample was diluted to an expected concentration within the BSA standards. In a 96-well plate, 
each well was provided with 200 µl of Lowry solution and subsequently 100 µl of the diluted protein 
solution or BSA standards was added and incubated at room temperature for 15 min. Subsequently, 
20 µl of Folin reagent was added and incubated for 30-60 min. The absorbance was measured in a 
plate reader at 650 nm (SpectraMAX GeminiXS microplate fluorescence reader; Molecular Devices, San 
Jose, CA, USA). The standard curve as well as the samples were done in duplicates or triplicates. 
2.8.3. SDS-PAGE 
Protein separation was done by sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-
PAGE). The composition of the used self-casted gels is shown in Table 13. Samples were mixed with 
Lämmli buffer (4 x Lämmli buffer: 200 mM Tris, pH 6.8, 8% SDS, 0.4% bromophenol blue, 40% glycerol, 
10% ß-mercaptoethanol) and incubated at room temperature (heat sensitive EH3) or 85 °C for 5 min. 
Very viscous samples were sheared trough an insulin syringe before loading. 1-60 µl of sample were 
loaded per pocket of the gel and run with 1 x PAA buffer (25 mM Tris, 250 mM glycine, 0.1% SDS, 
pH 8.3) at 80-100 V for 1-3 h (Bio-Rad PowerPac™ Basic Power Supply; Bio-Rad Laboratories, Inc., 
Hercules, CA, USA). 
 
Table 13: Composition of self-casted 12.5% Tris-glycine SDS-PAGE gels.  
 
Stacking gel (5%) 
[ml] 
Running gel (12.5%) 
[ml] 
Water 20.6 24.8 
Rotiphorese® Gel 30 5.0 33.3 
1.5 M Tris pH 8.8 3.75 - 
1 M Tris pH 6.6 - 20 
10% SDS 0.3 0.8 
10% APS 0.3 0.8 
TEMED 0.032 0.032 
The specified volumes are adequate for 7 gels of 8 x 9 cm size. Adapted from Bettina Hew, ETH Diss. 
No. 25662, (Hew, 2019) 
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2.8.4. Coomassie staining 
To visualize the separated protein bands, SDS-PAGE gels were incubated with Coomassie brilliant blue 
solution (0.25 g Brilliant blue R250, 0.25 g G250 in 45% (v/v) methanol and 10% (v/v) acetic acid) for at 
least 20 min at room temperature and de-stained by incubation in de-staining solution (15% 
isopropanol, 10% acetic acid) for 4-18 h.  
2.8.5. Western blot analysis 
Western blotting was performed to detect and quantify specific proteins from tissue lysates, cultured 
cells or bacterial expressions. The proteins were separated by SDS-PAGE and blotted onto a PVDF 
membrane (Immobilion-P, Merck Millipore, Burlington, MA, USA) using the semi-dry blotting 
technique. A PVDF membrane was activated in methanol for 5 min and subsequently equilibrated in 
blotting buffer (25 mM Tris, 250 mM glycine, 0.1% SDS, pH 8.3, 20% methanol). Two filter papers were 
soaked in blotting buffer and placed into the transfer chamber. The membrane was placed on one filter 
paper and the SDS-PAGE gel put on top and both was covered with the second filter paper. Air bubbles 
were removed using a blot roller.  
After blotting for 30 min at 25 V and 1.0 A (Bio-Rad Trans Blot Turbo Transfer System; Bio-Rad 
Laboratories, Inc., Hercules, CA, USA) the membrane was blocked for 1 h in blocking buffer (Odyssey 
Blocking Buffer (LI-COR Biosciences, Lincoln, NE, USA) for Odyssey secondary antibodies or 2.5% 
skimmed milk powder for alkaline phosphatase (AP) conjugated secondary antibodies). The membrane 
was then incubated with the primary antibody diluted 1:1000 in blocking buffer for 1 h at room 
temperature or overnight at 4 °C if not specified otherwise. To remove excessive antibody, the 
membrane was washed 3 times for 15 min in TBS (10 mM Tris, 150 mM NaCl, pH 8.0). Subsequently, 
the secondary antibody was added in a 1:8000 dilution in TBS and incubated for 1 h at room 
temperature. The membrane was washed 3 times for 15 min in TBS and scanned with the Odyssey 
reader (LI-COR Biosciences) or developed by AP. For AP detection, the membrane was incubated in AP-
buffer (100 mM NaCl, 100 mM Tris, 5 mM MgCl, pH 9.5) for 5 min. Under exclusion of air the membrane 
was then incubated with a mix of 33 µl Bcip and 66 µl NBT in a plastic bag in the dark. The reaction was 
stopped with EDTA solution as soon as the appearing purple bands were of desired intensity.  
2.9. Virus production  
Production of AAV was done in collaboration with the Viral Vector Facility of the University of Zurich 
and protocols were kindly provided by Dr. Jean-Charles Paterna. The detailed procedure is described 
in the doctoral thesis of Bettina Hew (Hew, 2019). In summary, the pAM-CAG vector providing the 
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transgene to be packed into the virus particles was co-transfected into HEK293T cells together with a 
helper plasmid providing rep and cap genes and a helper plasmid providing adenovirus functions. After 
three days, the cells were harvested, lyzed and the viral particles was purified by iodixanol gradient 
ultracentrifugation. After diafiltration to reduce the sample volume and to exchange the iodixanol 
buffer with PBS-MK buffer (PBS pH 7.4, 1 mM MgCl2, 2.5 mM KCl), the viral genome (vg) containing 
particles were quantified using a QubitTM 2.0 with the QubitTM dsDNA HS Assay Kit (Thermo Fischer 
Scientific, Waltham, MA, USA). The obtained virus solution was aliquoted and stored at -80 °C. 
 
2.10. Peptide analysis by LC-MS/MS 
2.10.1. In-solution digestion 
Inclusion bodies separated from soluble protein by centrifugation were resuspended in 50 mM Tris, 
pH 8, 8 M urea, and vortexed until the sample was clear. The sample was then diluted 1:10 with 50 mM 
ammonium bicarbonate, pH 8, to lower the urea concentration below 1 M. Trypsin (Pierce Trypsin 
Protease, MS Grade; Thermo Fisher Scientific, Waltham, MA, USA) was added with a final protease to 
protein ratio of 1:20 to 1:50 and incubated overnight at 37 °C. SPE was used to clean up the peptide 
samples prior MS analysis.  
2.10.2. In-gel digestion 
Samples (e.g. mammalian cell culture, bacterial or mouse tissue lysates) were separated using SDS-
PAGE and the gel was stained with Coomassie for protein visualization. The gel was washed twice with 
water and protein bands of interest were cut out and chopped into 1 mm3 pieces. To de-stain and 
shrink the gel pieces, they were incubated twice with 50% ACN in 20 mM ammonium bicarbonate 
buffer for 30 min at 37 °C (220 rpm, Sartorius Certomat R). The buffer was removed, and the gel pieces 
were dried under a flow of nitrogen. In case the protein of interest did not contain a cysteine, the dried 
gel pieces were directly soaked with trypsin (Pierce Trypsin Protease, MS Grade; Thermo Fisher 
Scientific, Waltham, MA, USA) in digestion buffer (5 ng/µl in 10 mM ammonium bicarbonate, 10% ACN, 
0.01% triton X-100, pH 8.0) and incubated at 37 °C overnight. Proteins with cysteine containing 
peptides of interest were reduced and alkylated prior digestion. The dried gel pieces were soaked with 
dithiotreitol (DTT) (10 mM in 25 mM NH4HCO) for 45 min at 37 °C, washed with water and then 
incubated with iodoacetamide (55 mM in 25 mM NH4HCO) for 60 min at room temperature in the dark. 
The gel pieces were washed, dried again and soaked with trypsin in digestion buffer and incubated at 
Materials and methods 
 
 
43 
 
37 °C overnight. The digested sample was sonified for 5 min, the liquid fraction was collected, and the 
gel pieces were sonified twice with 200 µl ACN which was collected again. The collected peptide 
containing fractions were dried under a flow of nitrogen and reconstituted in MS-buffer (15% ACN, 
0.1% FA) prior to LC-MS/MS analysis. 
2.10.3. Filter aided sample preparation (FASP) protein digestion 
Protein precipitation was performed to decrease the sample volume for the following FASP digestion. 
100 µl of sample (his tag enriched protein from mouse liver or brain homogenates) were provided in a 
1.5 ml Eppendorf tube and 400 µl methanol and subsequently 100 µl of chloroform were added and 
mixed well after each addition. Following, 300 µl of water were added, vortexed, and centrifuged for 
5 min at 10’000 g (Eppendorf Centrifuge 5430R, rotor FA-45-30-11; Eppendorf AG, Hamburg, 
Germany). The upper phase was immediately removed without disturbing the precipitated protein 
band at the interphase. 300 µl of methanol were added to the sample, vortexed and the protein was 
pelleted by centrifugation at 10’000 g for 5 min. The supernatant was completely removed and the 
pellet was washed with 1 ml of ice-cold acetone (-20 °C) and pelleted again at 10’000 g for 1 min. The 
acetone supernatant was removed and the protein pellet was air-dried for 15 min.  
30 µl SDS-lysis buffer (4% (w/v) SDS, 100 mM Tris pH 8.2, 0.1 M DTT) was added to the protein pellet, 
mixed well and spun down briefly. After the addition of 200 µl UA buffer (8 M urea in 100 mM Tris 
pH 8.2) the sample was mixed well, loaded onto the filter unit (Microcon-30 kDa Centrifugal Filter Unit 
with Ultracel-30 membrane, MRCF0R030, Merck Millipore, Burlington, MA, USA) and centrifuged for 
45 min at 14’000 g, 20 °C. Another 200 µl UA buffer were centrifuged trough the filter unit (14’000 g, 
45 min, 20 °C). Subsequently 100 µl IAA solution (0.05 M Iodoacetamide in UA buffer) were loaded 
onto the filter unit, mixed at 600 rpm for 1 min (orbital shaker) and incubated on the bench for 5 min. 
The filter unit was centrifuged again for 45 min at 14’000 g, 20 °C. The flow through was discarded 
after all steps. 
To wash the sample and remove the SDS, the filter unit was flushed 3 times with 100 µl UA buffer 
(14’000 g, 25 min, 20 °C) and two times with 100 µl 0.5 M NaCl (14’000 g, 25 min, 20 °C). The filter unit 
was then transferred to a new collection tube and 120 µl of TEAB (0.05 M triethylammonium 
bicarbonate in water) with trypsin (Pierce Trypsin Protease, MS Grade; Thermo Fisher Scientific, 
Waltham, MA, USA), in a ratio of 1:50 trypsin to protein, was added and mixed well at 600 rpm for 
1 min (orbital shaker). The units were incubated in a wet chamber at room temperature overnight. The 
following day the units were centrifuged for 25 min at 14’000 g, 20 °C and the resulting flow through 
was acidified with 5% TFA solution to a final concentration of 0.5% TFA in the sample. 
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2.10.4. Solid phase extraction (SPE) 
SPE columns (ISOLUTE C18 (EC) 100 mg/1 ml, Biotage, SWE) were used to desalt the peptide samples 
before LC-MS/MS analysis. The columns were primed with 2 ml ACN and subsequently washed with 
2 ml of buffer A (3% ACN, 0.1% TFA). The sample was then loaded onto the column, collected and 
loaded for a second time. After washing the SPE column again with 2 ml of buffer A, the sample was 
eluted with 1 ml of buffer B (60% ACN, 0.1% TFA) and subsequently 1 ml of ACN. The eluate was 
collected, dried under a flow of nitrogen and resuspended in MS buffer (15% ACN, 0.1% FA). 
 
2.10.5. LC-MS/MS analysis 
2.10.5.1. LC-MS/MS analysis on the TripleTOF 6600 
Peptide samples obtained from protein digestion were analyzed using LC-MS/MS. Sample separation 
was performed on a Kinetex C18 reversed phase column with particle size 2.6 μm, pore size 100 Å, 
length 30 mm and internal diameter 2.1 mm (Phenomenex, Aschaffenburg, Germany) using a Dionex 
UltiMate 3000 rapid separation LC system (RSLC) (Thermo Fisher Scientific, Waltham, MA, USA). The 
mobile phase consisted of (A) water containing 0.1% FA and (B) ACN containing 0.1% FA at a flow rate 
of 470 μl/min. 5-20 µl sample were injected. Starting conditions of 15% buffer B were maintained for 
1 min followed by a 2-step linear gradient from 15% to 50% B within 8 min and from 50% to 90% within 
1 min. An isocratic flow of 90% B was held for 1 min before the column was re-equilibrated for 1 min 
with 15% B. The column oven temperature was set to 40 °C and the autosampler was cooled to 7 °C.  
The RSLC system was coupled to a QTOF MS instrument (TripleTOF 6600; Sciex, Concord, Ontario, 
Canada) with resolving power (full width at half-maximum at 400 m/z) set to 35’000 in MS and 30’000 
in SWATH MS/MS (high-resolution mode). The Turbo V ion drive source equipped with a stainless-steel 
electrode (100 μm internal diameter) was operated with the following MS conditions: gas 1, nitrogen 
(50 psi); gas 2, nitrogen (60 psi); ion spray voltage, 5500; ion-source temperature, 450 °C; curtain gas, 
nitrogen (20 psi); and collision energy, 10 eV. The automated calibration device system (CDS) 
performed an external calibration every five samples. The MS was operated in the SWATH acquisition 
mode where one complete cycle consists of a survey scan and a Q1 isolation strategy. The survey scan 
covered a mass range of 100 to 1600 m/z with an accumulation time of 50 ms. The Q1 isolation strategy 
covered a mass range of 100-1700 m/z with a 123 Da SWATH window for Q1 isolation (overlap 1 Da). 
With every SWATH window (in total 13) collision energy was increased with approx. 7.8 eV steps from 
4.1 to 97 eV with a spread of ± 15 eV. Accumulation time was 100 ms in high-resolution mode. The 
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total cycle time was 1.4 s. All MS parameters were controlled by AnalystTF Software 1.7 (Sciex). Data 
was processed with PeakView 2.2 Software (Sciex), MasterView 1.1 (Sciex), and MultiQuant 2.1 
software (Sciex). 
2.10.5.2. LC-MS/MS analysis on the QTrap 4000 
Sample separation was performed on an Agilent Zorbax 300SB-C18 (particle size 5 µM, internal 
diameter 2.1 mm, length 150 mm) column with a 1 mm C18 OPTI-GUARD® pre-column (Optimize 
Technologies Inc., Oregon City, USA) using an Agilent 1100 liquid chromatography system. The mobile 
phase consisted of (A) water containing 0.1% FA and (B) ACN containing 0.1% FA at a flow rate of 
170 μl/min. 5-40 µl sample were injected. Starting conditions of 2% buffer B were maintained for 5 min 
followed by a 3-step linear gradient from 2% to 15% B within 5 min, from 15% to 50% within 35 min 
and from 50% to 100% within 5 min. An isocratic flow of 100% B was held for 1 min before the column 
was re-equilibrated for 2 min with 0% B. The HPLC system was coupled to a 4000 QTrap hybrid 
quadrupole linear ion trap mass spectrometer (Applied Biosystems) equipped with a Turbo V source 
and electrospray (ESI) interface. Analytes were recorded using information dependent acquisition 
(IDA). The survey scan was performed with multiple reaction monitoring (MRM) in positive mode 
(+MRM) using the following source specific parameters: gas 1, nitrogen (40 psi); gas 2, nitrogen 
(50 psi); ion spray voltage, 4500 V; ion-source temperature, 70 °C; curtain gas, nitrogen (25 psi); and 
collision gas set to high. Transitions and transition specific parameters are summarized in Table 14. 
Enhanced Product Ion (EPI) scan was performed as dependent scan under the following conditions: 
gas 1, nitrogen (40 psi); gas 2, nitrogen (50 psi); ion spray voltage, 5000 V; ion-source temperature, 
450 °C; curtain gas, nitrogen (20 psi); and collision gas set to high. MRM signals with a mass tolerance 
of 250 mDa exceeding 200 cps triggered the EPI with rolling collision energy. After three occurrences 
a target ion was excluded for 20 s.  
All MS parameters were controlled by AnalystTF Software 1.7 (Sciex, Concord, Ontario, Canada). Data 
was visualized directly in the Analyst Software and was qualitatively analyzed by hand and quantified 
with MultiQuant 2.1 software (Sciex). Expected parent ion and fragment masses were calculated 
manually or with Skyline 4.1.0.18169 software (University of Washington, USA).  
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Table 14: Technical details of the LC-MS/MS detection of CatNuc peptides 
Peptide Transition DP [V] CE [V] CXP [V] EP [V] 
Cif CatNuc +4y5 762.400 ->   573.300 70.0 36.0 15 10 
Cif CatNuc +3y14 1016.500 -> 1673.963 70.0 52.9 15 10 
Cif CatNuc +4y21 762.627 -> 1236.952 70.0 39.1 15 10 
EH3 CatNuc +4y 780.445 ->   700.600 81.0 33.0 15 10 
EH3 CatNuc +4y9 779.900 -> 1139.610 88.0 31.3 15 10 
EH3 CatNuc +4 781.000 ->   350.700 80.0 35.0 15 10 
EH3 CatNuc +3 1040.900 ->   175.300 120.0 85.0 15 10 
EH4 CatNuc +4y8 1022.492 -> 1057.600 61.0 39.0 15 10 
EH4 CatNuc +4b24 766.900 ->   930.200 100.0 15.0 15 10 
Mest CatNuc +3a1 745.219 ->     86.202 56.0 95.0 15 10 
Mest CatNuc +2a1 1117.211 ->     86.202 146.0 129.0 15 10 
Mest CatNuc +3y2 745.600 ->   338.200 68.0 24.0 15 10 
sEH CatNuc +2y15 1628.810 -> 1832.886 149.9 88.6 15 10 
sEH CatNuc +4y5 815.500 ->   711.800 100.0 35.0 15 10 
sEH CatNuc +3y15 1086.210 -> 1832.886 110.3 40.8 15 10 
mEH CatNuc +4y9 849.669 ->   978.573 93.1 33.4 15 10 
mEH CatNuc +3y12 1132.556 -> 1324.704 113.7 42.2 15 10 
mEH CatNuc +2y16 1698.331 -> 1797.935 154.9 92.5 15 10 
mEH CatNuc +3y5 1133.700 ->   567.600 100.0 65.0 15 10 
mEH CatNuc +3y22 1133.700 -> 1200.000 100.0 45.0 15 10 
mEH CatNuc +3y12 1133.700 -> 1325.500 100.0 60.0 15 10 
CE, collision energy; CXP, collision exit potential; EP, entrance potential; DP, declustering potential  
2.11. Fluorometric assay for the analysis of trypsin 
performance  
To exclude unspecific cleavage or inactivity of the used trypsin, a Foerster resonance energy transfer 
(FRET)-based assay, which was established in our group, was performed. FRET can detect protein-
protein interaction in the range of 1-10 nm. A FRET-pair consists of a donor and an acceptor 
fluorophore. The FRET-donor is excited at its specific excitation wavelength and its emission 
wavelength is the excitation wavelength of the acceptor fluorophore, which gets excited by means of 
non-radiative energy transfer. The used assay consisted of two different fusion proteins of the FRET-
pair Cerulean (donor) and Ruby (acceptor) separated by a short linker. In one protein construct the 
linker carried an ideal trypsin restriction site (RK), which was well presented on the 10 amino acids long 
linker. In the second fusion protein Cerulean and Ruby were separated by a linker missing the trypsin 
restriction site, thus impeding trypsin restriction. FRET can only occur when the donor and the acceptor 
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fluorophore are in close proximity (1-10 nm), this means that the energy transfer from Cerulean to 
Ruby is not possible anymore upon cleavage of the linker by trypsin.  
2 µg of the respective fusion protein were premixed in 200 µl of Tris-buffer (20 mM Tris, 100 mM NaCl, 
pH 7.5) in a 96-well plate. After the initial reading 1 µl of trypsin solution (0.2 mg/ml) was added and 
mixed well by shaking. The digests were immediately monitored by measuring the total emission 
spectrum from 470 to 700 nm at an excitation wavelength of 435 nm every minute for 20 min with a 
fluorescence reader (Tecan Infinite 200 Pro, gain set to 90; Tecan Group, ZH, Switzerland).  
2.12. In vitro trapping experiments 
2.12.1. EET trapping with EHs expressed in E. coli 
Purified enzymes were incubated with 5 µM of the respective EETs (11,12-EET for mEH, 14,15-EET for 
sEH) for 20 min at 37 °C. As negative control, the same amount of trapping EH was incubated for 20 min 
at 37 °C without EET. Subsequently, the proteins were in-gel digested with trypsin and analyzed using 
SWATH on the TripleTOF 6600 MS. The SWATH data of the mEH trapping approach was filtered for 
835.91519 m/z, the CatNuc peptide LGFQEFYIQGGDWGSLICTNMAQLVPSHVK (monoisotopic mass 
containing one 13C and carbamidomethyl C) and 929.97942 m/z corresponding to the 11,12-EET 
modified CatNuc peptide. In the sEH trapping experiment SWATH windows were filtered for 
815.1596 m/z which corresponds to the sEH CatNuc peptide LGLSQAVFIGHDWGGMLVWYMALFYPER, 
z = 4 (monoisotopic mass containing one 13C) and 895.2184 m/z corresponding to the mass of the 
CatNuc peptide plus the mass of 14,15-EET.  
2.12.2. EET trapping in HEK293T cells 
A 10 cm dish of HEK293T cells was transiently transfected with trapping EH (mEH HQ or sEH HQ) or the 
WT variant. Transgene expression was allowed for 24 h, subsequently fresh cell culture medium 
containing 5 µM 11,12-EET (mEH) or 14,15-EET (sEH) was added to the cell culture. After 24 h 
incubation with the substrate, additional 5 µM of the respective EET was added to the cell culture 
medium. The cells were harvested 3 h later, homogenized and the proteins were in-gel digested with 
trypsin and analyzed using SWATH on the TripleTOF 6600 MS. The SWATH data was filtered for the 
same m/z as in 2.12.1. 
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2.13. Animal experiments 
Two different mouse strains were used, C57BL/6J WT originally purchased from The Jackson 
Laboratory (Bar Harbor, ME, USA) and C57BL/6J mEH KO mice (Miyata et al., 1999) kindly provided by 
Dr. F. J. Gonzalez, NH Bethesda, MD, USA. Colonies were maintained by the Laboratory Animal Service 
Center (LASC) of the University of Zurich. Animals were kept in a 12 h light/ dark cycle and had access 
to food and water ad libitum. All animal experiments were approved by the Swiss cantonal veterinary 
office (Zurich, license number 005/2016).  
 
2.13.1. In vivo trapping 
100 µl virus suspension (1-4 x 1012 vg/ml) was injected into the tail vein of 6-11 week old female mice 
and animals were sacrificed 14 days later if not indicated otherwise. Brain, liver, heart, kidneys, lung, 
stomach and a piece of hamstring muscle was excised and frozen at -80 °C for analysis. Mice used for 
IHC staining of tissue sections were deeply anesthetized and transcardially perfused with PBS (pH 7.4) 
and post-fixed for 2 h with 4% paraformaldehyde (PFA) on ice and subsequently incubated in PBS 
containing 30% sucrose overnight at 4 °C for cryoprotection.  
2.13.2. GFP fluorescence in tissue sections 
Cryoprotected tissue was sectioned with a Hyrax S30 sliding microtome (Zeiss, Oberkochen, Germany) 
at 40 μm. After washing with PBS 274 mM NaCl three times for 10 min, the sections were mounted on 
Superfrost Plus glass slides (Thermo Fisher Scientific, Waltham, MA, USA). Tile scans of fluorescent 
images were acquired on a Zeiss Apotome.2 microscope. Free-floating sections were stored in 
antifreeze solution (50 mM PB, 30% glucose (m/v), 30% ethylene glycol (v/v), 6.7 mM sodium azide, 
pH 7.4) at -20 °C. 
2.13.3. IHC staining of liver and brain sections 
Cryoprotected tissue was sectioned with a Hyrax S30 sliding microtome at 40 μm. Free-floating 
sections were washed three times for 10 min with 50% ethanol, twice with PBS with 274 mM NaCl and 
were then incubated in 0.3% Triton X-100, 10% normal donkey serum (NDS) in PBS with 274 mM NaCl 
for 1 h. Sections were incubated overnight at 4 °C with the primary antibody (anti-His-tag or anti-
human mEH, 1:3000) in NDS blocking buffer. The next day, sections were extensively rinsed with PBS 
and incubated with the secondary antibody cyanine 3 (Cy3) (1:700) and DAPI (1:10’000) in 0.3% Triton 
X-100, 10% NDS in PBS with 274 mM NaCl for 45 min at room temperature. After washing with PBS 
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274 mM NaCl three times for 10 min the sections were mounted on Superfrost Plus glass slides 
(Thermo Fisher Scientific, Waltham, MA, USA). Tile scans of fluorescent images were acquired on a 
Zeiss Apotome.2 microscope. Free-floating sections were stored in antifreeze solution (50 mM PB, 30% 
glucose (m/v), 30% ethylene glycol (v/v), 6.7 mM sodium azide, pH 7.4) at -20 °C. 
2.13.4. Behavioral experiments 
Animals were placed onto a rotarod setup (IITC, Woodland Hills, CA) and the speed was linearly 
accelerated from 4 to 40 rpm over a time period of 300 s. Two training sessions were performed before 
the latency to fall was measured in 5-6 test sessions per mouse. An interval of at least 10 min during 
which the mouse was placed back into its home cage was allowed between consecutive test sessions. 
2.14. Enzyme assay 
EETs, 17,18-EpETE, 19,20-EpDPA, leukotoxin and isoleukotoxin were obtained from Cayman Chemical 
(Ann Arbor, MI, USA) and hepoxilin A3 and B3 from Biomol (Hamburg, Germany). ESA was synthesized 
as described in (Muller et al., 1997). Typically, 100 ng purified enzyme was incubated with different 
substrate concentrations in 20 mM Tris 0.1 M NaCl for 10 min at 37 °C in a final volume of 20 µl. The 
reaction was stopped by the addition of 30 µl acetonitrile and thorough vortexing. To reduce the 
percentage of organic solvent interfering with the chromatography, 50 µl water was added.  
Product formation was quantified by LC-MS/MS. Sample separation was performed on a Gemini XS-
C18 reversed phase column (2.1 μm x 150 mm, 5 μm pore size, Phenomenex, USA) with a 
corresponding 1 mm C18 OPTI-GUARD® pre-column (Optimize Technologies Inc., Oregon City, USA) 
using an Agilent 1100 liquid chromatography system. Mobile phases consisted of (A) water containing 
0.0125% NH4OH and (B) 95% acetonitrile 5% methanol containing 0.0125% NH4OH. Analytes were 
eluted with a three-step linear gradient from 16% B to 26% B in 2 min, 26% B to 36% B in 5 min and 
36% B to 95% B in 0.7 min, at a flow rate of 350 μl/min. Hepoxilin A3 and B3 were analyzed under the 
same conditions except the second linear gradient from 26% B to 36% B which was in 16 min instead 
of 5 min.  
The HPLC system was coupled to a 4000 QTRAP hybrid quadrupole linear ion trap mass spectrometer 
(AB Sciex) equipped with a TurboV source and electrospray (ESI) interface. Analytes were recorded 
using multiple reaction monitoring (MRM) in negative mode (-MRM) using the following source specific 
parameters: gas 1, nitrogen (50 psi); gas 2, nitrogen (50 psi); ion spray voltage, -3800 V; ion-source 
temperature, 550 °C; curtain gas, nitrogen (30 psi); and collision gas set to medium. The transition and 
the respective parameters are summarized in Table 16. Quantification was done using MultiQuant 
software (Sciex) and comparison to synthetic standards. 
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Table 15: Technical details of the LC-MS/MS detection of epoxides and corresponding diols 
Compound Transition DP [V] CE [V] CXP [V] EP [V] 
8,9-EET 319.171 -> 68.900 -70 -30 -1 -10 
11,12-EET 319.200 -> 167.100 -65 -18 -13 -10 
14,15-EET 319.186 -> 218.800 -70 -16 -13 -10 
8,9-DHET 337.209 -> 126.800 -70 -28 -7 -10 
11,12-DHET 337.198 -> 166.800 -70 -26 -11 -10 
14,15-DHET 337.193 -> 206.900 -70 -26 -15 -10 
Hepoxilin A3 335.156 -> 273.300 -80 -20 -9 -10 
Trioxilin A3 353.159 -> 126.900 -55 -30 -7 -10 
Hepoxilin B3 335.156 -> 317.200 -80 -18 -3 -10 
Trioxilin B3 353.191 -> 194.900 -55 -24 -13 -10 
Leukotoxin 295.200 -> 171.100 -55 -17 -10 -10 
Leukotoxin-diol 313.200 -> 201.100 -60 -23 -10 -10 
Isoleukotoxin 295.200 -> 195.100 -55 -17 -10 -10 
Isoleukotoxin-diol 313.200 -> 183.100 -60 -23 -10 -10 
Epoxystearic acid 297.208 -> 279.200 -80 -28 -11 -10 
Epoxystearic acid 2 297.208 -> 171.000 -100 -28 -47 -10 
Epoxystearic acid diol 315.083 -> 140.800 -85 -38 -11 -10 
CE, collision energy; CXP, collision exit potential; EP, entrance potential; DP, declustering potential  
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3. RESULTS  
3.1. Deciphering the (patho)physiologic role of epoxide 
hydrolases by ex vivo cartography of their substrate landscape  
3.1.1. Strategy  
The goal of this project was to identify physiologically relevant substrates of EHs. With the trapping 
mutant approach, we expressed point-mutated versions of EHs in vivo in mice which can bind but not 
hydrolyze their substrates. These enzymes trap their preferred in vivo substrate and were extracted 
and analyzed by mass spectrometry. For this, the enriched proteins were digested with trypsin and the 
peptides containing the catalytic nucleophile (CatNuc) with the bound substrates were analyzed. An 
increase in mass of the peptide reflects the mass of the substrate, which can be used to identify it. 
High transgene expression in vivo and a good analytical method are crucial for success. Figure 15 
summarizes our strategy to express the trapping EHs in the tissues of interest and to identify bound 
substrates using LC-MS/MS, which is explained in the following: 
The first step (left row of Figure 15) was the production of enough protein of interest to create methods 
on our in-house QTrap LC-MS/MS. The pRSET vector was used which allowed high transgene 
expression upon arabinose induction in E. coli BL21-AI. Since we did not require correctly folded 
enzymes to establish the methods, transgene expression was highly induced leading to the formation 
of inclusion bodies which could be separated from the soluble fraction by centrifugation. The 
solubilized and digested inclusion bodies were used to create and optimize the QTrap LC-MS/MS 
methods for the unmodified CatNuc peptides.  
Because the pRSET is small, this plasmid was also used for site-directed mutagenesis PCR to obtain the 
trapping mutants (top left of Figure 15). We created three different mutants for every EH. In the 
trapping mutant HQ, the catalytic His (H) was replaced by Gln (Q) which is of similar size. In case of 
expression problems due to this mutation, we also created the HA trapping mutant, replacing the His 
(H) with Ala (A) which possesses the simplest side chain. In the third mutant, DA, we replaced the 
CatNuc Asp (D) with Ala (A) leading to an enzyme unable to covalently bind the substrate, serving as 
negative control. 
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Figure 15: Initial strategy to trap and analyze substrates in vivo with EH trapping enzymes. Detailed 
description in the text. The red numbers indicate the respective chapters in the results section.  
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For the main experiment, the trapping and identification of in vivo substrates in mice (right row of 
Figure 15), high transgene expression in the target organs was required. We chose AAV as a viral vector 
for transgene delivery due to its long-lasting high transgene expression, non-pathogenicity, low 
immunogenicity, and the ability to transduce dividing and non-dividing cells (Kaplitt et al., 1994; Lo et 
al., 1999; Mastakov et al., 2002).  
To produce AAVs, the transgenes were cloned into the pAM-CAG vector. To increase transgene 
translation efficacy, the Kozak consensus sequence (GCCGCC) was added upstream of the start codon 
of the transgene. This sequence is present in eukaryotic mRNA and is important for the initiation of 
translation (Kozak, 1984). A scaffold attachment region (SAR), which was shown to increase retroviral 
transgene expression in primary human lymphocytes, was included in the pAM-CAG vector and the 
effect on transgene expression was tested. The virus serotype determines the infectivity of the virus 
towards different tissues and cell types. Our goal was to achieve high expression in various tissues after 
tail vein injection of the viral solution with highest priority for liver, brain, lung, kidney and heart. The 
brain, being the most difficult organ to reach after i.v. injection, could also be targeted by direct 
injection through the skull. The most suitable serotype was elected in preliminarily tests. 
After expression in mice, the trapping enzymes were enriched using His-tag purification, digested with 
trypsin and analyzed for modifications of the CatNuc peptide with a substrate. By measuring the exact 
mass of the bound substrate with high resolution mass spectrometry, the chemical formula can be 
derived. If not yet determinable from the chemical formula, the final structure of these substrates can 
be obtained by release of the substrate from the protein and further analysis.  
3.1.2. Cloning 
Six pRSET constructs containing the wild type EHs of interest were generated using the primers 
described in Table 2 and the indicated restriction sites. Sanger sequencing confirmed correct insertion 
of the genes in frame with the N-terminal His-tag. Two additional pRSET constructs were generated 
which contain N-terminally truncated EH3 and EH4 to improve the otherwise difficult expression of 
these two enzymes in E. coli (Decker et al., 2012). The two different trapping mutants and the negative 
control were generated by site-directed mutagenesis PCR of the pRSET constructs using the primers 
listed in Table 3. If possible, an additional silent mutation creating or removing an endonuclease 
restriction site was inserted to test successful mutagenesis. Sequences were confirmed by Sanger 
sequencing.  
The pAM-CAG constructs of the wild type and the three mutants of every EH were generated using the 
primers listed in Table 4. The respective forward primers were used to insert the Kozak consensus 
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sequence GCCGCC before the start codon. Sanger sequencing confirmed the correct sequences in 
frame with the C-terminal His-tag. 
3.1.3. Protein expression 
To obtain inclusion bodies of the six EHs for MS method development, the enzymes were expressed in 
E. coli BL21-AI using the pRSET vector constructs. Expression was induced with 1 µM arabinose and 
performed over night at 30 °C. After lysis of the bacteria with French press, the sample was centrifuged 
(4000 g, 15 min, 4 °C) to separate inclusion bodies from the soluble protein and analyzed by SDS-PAGE 
(Figure 16).  
 
Figure 16: SDS-PAGE analysis of inclusion bodies of the six different EHs expressed in E. coli. Inclusion 
bodies were separated from soluble protein by centrifugation and an equivalent of 600 µl bacterial 
culture was analyzed with SDS-PAGE and stained with Coomassie. Protein size was compared to the 
molecular weight standard, indicated with arrows. For EH3 and EH4, the truncated proteins missing 
the N-terminal membrane anchor were expressed.  
Proteins with the correct size (arrows) were obtained in adequate purity. Only the analysis of EH4k 
inclusion bodies showed another prominent protein of 70-100 kDa size which is most likely an EH4k 
dimer generated during sample preparation. For EH3 and EH4, the truncated proteins EH3k and EH4k 
which still contain the relevant sequence parts for MS analysis were expressed to increase protein 
expression yield.  
3.1.4. Virus production 
AAV were used to mediate long-lasting and high transgene expression in mice after virus injection into 
the tail vein. To maximize transgene expression in the target organs liver, brain, kidney, heart, stomach, 
and lung, transcription and translation were optimized, and different serotype were tested which is 
described in detail in the doctoral thesis of Bettina Hew (Hew, 2019). The results are summarized in 
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the following section. Viruses were produced ourselves (description of the method available in the 
doctoral thesis of Bettina Hew (Hew, 2019)) or by the Viral Vector Facility of the University of Zurich.   
An SAR element, which was reported to increase retroviral transgene expression in primary human 
lymphocytes (Agarwal et al., 1998), was included in the pAM-CAG vector but did not increase transgene 
expression when transfected into cultured cells and was therefore omitted. It was futher shown that 
an 11 bp deletion in the 3’-ITR of the pAM-CAG constructs did not lower the titer of the produced virus 
nor impair the infectivity of the viral paricles towards U87 glioma cells in cell culture.   
Depending on the serotype, a virus can infect different cells and tissues. To match the native expression 
pattern of the different EHs, the two serotypes rh10 and PHP.B were tested with a reporter virus 
mediating GFP expression. With serotype rh10, western blot analysis showed highest GFP expression 
in liver, followed by the heart, stomach and kidneys but no expression in the brain. Serotype PHP.B 
resulted highest GFP expression in liver and bain. Detectable transgene expression in the muscle and 
lung was not achieved with either of the two serotypes. The experiments showed furhtermore that 
first detectable transgene expression occured after three days in the liver and after seven days in the 
brain and that highest transgene expression was achieved 14 days post-infection. Analysis of native 
GFP fluorescence in brain (serotype PHP.B) and liver (serotype rh10) sections showed wide expression 
throughout these organs. Judged from the shape of the labelled cells, predominantely neurones were 
targeted in the brain with a extraordonary high expression in the CA2 region of the hippocampus which 
is in line with the reported expression pattern (Deverman et al., 2016). In the liver, the virus mediated 
GFP expression in hepatocytes.  
3.1.5. LC-MS/MS method development 
The development of a QTrap LC-MS/MS method for a peptide modified with an unknown substrate is 
challenging because the mass as well as the retention time are unknown. The modified peptide needs 
to be identified solely by its MS/MS fragments which are predictable from the peptide sequence. The 
properties of our peptides of interest are summarized in Table 16. 
 
Table 16: Properties of the six CatNuc peptides. 
Name Sequence Sum formula Mass [Da] m/z [Da] 
mEH  LGFQEFYIQGGDWGSLIC[CAM]TNMAQLVPSHVK C154H231N39O44S2 3396.655 850.172 
sEH  LGLSQAVFIGHDWGGMLVWYMALFYPER C156H222N36O37S2 3257.611 815.411 
EH3 C[CAM]ILVAHDWGALLAWHFSIYYPSLVER C149H214N36O36S1 3116.578 780.152 
EH4 C[CAM]VLIGHDWGGMIAWLIAIC[CAM]YPEMVMK C140H215N33O34S5 3064.478 767.127 
Cif  QFSPDRPFDLVAHDIGIWNTYPMVVK C142H209N35O38S1 3045.525 762.389 
MEST INLLSHDYGDIVAQELLYR C101H158N26O31 2232.162 745.062 
D, CatNuc and site of modification; Mass, mass of the most abundant isotope, z = 4 except MEST z = 3 
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MRM EPI methods were developed on the in-house QTrap 4000 for the unmodified CatNuc peptides 
for which both parent mass and fragment masses are known. Recombinantly expressed inclusion 
bodies were solubilized with 8 M urea, in-solution digested with trypsin or chymotrypsin and cleaned 
up by SPE. MS method development was done by direct peptide infusion (15 µl/min). To ensure that 
the correct parent mass and typical fragment masses were used for optimization, tuning was done 
manually. Methods could be developed for the Cif CatNuc peptide digested with trypsin or 
chymotrypsin (peptide concentration 66 ng/µl) and the MEST CatNuc peptide digested with trypsin 
(peptide concentration 2.5 ng/µl). Figure 17 shows representative chromatograms of the Cif CatNuc 
which eluted with a retention time of 40.74 min (Figure 17A) and produced typical Cif CatNuc peptide 
fragments (Figure 17B).  
 
Figure 17: MS spectrum (A) and MS/MS spectrum (B) of Cif CatNuc peptide. Cif inclusion bodies were 
digested with trypsin and analyzed on a QTrap 4000 with MRM EPI data acquisition. The parent ion 
with 762.403+ m/z eluted with a retention time of 40.74 min and the MS/MS spectrum showed seven 
typical Cif CatNuc peptide fragments. 
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The method development for the CatNuc peptides of the other enzymes was not successful. No parent 
ion with the correct mass could be detected. Furthermore, protein digestion with the proteases GluC 
or chymotrypsin, which cleave the peptide bond after Glu and Asp or aromatic amino acids, 
respectively, was not successful.  
To verify that the peptides were not lost during sample clean-up using SPE, we determined the protein 
concentration after every step of sample preparation using the Lowry protein assay. EH3k and Cif 
inclusion bodies were digested with trypsin and protein concentrations were measured before the 
addition of trypsin, after the digestion, after the elution from the SPE column and after solvent 
evaporation and reconstitution of the sample. Furthermore, the flow-through during sample loading 
on the SPE column and during washing was analyzed (Figure 18).  
  
Figure 18: Peptide recovery during sample preparation with in-solution digestion and SPE. Protein 
concentration was determined in triplicates after every step of sample preparation of Cif and EH3k 
inclusion bodies using Lowry protein assay. Calibration curves were determined with matching buffer 
compositions. The error bars show the standard deviation of three separate determinations. 
For both Cif and EH3k, the concentrations before digestion and after reconstitution were comparable, 
indicating good general recovery of the peptides during SPE. The collected fractions during loading and 
washing resulted in signals summing up to 25% of the initial sample. This indicates a moderate loss of 
peptides during these steps. However, the signal might also be caused by other substances present in 
the sample which interfere with the Lowry assay. Taken together, peptide recovery is high, yet we 
cannot exclude that we lose individual peptides during SPE. 
So far, we have only focused on the analysis of the CatNuc peptides which are not present in the 
publicly available trypsin peptide libraries (except for MEST and mEH) indicating that they are difficult 
to detect. Other peptides that are generated by tryptic digestion of EHs and may possess better 
properties can be included in the LC-MS/MS method to confirm the presence of the protein. With 
methods created in silico using the Skyline Software, we were able to detect other peptides of mEH, 
sEH, EH3k, and Cif that were obtained when inclusion bodies were digested with trypsin. Figure 19 
shows an example chromatogram of EH3k digested with trypsin.  
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Figure 19: Total ion chromatogram of EH3k digested with trypsin. Three peptides of EH3k were 
detected whereas the CatNuc peptide was not found. 
In contrast to the successfully detected Cif and MEST CatNuc peptides, the mEH, EH3 and EH4 CatNuc 
peptides contain one or more cysteines. Cysteines can form disulfide bridges which can affect the mass 
of the respective peptides or the digestion. To detect these peptides, the cysteine residues were 
reduced and alkylated with dithiothreitol and iodoacetamide (Sechi & Chait, 1998). The resulting 
carbamidomethyl cysteine gives a mass increase of 57.0215 Da (H3C2NO). With the new digestion 
protocol, we were able to detect the CatNuc peptide of EH3. At the same time, the intensity of the 
peptide SHYMFLFQLPWLPEK was reduced (Figure 20). 
To develop methods for mEH, sEH and EH4 CatNuc peptides, pure synthetic peptides were ordered 
from JPT Technologies (Berlin, Germany). With the synthetic peptides, MRM EPI methods for the 
missing CatNuc peptides were developed and the existing methods were optimized.  
In order to detect substrate modified CatNuc peptides from mouse tissue, we needed a method where 
the detection was triggered based on a fragment alone and not based on an MRM transition because 
the parent ion mass was unknown. In the first approach, approximately 100 MRM transitions were 
added to the method with the identical fragment ion but increasing parent ion masses. Like this, 
peptides with higher parent masses that produce the same specific fragment trigger EPI acquisition. 
We chose to increase the parent mass by steps of 0.3 Da. As all peptides except MEST are charged with 
z = 4, every step represents an increase of 1.2 Da and a range of approximately 100 Da could be 
covered per run. The second approach was the use of the precursor ion scan mode where the Q3 
quadrupole is fixed at a specific m/z and the Q1 scans a mass range. In our case, the Q3 mass was fixed 
to a typical CatNuc peptide fragment which was known and the Q1 scan identified all masses of 
molecules that produced the specified fragment.  
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Figure 20: Detection of the CatNuc peptide and other peptides of EH3k reduced and alkylated prior 
to trypsin digestion and analyzed with MRM EPI data acquisition. (A) shows the total ion 
chromatogram (TIC) of four precursor ions including the CatNuc peptide of EH3k. The identity of the 
CatNuc peptide was confirmed with (B) the MS/MS spectrum triggered at retention time = 42.44 min 
which shows a series of expected y- and b-fragments. 
With the new methods to identify substrate modified peptides we analyzed in-gel digested liver tissue 
from AAV-PHP.B sEH HQ infected mice. The presence of sEH in the sample was confirmed by the 
detection of other specific sEH peptides, while the unmodified CatNuc peptide was not detected. In 
the adduct mass range of 240-375 Da, which contains the typical known sEH substrates, we identified 
five peptide-substrate complex masses which triggered EPI acquisition. The hit with the best fragment 
spectrum is shown in Figure 21. The peptide eluted at 63.71 min and produced three typical sEH 
CatNuc peptide fragment ions in the MS/MS. However, the same molecule was also found in the 
negative control, indicating that the result was a false positive. This was also the case for the other 
identified parent masses. In all cases, the acquisition was triggered by the y5 fragment 711.800 m/z, 
which was most intense in the analysis of the unmodified sEH CatNuc peptide. However, this fragment 
was not present in the obtained fragment spectrum, indicating that the triggering signal was low. To 
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reduce false positive results, the threshold for the signal that triggers acquisition could be increased 
with the risk of missing peptide-substrate amounts below the threshold. Another approach is to use 
high resolution mass spectrometry, what we finally did. 
 
 
Figure 21: Best hit for a substrate modified CatNuc peptide of sEH HQ expressed in mouse liver. sEH 
HQ was in-gel digested with trypsin and analyzed with MRM EPI. (A) The extracted ion chromatogram 
(XIC) shows the identified parent mass of 884.600 m/z putatively representing a peptide-substrate 
complex which eluted at 63.71 min and (B) produced three typical sEH CatNuc peptide fragment ions 
in the MS/MS spectrum triggered at 63.9 min.  
Via our collaborators at the Institute of Forensic Medicine (IRM Zurich) we could get access to a 
TripleTOF 6600. This MS offers high resolution and can be coupled to SWATH technology. High 
resolution MS offers the advantage that the isotope pattern of multiply charged analytes can be 
resolved and allows conclusions on the molecular formula. SWATH is suited for our problem because 
parent and fragment masses are measured all the time, recording data for every molecule that is 
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present above the detection limit. Data acquired with SWATH contain information about all molecules 
with all possible charge and isotope variants and can be analyzed multiple times, for example when 
more information about the peptide or the substrate has been gained, without repeating the 
measurement. The drawback of the SWATH technology is lower sensitivity compared to a targeted 
approach. However, direct comparison of dilution series of the synthetic peptides analyzed with the 
TripleTOF 6600 and the QTrap 4000 showed similar or even better performance with the TripleTOF 
6600. Especially, the fragmentation patterns obtained on the TripleTOF were better in the way that a 
higher number and more exact fragments of our peptides were detected, except for Cif. Additionally, 
the TripleTOF measurements showed less background. Taking these advantages into account, we 
decided to measure the in vivo trapping tissue samples with the TripleTOF 6600 system at the IRM 
Zurich. The SWATH method used consisted of 123 Da windows covering a precursor ion mass range 
from 100-1700 Da.  
3.1.6. TripleTOF method characterization 
In this project we aim to identify the mass of a bound substrate but exact quantification is not required. 
Therefore, the precision, linearity and limit of detection of the method were characterized but no 
further validation was required.  
The TripleTOF 6600 method was tested with 100 ng of each synthetic peptide. The six peptides could 
be chromatographically separated from each other and all were eluted in the second third of the 
LC-program (Figure 22). This centered and rather narrow elution profile is suitable for the trapping 
experiments because binding of a substrate might change the retention time of the peptide in either 
direction in an unpredictable manner.  
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Figure 22: MS spectra of the six synthetic peptides of interest. 100 ng of each peptide were injected 
and analyzed on the TripleTOF 6600 using SWATH. Data extraction was done with PeakView 2.2 
software.  
The MEST peptide resulted in the highest peak intensity which was expected as it has optimal length 
and it was present in peptide libraries (PeptideAtlas) indicating good properties for LC-MS/MS 
detection. Figure 23 shows the MS and MS/MS spectra of each synthetic peptide. In the MS/MS 
spectra, sEH and MEST peptides showed a series of y- and/or b-fragments with high intensities whereas 
for mEH, EH3 and EH4 less typical fragments were detected. Cif resulted in only one predicted 
fragment, the y5-fragment. When Cif was analyzed on the QTrap 4000, more fragments were detected 
(Figure 17) probably due to peptide specific parameter optimization. However, one specific Cif 
fragment was enough to identify the modified peptide and further analysis could be performed on the 
QTrap 4000. The MS spectra in Figure 23 show multiple peaks for sEH, EH3 and Cif that are not present 
in Figure 22. The graphs were obtained from different experiments but the additional peaks are most 
likely due to differences in the data analysis procedure. If the precursor mass is known as was the case 
here, the MS spectrum is filtered with the PeakView 2.2 software for a certain mass of interest. The 
filter specificity can be increased by decreasing the tolerated error which can eliminate additional 
peaks.  
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Figure 23: MS and MS/MS spectra for the synthetic CatNuc peptides. 100 ng of each peptide were 
injected and analyzed on the TripleTOF 6600 using SWATH. Data extraction was done with PeakView 
2.2 software.  
The precision of the method was determined by repetitive measurements of the identical sample 
containing 10 ng/µl of each synthetic peptide. The coefficients of variation (CV) are given in Table 17, 
calculated from six injections of the same sample. 
 
Table 17: Average AUC, standard deviation and coefficients of variation of indicated peptides. 
 Average AUC SD  CV [%] 
MEST 113900    2408     2.11 
sEH 24411  3049   12.49 
Cif 9207  739     8.03 
mEH 5916  236     3.99 
EH3 13925  1758   12.62 
EH4  13918  499     3.59 
 
The limit of detection and linearity of the method were tested with a 1:3 dilution series of the synthetic 
peptide mix. The relation between area under the curve (AUC) and the amount of injected peptide was 
plotted (Figure 24). While the graphs of mEH, EH3 and MEST displayed good linearity, sEH, EH4 and Cif 
did not. The limit of detection was 11 ng for all CatNuc peptides except for MEST, which had a limit of 
detection of 3 ng.  
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Figure 24: Linear regression of a dilution series of the synthetic CatNuc peptides. A 1:3 dilution series 
of a synthetic peptide mix (100 ng/µl of each synthetic peptide) was measured with the TripleTOF 6600 
using SWATH. Data extraction and quantification was done with the PeakView 2.2 software.  
3.1.7. Viral expression of trapping EHs in mice 
For mEH, sEH, EH4 and MEST which are naturally expressed in the brain and in peripheral organs, 
viruses with both serotypes, PHP.B targeting the brain and rh10 targeting peripheral organs, were 
used. For Cif and EH3 expression, only the serotype rh10 was required as the target organs are the 
lung for Cif and the stomach for EH3. The performed virus injections are summarized in Table 18. 100 µl 
virus solution corresponding to 1-4 x 1012 vg/ml were injected into the tail vein of the animals. After 
14 days, the mice were euthanized, and the tissues of interest were snap frozen and stored at -80 °C. 
For IHC analysis, animals were perfused. Unexpectedly, mice injected with the virus AAV-PHP.B mEH 
HQ developed a phenotype described in chapter 3.1.10 and had to be euthanized 2-3 days earlier than 
planned. To study this phenotype, more mice including mEH KO mice were injected and a second virus 
preparation as well as a virus which mediates the expression of wild type mEH were used. 
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Table 18: Virus injections in female C57BL/6J WT and C57BL/6J mEH KO mice. 
Virus  Number of mice 
AAV-PHP.B sEH HQ  7 WT 
AAV-rh10 sEH HQ  4 WT 
AAV-PHP.B mEH HQ*  7 WT + 2 mEH KO 
AAV-rh10 mEH HQ  2 WT 
AAV-PHP.B mEH WT  1 WT + 2 mEH KO 
AAV-rh10 EH3 HQ  5 WT 
AAV-PHP.B EH4 HQ  6 WT 
AAV-PHP.B MEST HQ  6 WT 
AAV-rh10 Cif HQ  2 WT 
*  Two different AAV-PHP.B mEH HQ virus preparations were uses for these injections. 
 
The analysis of the mouse tissue by WB and IHC is described in detail in the doctoral thesis of Bettina 
Hew (Hew, 2019). The following section summarizes the results relevant for further LC-MS/MS 
analysis.  
The preliminary virus expression experiments with the GFP reporter viruses showed highest transgene 
expression in the brain and in the liver (Hew, 2019), therefore analysis was focused on these two 
organs even though they were not of primary interest for Cif and EH3.  
Manual IMAC using 1 ml HiTrap FF columns was performed to enrich the virally expressed trapping EHs 
from liver and brain tissue. Western blot analysis of the obtained protein solutions confirmed the 
presence of mEH, sEH, EH4, MEST and Cif in the liver, and mEH, sEH, and EH4 in the brain (Figure 25). 
 
Figure 25: Western blot of trapping EHs enriched from liver and brain tissue by manual IMAC. 
Enriched protein from an equivalent of 5 mg tissue was analyzed. Arrows indicate the proteins of 
expected size. No signal was detected for EH3 in the liver and MEST in the brain. Adapted from Bettina 
Hew, ETH Diss. No. 25662, (Hew, 2019). 
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The amounts of protein virally expressed in the mouse tissue were estimated to 100-200 ng/mg tissue 
sEH HQ, 50-100 ng/mg tissue mEH HQ, 1-5 ng/mg liver tissue MEST HQ and 0.1-0.5 ng/mg tissue EH4 
HQ and Cif HQ.  
Transgene expression was further characterized by IHC which is discussed in detail in the doctoral 
thesis of Bettina Hew. Judging from the shape of the labelled cells, AAV mediated mEH HQ expression 
primarily in hepatocytes in the liver and neurons in the brain (Hew, 2019).  
3.1.8. Mass spectrometric analysis of trapped substrates 
For mass spectrometric analysis, the expressed trapping EHs were enriched with IMAC of 200 mg liver 
or brain tissue and digested using FASP. This resulted in the digestion of approximately 30 µg sEH HQ 
and 15 µg mEH HQ and injection of 250 ng sEH HQ CatNuc peptide and 125 ng mEH HQ CatNuc peptide 
into the MS, assuming efficient sample preparation (1/6 of the digest was injected and the CatNuc 
peptide is approximately 1/20 of the protein). With a detection limit of 11 ng, these amounts should 
be detectable even if some sample is lost during preparation. For the EH4, Cif and MEST trapping 
mutants that showed low tissue expression (Figure 25), amounts of approximately 0.5 ng EH4 HQ and 
Cif HQ CatNuc peptide and 10 ng MEST HQ CatNuc peptide could be injected into the MS, which 
suggests that the only peptide above the detection limit is the MEST CatNuc but not the CatNuc 
peptides of EH4 and Cif. 
The first step of data analysis was to confirm the presence of the EHs in the sample by the identification 
of other peptides that were specific for the respective trapping EH. Presence was confirmed with two 
to six peptides of the trapping mEH, sEH, MEST and Cif in the liver and trapping mEH and sEH in the 
brain sample. EH3 and EH4 could not be detected in the mouse tissue. EH sequences showing all 
peptides separated by dots are listed below. The detected peptides are highlighted in bold and 
underlined. The CatNuc is marked with a star. 
 
Sequence of trapping sEH 
MTLR.AAVFDLDGVLALPAVFGVLGR.TEEALALPR.GLLNDAFQK.GGPEGATTR.LMK.GEITLSQWIPLMEENCR.
K.CSETAK.VCLPK.NFSIK.EIFDK.AISAR.K.INRPMLQAALMLR.K.K.GFTTAILTNTWLDDR.AER.DGLAQLMCELK.
MHFDFLIESCQVGMVKPEPQIYK.FLLDTLK.ASPSEVVFLDDIGANLKPAR.DLGMVTILVQDTDTALK.ELEK.VTGI
QLLNTPAPLPTSCNPSDMSHGYVTVKPR.VR.LHFVELGSGPAVCLCHGFPESWYSWR.YQIPALAQAGYR.VLAM
DMKGYGESSAPPEIEEYCMEVLCKEMVTFLDK.LGLSQAVFIGHD*WGGMLVWYMALFYPER.VR.AVASLNTPFIP
ANPNMSPLESIK.ANPVFDYQLYFQEPGVAEAELEQNLSR.TFK.SLFR.ASDESVLSMHK.VCEAGGLFVNSPEEPSLS
R.MVTEEEIQFYVQQFK.K.SGFR.GPLNWYR.NMERNWK.WACK.SLGR.K.ILIPALMVTAEK.DFVLVPQMSQHM
EDWIPHLK.R.GHIEDCGQWTQMDKPTEVNQILIK.WLDSDAR.NPPVVSK.MASNR.EHHHHHHR.E 
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Sequence of trapping mEH 
MWLEILLTSVLGFAIYWFISR.DK.EETLPLEDGWWGPGTR.SAAR.EDDSIRPFK.VETSDEEIHDLHQR.IDK.FR.FTP
PLEDSCFHYGFNSNYLK.K.VISYWR.NEFDWK.K.QVEILNR.YPHFK.TK.IEGLDIHFIHVKPPQLPAGHTPKPLLMVH
GWPGSFYEFYK.IIPLLTDPK.NHGLSDEHVFEVICPSIPGYGFSEASSK.K.GFNSVATAR.IFYKLMLR.LGFQEFYIQG
GD*WGSLICTNMAQLVPSHVK.GLHLNMALVLSNFSTLTLLLGQR.FGR.FLGLTER.DVELLYPVK.EK.VFYSLMR.E
SGYMHIQCTKPDTVGSALNDSPVGLAAYILEK.FSTWTNTEFR.YLEDGGLER.K.FSLDDLLTNVMLYWTTGTIISS
QR.FYK.ENLGQGWMTQK.HER.MK.VYVPTGFSAFPFELLHTPEK.WVR.FK.YPK.LISYSYMVR.GGQFAAFEEPEL
LAQDIR.K.FLSVLER.QASNR.EHHHHHHR.E 
 
Sequence of trapping MEST 
MVR.R.DR.LR.R.MR.EWWVQVGLLAVPLLAAYLHIPPPQLSPALHSWK.SSGK.FFTYK.GLR.IFYQDSVGVVGSPEI
VVLLHGFPTSSYDWYK.IWEGLTLR.FHR.VIALDFLGFGFSDKPRPHHYSIFEQASIVEALLR.HLGLQNR.R.INLLSHD
*YGDIVAQELLYR.YK.QNR.SGR.LTIK.SLCLSNGGIFPETHRPLLLQK.LLK.DGGVLSPILTR.LMNFFVFSR.GLTPVF
GPYTRPSESELWDMWAGIR.NNDGNLVIDSLLQYINQR.K.K.FR.R.R.WVGALASVTIPIHFIYGPLDPVNPYPEFLEL
YR.K.TLPR.STVSILDDHISQYPQLEDPMGFLNAYMGFINSFASNR.EHHHHHHR.E 
 
Sequence of trapping Cif 
MVLDR.LCR.GLLAGIALTFSLGGFAAEEFPVPNGFESAYR.EVDGVK.LHYVK.GGQGPLVMLVHGFGQTWYEWHQ
LMPELAK.R.FTVIAPDLPGLGQSEPPK.TGYSGEQVAVYLHK.LAR.QFSPDRPFD*LVAHDIGIWNTYPMVVK.NQ
ADIAR.LVYMEAPIPDAR.IYR.FPAFTAQGESLVWHFSFFAADDR.LAETLIAGK.ER.FFLEHFIK.SHSSNTEVFSER.LL
DLYAR.SYAKPHSLNASFEYYR.ALNESVR.QNAELAK.TR.LQMPTMTLAGGGHGGMGTFQLEQMK.AYADDVEG
HVLPGCGQWLPEECAAPMNR.LVIDFLSR.GR.GGDLASNR.EHHHHHHR.E 
 
The next step was to search for the substrate modified CatNuc peptides. For this, the MS/MS spectra 
were filtered for typical fragments of the CatNuc peptides using the Analyst Software. For mEH HQ a 
promising MS/MS spectrum could be identified. The MS/MS spectra of the single SWATH windows 
were filtered for the mEH CatNuc peptide fragments y5 or y6 with 567.3249 m/z and 666.3933 m/z, 
respectively. In the SWATH window from 960.5 to 1084.6 Da, a spectrum with three characteristic 
fragments was identified at a retention time of 1.34 min (Figure 26A and B). The highest peak in the 
fragment spectrum is 975.5593 m/z which is most likely the precursor ion. Indeed, when the data was 
filtered for this precursor m/z, a peak was identified with a retention time of 1.34 min (Figure 26A) 
which resulted in the same fragment spectrum which was identified before (Figure 26B). Besides the 
fragment spectrum, also the precursor spectrum at the time of peptide elution was analyzed to check 
the isotope pattern of the found peptide. The CatNuc mEH HQ peptide is expected to have a charge 
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state of 4+, thus the isotope pattern of the precursor should reveal intervals of 0.25 Da, which is not 
the case for the identified parent mass (Figure 26C), eliminating it as a candidate for the substrate 
modified CatNuc peptide.  
 
Figure 26: Detection of a peptide with three expected y-fragments but incorrect isotope pattern. 
Trapping mEH enriched from 500 mg mouse liver infected with AAV-PHP.B mEH HQ was digested with 
trypsin and analyzed with SWATH. The MS/MS spectra were filtered for typical mEH CatNuc peptide y-
fragments. (A) shows the MS spectrum of the best hit, the precursor ion with 775.5528 m/z. (B) shows 
the corresponding fragment spectrum where three typical fragments of the mEH CatNuc peptide, 
y8+2, y5 and y6, were detected. (C) is the MS spectrum at the retention time = 1.336–1.348 showing 
the isotope pattern of the precursor ion. 
No other spectra showed typical fragments except some spectra from MEST HQ from the liver and 
mEH HQ from liver and brain. However, these spectra were obtained from the unmodified peptide. 
Detecting unmodified peptides indicates that substrate trapping failed for mEH and MEST or that the 
substrate was lost during sample preparation.  
sEH HQ expression in vivo was higher than expression of all other trapping EH. Failing to detect the sEH 
CatNuc peptide with analyzed amounts 20-times above the detection limit was unexpected. Trouble 
shooting, which was done in parallel to the tissue analysis, is summarized in the following 
chapter 3.1.9.  
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3.1.9. Trouble shooting  
Trapping and analysis of substrates in vivo was difficult and not successful. Especially in the case of 
trapping sEH, where amounts 20 times above the determined detection limit of the MS method were 
analyzed, failing to detect the CatNuc peptide was unexpected. Possible explanations for this are 
substantial peptide loss during sample preparation or trapping of many different substrates reducing 
the signal of every substrate-peptide adduct below detection limit. In the case of mEH and MEST, the 
unmodified CatNuc peptide was detected but it remains unclear whether the enzymes are partially 
unmodified or whether the trapping failed completely. 
To test and improve the sample preparation, the procedure was analyzed step by step to ensure 
efficient production and recovery of peptides of interest. This was done in parallel to the analysis of 
the mouse tissue and is described in the following subchapters. To avoid wasting mouse tissue for the 
optimization and to obtain sufficient protein amounts, trapping EHs were recombinantly expressed in 
HEK293T cells and E. coli as described in doctoral thesis of Bettina Hew (Hew, 2019). As a final measure, 
in vitro trapping experiments with recombinantly expressed trapping enzyme and known substrates 
were performed. This was done for mEH, sEH and Cif because the WT forms of these enzymes can be 
expressed actively in E. coli and their substrates are known and available.  
3.1.9.1. Optimization of tissue sample preparation 
The sample preparation for proteomic analysis consists of multiple steps. Figure 27 shows a scheme of 
different combinations of methods that were used for the tissue sample preparation before SWATH 
acquisition on the TripleTOF 6600.  
The first step in sample preparation is denaturation/dissolution of the protein. Protein obtained either 
directly from cell culture or animal tissue or after His-tag enrichment was denatured with SDS either 
prior to SDS-PAGE with Lämmli buffer or during FASP with SDS-lysis buffer. The second step, the 
digestion with trypsin, was performed overnight either in-gel or on a filter (FASP). Before injection into 
the MS, the sample was cleaned up either by SPE or solvent evaporation and reconstitution.  
First, the performance of trypsin was analyzed (3.1.9.1.1) and the peptide yield was compared 
between in-gel and filter-assisted digestion (3.1.9.1.2). To rule out that the peptides of interest are lost 
during clean-up, every step was analyzed individually with a mix of the synthetic peptides (3.1.9.1.3).  
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Figure 27: Scheme of sample preparation prior to TripleTOF LC-MS/MS analysis. Protein samples can 
be digested using in-gel digestion or FASP (filter assisted sample preparation). In-gel digest includes 
sample solubilization with SDS prior to separation by SDS-PAGE. Proteins are visualized using 
Coomassie and excised. The gel pieces are washed to remove SDS and digestion takes place directly 
within the gel piece. The peptides are extracted from the gel piece with ultrasound. FASP includes 
protein solubilization with SDS prior to loading of the proteins on the filter. SDS, impurities and proteins 
smaller than the filter cutoff are washed away before digestion. The peptides obtained after digestion 
are small enough to pass the filter and are eluted by centrifugation. FASP is usually combined with SPE 
to remove triethylammonium bicarbonate present in the elution buffer. Both digestion protocols can 
be used for homogenized tissue/cultures directly or after protein enrichment using IMAC.  
3.1.9.1.1. Functionality and specificity of the trypsin digestion 
To exclude unspecific cleavage or inactivity of the used trypsin, a Foerster resonance energy transfer 
(FRET)-based assay with the FRET-pair Cerulean-Ruby, which was established in our group, was 
performed. The FRET-signal of the construct with a linker including trypsin restriction sites is gradually 
and completely lost over the 20 min trypsin digest, seen by the reduction of the Ruby emission peak 
at 590 nm (Figure 28A). At the same time, the Cerulean emission peak at 480 nm is gradually increasing 
due to the lost energy transfer (de-quenching). This suggests efficient digestion of the linker by trypsin. 
The same experiment done with the FRET-construct lacking the trypsin restriction sites showed 
constant FRET-signal over time (Figure 28B) indicating that no unspecific digestion occurs. The small 
reduction of both peaks in parallel is probably due to partial digestion of the fluorophores. Taken 
together, these data indicate that trypsin digests exposed protein structures available in denatured 
protein efficiently and no unspecific cleavage occurs.  
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Figure 28: FRET analysis of the trypsin digest of the two different Cerulean-Ruby fusion proteins. 2 µg 
of the respective fusion protein (A) containing or (B) lacking trypsin specific restrictions site within the 
linker, was incubated with 0.2 µg trypsin at 30 °C and excited at the excitation wavelength of Cerulean, 
435 nm. The digest was monitored every minute for 20 min by measuring the emission spectrum from 
470 nm to 700 nm. The color shift from dark to bright indicates the different measurements over time. 
The Ruby emission peak at 590 nm shows FRET between the two fluorophores which is gradually lost 
with the fusion protein containing a trypsin specific restriction site. 
3.1.9.1.2. Comparison of FASP and in-gel digestion  
Tissue samples from the in vivo trapping experiments were initially processed using in-gel digestion. 
With this method the proteins are first separated by SDS-PAGE, thus proteins are efficiently solubilized 
by SDS, many impurities are removed, and the protein of interest is enriched in the excised gel-plug. 
However, the gel matrix might prevent peptide recovery. FASP, which has recently become the gold 
standard in proteomics, combines the use of strong detergents for universal solubilization with 
efficient clean-up before digestion to obtain purified peptides while avoiding the disadvantages of the 
gel format (Manza et al., 2005; Wisniewski et al., 2009). With the help of the Functional Genomics 
Center Zurich (FGCZ, Irchel Campus, Zurich) we compared these two methods measuring a liver MEST 
trapping sample. The MEST trapping mutant expressed in mouse liver (145 mg liver) was manually 
enriched by IMAC and the subsequent sample preparation for MS-detection was done either by in-gel 
digestion or FASP followed by SPE.  
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Table 19: Intensities and AUC of liver MEST trapping samples prepared via FASP or in-gel digestion 
measured with SWATH. 
 Intensity MEST CatNuc 3+  
745.06113 m/z  
AUC MEST CatNuc 3+  
745.06113 m/z 
FASP 31958 1856 
In-gel digest 22875 1125 
 
The MEST CatNuc peptide was detected in both samples with correct fragmentation pattern. The FASP 
technique provided slightly better results with higher peak areas, intensities and fragmentation 
patterns (Table 19). Because of these results, FASP became the favored technique for the time being 
for mouse tissue sample preparation. 
3.1.9.1.3. Selective peptide loss during FASP sample preparation 
FASP has been used for efficient detection of hydrophobic membrane proteins (Wisniewski et al., 
2009). However, this study, like most proteomics studies, did not require the detection of one specific 
peptide but any peptide can be used for protein identification. To rule out whether we lose the CatNuc 
peptides specificly during sample preparation, the synthetic peptide mix (100 ng/µl of each peptide) 
was processed like a protein sample using a combination of FASP and SPE and quantified on the 
TripleTOF 6600 after every step (Figure 29). 
Surprisingly, the peptide recovery was strikingly different for the six different synthetic CatNuc 
peptides. Cif and MEST were recovered in high amounts but the other peptides were almost 
completely lost. The addition of trypsin alone already caused mEH to lose about 80% of its signal 
intensity. Evaporation of the solvent and subsequent reconstitution of the synthetic peptides in MS-
buffer was causative for the substantial loss of the mEH, sEH, EH3 and EH4 CatNuc peptides. With every 
further processing step (FASP, SPE), the recovery of the synthetic peptides decreased. With our current 
protocol which combines FASP digestion followed by SPE and evaporation, only approximately 60% of 
MEST and Cif CatNuc peptides could be recovered, the other peptides were almost completely lost.  
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Figure 29: mEH, sEH, EH3 and EH4 CatNuc peptides were selectively lost during sample preparation. 
A mix of 100 ng/µl of each synthetic peptide was processed like a protein sample and the peptide 
content was quantified using LC-MS/MS after every step. Amounts are expressed in % signal of the 
unprocessed synthetic peptide mix. Try = trypsin was added to the synthetic peptide, evap = the 
sample was dried under a stream of nitrogen and reconstituted in MS-buffer, FASP = the sample was 
digested on a filter and spun through, SPE = the sample was purified using SPE. 
The same phenomenon was also observed when the synthetic peptide mix was processed in a liver 
tissue matrix (Figure 30). Furthermore, the peptides of MEST and Cif, which were highly recovered 
before, have a higher loss when liver matrix was present.  
 
Figure 30: Peptide recovery with a liver matrix was lower but TWEEN coating increased mEH CatNuc 
peptide recovery. A mix of 100 ng/µl of each synthetic peptide was processed like a protein sample 
and the peptide content was quantified after every step in % signal of the unprocessed synthetic 
peptide mix. (A) the sample preparation was done in a liver tissue matrix. (B) all filters and tubes were 
coated with 5% TWEEN to reduce peptide adsorption and elution was performed under normal 
conditions, with pure ACN or after acidification with a final concentration of 0.5% TFA. Try = trypsin 
was added to the synthetic peptide, evap = the sample was dried under a stream of nitrogen and 
reconstituted in MS-buffer, FASP = the sample was digested on a filter and spun through, SPE = the 
sample was purified using SPE, ACN = acetonitrile, TFA = trifluoroacetic acid. 
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To reduce peptide loss after FASP and evaporation we coated FASP filters and used vials with 5% 
TWEEN, which is known to reduce protein adsorption to surfaces (Erde et al., 2014). With this the 
recovery of mEH was highly increased. Elution of the FASP filters under acidic conditions with 0.5% TFA 
or with pure ACN did not increase recovery of the peptides (Figure 30).  
Based on these results, we decided to use in-gel digestion combined with His-tag enrichment for all 
future samples of the in vivo trapping experiment and to treat plastic wear with TWEEN for preparation 
of mEH samples. 
3.1.9.2. In vitro trapping  
Recombinant trapping mEH and sEH were incubated with their known preferred substrates, 11,12-EET 
for mEH and 14,15-EET for sEH, in-gel digested with trypsin and analyzed for CatNuc peptide-EET 
adducts. The trapping experiment was done with purified trapping enzymes recombinantly expressed 
in E. coli, as well as with HEK293T cells (Hew, 2019) expressing these trapping mutants to have a more 
complex and eukaryotic in vitro system. The samples were analyzed by LC-TripleTOF 6600 using 
SWATH. As the substrate mass is known (EET, 320.235 Da) the parent masses of the substrate modified 
CatNuc peptides could be calculated. Thus, the SWATH data could be filtered for the known m/z of the 
modified and unmodified CatNuc peptides and the percentage of substrate modified vs. unmodified 
CatNuc peptide was determined. SWATH data was analyzed using the PeakView 2.2 software (AB 
Sciex). 
Figure 31 shows representative spectra of sEH expressed in HEK293T cells. The unmodified sEH CatNuc 
peptide eluted at 7.28 min (Figure 31A) with the same retention time as the synthetic standard. The 
MS/MS spectrum derived at this time contains the typical y-fragments also obtained with the synthetic 
peptide (Figure 31B). A molecule with the m/z of 895.2177 corresponding to the mass of the peptide 
modified with EET eluted at 9.03 min and resulted in the same MS/MS pattern as the unmodified 
peptide (Figure 31C and D) indicating that it is indeed the substrate modified peptide. In the trapping 
sEH sample derived from HEK293T cells, two thirds of the peptide were substrate modified and one 
third was unmodified. The modified peptide was also found with the purified recombinant sEH HQ, 
however, the percentage of the modified peptide was much lower, between 2 and 8% and could not 
be quantified reliably. The modified peptide was also found when the data was filtered for MS/MS 
fragments without the information about the modification. This confirms that data filtering works as 
expected. As control, the same experiment was performed with sEH WT where no modified peptide 
was detected as expected.  
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Figure 31: Detection of the sEH HQ CatNuc peptide modified with EET. Representative spectra from 
the analysis of sEH HQ expressed in HEK293T cells incubated with 1 µM 14,15-EET. (A) shows the MS 
spectrum of the precursor ion 815.15824+ corresponding to the unmodified sEH CatNuc peptide. The 
identity of the peptide is confirmed with the fragment ion spectrum in (B) which shows a series of y-
fragments as well as with its retention time of 7.28 min which is identical to the synthetic peptide. (C) 
shows the MS spectrum of the precursor ion 895.21774+ corresponding to the sEH CatNuc peptide 
modified with EET. The retention time of this peptide is shifted to 9.03 min due to the modification. 
The identity of the peptide is confirmed with the fragment ion spectrum in (D) which shows a series of 
y-fragments similar to the unmodified peptide.  
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The SWATH analysis of the trapping mEH (bacterially expressed and in HEK293T) revealed that mEH 
HQ did not bind its substrate 11,12-EET (data not shown). No substrate modified peptide was found 
and the signal for the unmodified peptide was comparable in both mEH trapping sample and mEH WT 
sample. This is in line with the results from the in vivo trapping and indicates, that trapping mEH is non-
functional and is not able to bind the substrate at all.  
An in vitro trapping experiment with Cif HQ was planned but recombinant expression in bacteria failed. 
Trapping Cif expression in E. coli with the pET construct led to inclusion body formation and no 
functional Cif HQ could be purified (data not shown). 
3.1.10. Mice infected with AAV-PHP.B mEH HQ developed a trembling 
phenotype  
The in total seven wild type mice that were successfully injected with the virus AAV-PHP.B mEH HQ 
(see Table 18) developed a phenotype with the first signs 8 days post-infection. At the beginning, the 
animals showed slight trembling of the whole body which increased over time. Around 10 days post-
infection, mice showed obvious shaking during movement and during rest which was combined with 
insecure walk. Shaking of the head was more intense than of the rest of the body. No signs of pain 
were observed, and grip strength observed while handling the animals was comparable to non-
infected animals. The mice were euthanized 11 or 12 days post-infection as food and water intake was 
not guaranteed anymore. 
The animals infected with AAV-rh10 mEH HQ, the virus serotype that does not lead to transgene 
expression in the brain, or animals infected with any other virus did not show any sign of trembling. To 
exclude that the phenotype was due to a contamination of the virus preparation, a second virus was 
produced which was used to inject three of the total seven animals. The phenotype developed after 
virus injection was not different between the two virus preparations. 
In contrast to the trapping enzyme, the virus AAV-PHP.B mEH WT mediating wild type mEH expression 
did not elicit any phenotype. Furthermore, the virus AAV-PHP.B mEH HQ was tested in two mEH KO 
mice. The mEH KO mice developed the same phenotype seen with wild type mice but with a later onset 
around 11-12 days after injection and slower progression. No preterm euthanasia was required. 
Expression of wild type mEH in mEH KO mice did not lead to any phenotype as expected from the 
results with the wild type mice.  
The rotarod test, a behavioral test to assess motor function and coordination (Hamm et al., 1994), was 
used to get a quantitative measure of the trembling phenotype (Figure 32). However, due to the 
obvious phenotype, the investigator was not blinded during the experiment, and the number of 
animals was low as behavioral experiments were initially not planned. Mice infected with AAV-PHP.B 
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mEH HQ performed worse than control mice but no difference was seen between mice infected with 
AAV-PHP.B mEH WT and control mice. This result should be confirmed with higher animal numbers 
and assessment at different time points after virus injection.   
 
 
Figure 32: Mice expressing mEH HQ but not mice expressing mEH WT in the brain performed worse 
in the rotarod than non-infected control mice. Female mice infected with AAV-PHP.B mEH HQ or AAV-
PHP.B mEH WT and uninfected control animals were tested 14 days post-injection after two training 
sessions on the day before and in the morning of the experiment. The plotted values represent means 
of five repeated measurements per animal and horizontal lines represent means of the group. 
Unpaired 2-tailed t-tests revealed no significant difference between mEH WT to control (p=0.3471) but 
significant difference between mEH HQ and control (p=0.0372). The investigator was not blinded 
during the study. Mean ± SEM of control: 112.8±19.8 s, n=3; mEH WT: 149.1±27.78 s, n=3; mEH HQ: 
21.00±1.2 s, n=2. (ns = non-significant, * = significant, p<0.05) 
 
Absence of a phenotype in animals infected with the virus AAV-rh10 mEH HQ suggests that the 
phenotype is caused by trapping mEH expressed in the brain. A possible cause is the loss of 
dopaminergic neurons in the substantia nigra (SN), the pathologic feature of Parkinson’s disease (Kalia 
& Lang, 2015). IHC staining of brain sections obtained from mEH KO mice infected with AAV-PHP.B 
mEH HQ and AAV-PHP.B mEH WT confirmed expression in the SN and striatum (St), the brain regions 
involved in Parkinson’s disease pathology (Hew, 2019). Both mEH WT and mEH HQ were expressed 
throughout the whole brain including SN and St which is in line with the reported tropism of the AAV-
PHP.B serotype (Deverman et al., 2016). Based on these results, loss of dopaminergic neurons in the 
SN is a possible scenario but co-staining with specific markers for dopaminergic neurons (e.g. tyrosine 
hydroxylase) and cell death are required.  
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3.2. Kinetic analysis of Cif 
3.2.1. Cif expression and purification 
The plasmid pGEF Cif was available in the group (Dengler, 2012). Cif cDNA was initially obtained from 
the DNASU Plasmid Repository (CloneID PaCD00007278, The Biodesign Institute, Arizona State 
University, USA). The sequence contained a point mutation, H297Y, which was reversed using site-
directed mutagenesis before the gene was inserted into the pGEF expression vector to obtain a 
C-terminally His-tagged fusion protein.  
The construct was transformed into E. coli BL21-AI for recombinant expression with 5 µM arabinose 
overnight at room temperature. The E. coli periplasm was isolated using osmotic shock and used for 
the purification of His-tagged Cif by IMAC. The purified protein was diluted with 50% glycerin to a 
concentration of 100 µg/ml and was stored at -80 °C until further use. The recombinant protein was 
purified to apparent homogeneity, as judged by the absence of impurities on Coomassie stained SDS-
PAGE of 1 µg protein. 
3.2.2. Cif can hydrolyze endogenous epoxides 
It was shown that Cif is able to hydrolyze endogenous fatty acid epoxides (Flitter et al., 2016; Hvorecny 
et al., 2017). With a substrate screening, where Cif expressing E. coli lysates were incubated with 
3-5 µM of different substrates, we confirm these recent findings. Additionally to the reported 
substrates EpETEs, EpDPAs, and 14,15-EET, we found hydrolysis of isoleukotoxin and to a low extent 
11,12-EET and hepoxilin B3 (Figure 33). With mock-transfected E. coli, enzymatic activity was absent. 
The best substrates in our screening were 17,18-EpETE and 19,20-EpDPA which is in line with previous 
studies.  
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Figure 33: Fatty acid epoxide substrate screening with Cif expressing E. coli lysate. E. coli lysate was 
incubated with different substrates individually and turnover was quantified with LC-MS/MS. Data 
represent turnover in duplicates with three independent Cif expressions. The error bars show the 
standard deviation of the separate determinations. 
3.2.3. Enzyme kinetics with endogenous epoxides 
To get a better idea of the potential physiologic relevance of the 17,18-EpETE, 19,20-EpDPA and 14,15-
EET turnover by Cif, we determined the respective kinetic parameters. 100 ng purified Cif was 
incubated with different substrate concentrations ranging from 0.05 to 30 µM in a volume of 20 µl. 
Linear correlation of product formation with incubation time and enzyme amount was confirmed in a 
preliminary test (data not shown). With increasing substrate concentrations, a linear increase of the 
reaction rate was determined, and saturation of the enzyme was not achieved with substrate 
concentrations up to 30 µM (Figure 34). Higher substrate concentrations were not tested to avoid 
micelle formation and due to lack of physiological relevance. In the absence of enzyme saturation, it is 
not possible to determine the two central kinetic parameters, i.e. maximum reaction rate vmax and the 
Michaelis constant Km, but the catalytic efficiency kcat/Km can be determined (Figure 34). 
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Figure 34: Kinetic analysis of Cif catalyzed 19,20-EpDPA, 17,18-EpETE and 14,15-EET turnover. 100 ng 
purified Cif was incubated with substrate for 10 minutes using substrate concentrations ranging from 
0.05 to 30 µM in a volume of 20 µl. Michaelis-Menten kinetics (solid line) was linear over the entire 
concentration range tested. No enzyme saturation occurred with substrate concentrations up to 
30 µM. The Lineweaver-Burk plot was used to determine the catalytic efficiency kcat/Km. The individual 
symbols represent single determinations from 3-5 individual experiments. 
Although Cif hydrolyzes 17,18-EpETE and 19,12-EpDPA with similar turnover rates when tested in 
individual reactions, Hvorecny et. al found no 17,18-EpETE hydrolysis when tested in a mixed-substrate 
assay. They incubated a mixture of 14 epoxy-fatty acids (each at a final concentration of 1 µM) with 
purified Cif. In this competing substrate format, Cif was only able to hydrolyze epoxides from the 
EpDPA family and 14,15-EET, but not from the EpETE family. We performed a mixed approach only 
including the best substrate of each family, 17,18-EpETE, 19,12-EpDPA and 14,15-EET (Figure 35). In 
the substrate concentration range tested, Cif hydrolyzed all three substrates to the same extent as 
predicted from the individual turnovers.  
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Figure 35: Kinetic analysis of Cif catalyzed 17,18-EpETE, 19,20-EpDPA and 14,15-EET turnover in an 
individual format (left) compared to a competing format (right). 100 ng purified Cif was incubated 
with each substrate individually or with a mix of all substrates. Linear regression (solid line) is 
comparable in both, individual and competing format.   
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4. DISCUSSION  
4.1. Deciphering the (patho)physiologic role of epoxide 
hydrolases by ex vivo cartography of their substrate landscape  
Of the five mammalian EHs that belong to the α/β hydrolase fold enzyme family, mEH and sEH have a 
well described substrate spectrum and some substrates are known for EH3 but no substrate has been 
identified for MEST and EH4. Substrate identification for the orphan enzymes EH4 and MEST would 
bring new insight into their role, but also for mEH, sEH and EH3, which share overlapping substrate 
specificities, e.g. for EETs, more information is required to resolve their function especially in 
metabolism of endogenous signaling epoxides. For the bacterial EH Cif, some substrates have been 
described but an epoxide that links the EH activity of Cif to its effect on CFTR has not been identified 
yet.  
With the substrate trapping approach, we developed an unbiased strategy to identify the preferred 
substrates of EHs in vivo. This brings an advantage over classical approaches like substrate screening 
with recombinantly expressed enzymes and kinetic studies because: 1) The offered substrates do not 
depend on the researcher’s choice and are not limited to epoxides that are known and available, 2) 
the substrate is captured under physiologic conditions, keeping for example subcellular organization 
intact, and 3) no recombinant enzyme synthesis in bacteria is required.  
We have not succeeded in trapping and detecting substrates in vivo. The reasons for lack of success 
and potential measures to improve the in vivo trapping are discussed in the following subchapters. In 
chapter 4.3., current hypotheses and open questions regarding the role of the different EHs is 
discussed which the trapping approach could help to answer.  
4.1.1. LC-MS/MS detection of CatNuc peptides 
The LC-MS/MS based analysis of the in vivo substrate trapping was a major challenge, as our LC-MS/MS 
approach differed from a classical proteomics approach. We needed to detect one specific peptide of 
a protein and not just a subset of well detectable peptides of this protein. Furthermore, this peptide 
was modified with an unknown mass resulting in an unknown precursor mass which required 
identification by its fragment pattern.  
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A potential problem for LC-MS/MS method development and sample analysis were modifications of 
the CatNuc peptides (other than the bound substrate), either introduced by the expressing organism 
as post-translational modifications or artefacts from sample preparation. Post-translational 
modifications by bacteria were only an issue during method development with inclusion bodies but 
are of no concern for the analysis of proteins expressed in mice. Modifications that can be introduced 
during sample preparation include carbamylation, oxidation, deamination and intermolecular ester 
formation between Ser and Asp. For example, it was shown that urea used for inclusion body 
solubilization might lead to carbamylation of N-termini, Lys or Arg (Kollipara & Zahedi, 2013). To reduce 
this, urea buffer was freshly prepared before use and exposure to heat combined with urea 
concentrations above 1 M was avoided. With pure synthetic peptides we could circumvent the 
problem of modifications during method development. During tissue sample analysis there was no 
indication of protein modifications. The mEH and MEST CatNuc peptides were detected in the liver 
samples and the sEH and Cif CatNuc peptides did not show any modification (other than the substrate) 
when expressed in HEK cells (Hew, 2019). For the EH3 and EH4 trapping mutant CatNuc peptides, 
modifications cannot be excluded but the main issue here was most likely low protein concentration 
in the target tissues. Due to the unbiased recording of all peptides with SWATH, modifications that do 
not affect the main fragments of the CatNuc peptides would be detected in the same way as the 
modification with the substrate.  
The sensitivity for the MEST CatNuc peptide was higher than for all the other CatNuc peptides (Figure 
22), probably due to its smaller size of 19 compared to 26-30 amino acids. Guidelines for targeted 
proteomic assays suggest selection of peptides of 7-20 amino acid length, which only the MEST CatNuc 
peptide fulfilled (Hoofnagle et al., 2016). Moreover, of the peptides of interest, only the MEST and 
mEH CatNuc peptides are present in trypsin-based peptide data bases (PeptideAtlas), indicating that 
the other peptides are difficult to detect or are lost during routine sample preparation. We addressed 
the problem of peptide size by using the alternative protease chymotrypsin, which cleaves after 
aromatic amino acids. The Cif CatNuc peptide, which was 8 amino acids long, could be detected but 
the peptides of the other enzymes were not detected, probably due to their length of only 4-5 amino 
acids. With the alternative protease GluC, digestion would lead to adequate peptide sizes, but this 
enzyme cleaves the peptide bond after Asp or Glu including the CatNuc, which might be impaired if it 
is modified with a substrate. Based on this, we decided to focus on trypsin generated peptides. Another 
strategy to reduce the peptide size would be to introduce another trypsin restriction site (Lys or Arg) 
into the amino acid sequences of the trapping mutants by site-directed mutagenesis PCR. However, 
this would likely interfere with the substrate interaction, and potential induction of undesired artifacts 
(from altered substrate selectivity to non-reactivity) prohibits such an approach. 
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4.1.2. In vitro substrate trapping 
Trapping mutants of the rat mEH and sEH have been used before to trap radioactively labelled 
substrates in vitro (Arand et al., 1996; Arand et al., 1999a) to elucidate the reaction mechanism. 
Furthermore, successful detection of the substrate-peptide complex with LC-MS/MS was shown in a 
preliminary in vitro experiment performed in our group. However, these experiments were performed 
with the rat enzymes. In the in vitro trapping experiment performed in this project in parallel with the 
in vivo trapping, human trapping mEH and sEH were used.  
Of the trapping sEH expressed in HEK293T cells, two thirds were modified with the provided substrate, 
14,15-EET, confirming the functionality of the substrate trapping and detection method. Possible 
reasons for the occurrence of unmodified peptide are hydrolysis during sample preparation, residual 
hydrolytic activity of the trapping mutant or lack of ability to bind the substrate due to misfolding. 
However, the occurrence of unmodified peptide was low and of minor relevance for the trapping 
experiment. 
In contrast to the rat trapping mEH used by others, the human trapping mEH used here did not bind 
the offered substrate in the in vitro trapping experiment. As no residual hydrolytic activity could be 
detected with the recombinantly expressed mEH HQ in a turnover assay (data not shown) and no 
substantial hydrolysis during sample preparation is expected, the most likely explanation is that human 
mEH HQ is not functional. This difference between human and mouse trapping mEH was unexpected 
but demonstrates that the use of trapping EHs from a different species might be useful to overcome 
enzyme folding problems.   
In vitro trapping with recombinant Cif HQ failed due to misfolding of the protein which was confirmed 
by others during the course of this project (Flitter et al., 2016). 
4.1.3. In vivo substrate trapping 
In the in vivo trapping experiment, viral expression of mEH, sEH, MEST and Cif in situ was high enough 
to detect the protein by LC-MS/MS. However, no substrate modified CatNuc peptide could be detected 
from mouse tissue.  
Possible explanations for this outcome can be categorized in three main groups: 1) the peptide is 
absent, 2) the peptide is not modified or 3) the (modified) peptide was missed in the analysis. Absence 
of the peptide can occur if 1.1) the protein or peptide is lost during sample preparation or when 1.2) 
the expression of the enzyme in the tissue fails or is too low. Reasons that could explain why the 
peptide is not modified are that 2.1) the trapping enzyme is not functional and thus not able to perform 
the first catalytic step including binding of the substrate or that 2.2) the substrate-peptide ester bond 
is hydrolyzed during sample preparation. It is also possible that 2.3) the trapping enzyme did not meet 
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its substrate due to wrong expression site or that 2.4) the enzyme has residual activity leading to the 
hydrolysis and release of the product. The peptide can be missed in the analysis if 3.1) it carries a 
modification (besides the substrate modification) which changes the fragment fingerprint 
substantially. Also, if 3.2) the enzyme traps many different substrates the amount of every single 
peptide-substrate complex can be lowered below the detection limit of the LC-MS/MS. Another 
possibility is that 3.3) the data analysis failed and positive spectra were missed. 
In the case of sEH HQ, we assume that it is a combination of two reasons, peptide loss during sample 
preparation (1.1) and trapping of different substrates which lowers the amount of every peptide-
substrate complex below the detection limit (3.2). The unmodified peptide was not found, excluding 
problems that lead to unmodified peptides. In the in vitro trapping experiment, sEH CatNuc-EET 
intermediates were successfully detected (Figure 31) confirming that the trapping mutant is functional 
and that the peptide analysis works. However, analysis of the sample preparation showed selective 
and substantial loss of the sEH CatNuc peptide. EH3, EH4 and mEH CatNuc peptides were also lost to 
a major extend. Solvent evaporation or centrifugation through the filter used for FASP was enough to 
lose >80% of these peptides. In contrast, the recovery of Cif and MEST peptides was around 60% even 
after the combination of FASP, evaporation, and SPE (Figure 29). Judging from the LC-elution profile, 
sEH is the most hydrophobic peptide and Cif and MEST the most hydrophilic. It is well recognized that 
hydrophobic peptides can be lost during sample preparation and analysis due to nonspecific 
adsorption to vials, tips and parts of the HPLC (Hoofnagle et al., 2016). This effect is more prominent 
at low concentrations. Different approaches are proposed to reduce nonspecific adsorption including 
organic solvent, detergents, peptide mixtures or addition of BSA. The strategy must be compatible with 
the chromatography and the MS-analysis. For example, addition of peptides might lead to ion 
suppression and organic solvent or detergents might interfere with the chromatography. Success 
depends on the peptide and needs to be evaluated individually (Kovalchuk et al., 2015; Hoofnagle et 
al., 2016). We addressed this problem with substantial effort, including use of low binding plastic ware, 
pre-treating filters and vials with TWEEN, peptide elution under acidic conditions or elution with 
organic solvent. The initially very poor mEH CatNuc peptide recovery could be increased to >80% with 
use of TWEEN treated plastic ware. However, for sEH, EH3 and EH4, no improvement was achieved 
(Figure 30). 
The mEH HQ CatNuc peptide was due to the comparably high expression a promising candidate and 
the CatNuc peptide could be detected in liver and brain tissue, however, unmodified. The same result 
was obtained in the mEH HQ in vitro trapping. Residual activity in terms of diol formation of the 
recombinant trapping mEH expressed in bacteria was not observed (2.4) (data not shown), indicating 
that the trapping mEH is not capable of covalent substrate binding (2.1) or that the substrate is cleaved 
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off the enzyme/peptide during sample preparation (2.2). In the trapping mutants the His of the charge 
relay system was replaced by Gln. His is the only amino acid that can switch between the protonated 
and unprotonated form at physiologic pH, which potentially interferes with protein folding when 
absent. However, functionality of the Gln mutant was shown for rat sEH HQ and reported for rat mEH 
HQ (Arand et al., 1999b) which led to the decision to use the Gln mutant. As discussed later in this 
section, also Cif and MEST trapping mutants seem to be non-functional. Alternative trapping mutants 
like the HA mutant, enzymes in which the acidic residue of the catalytic triad is replaced, or trapping 
EHs from a different species, need to be evaluated in vitro. This is not possible for EH4 and MEST as no 
substrates are known.  
The CatNuc peptides of EH3 HQ and EH4 HQ were not detected at all. The poor viral expression of 
these enzymes in the mouse tissue is a major factor to explain this outcome (1.2). This was further 
aggravated by peptide loss during sample preparation (2.2). Low EH4 HQ expression was shown by 
western blot and the EH4 CatNuc peptide could not be detected with LC-MS/MS, which is in line with 
the estimated injected CatNuc peptide amount of 0.1-0.5 ng which is far below the detection limit of 
11 ng. Both enzymes are suggested to be membrane bound which poses a challenge for recombinant 
expression. EH3 was reported to cause problems in different expression systems (Decker et al., 2012) 
and we encountered problems with both enzymes in our bacterial expression system (Hew, 2019) 
where expression was only successful after removal of the membrane anchor. However, the cells of 
living mice should provide everything required for the expression of these enzymes as they naturally 
express EH3 and EH4 homologues. The lower tissue concentrations of EH3 and EH4 trapping mutants 
compared to the other enzymes is likely due to shorter half-lives of the EH3 and EH4 proteins and 
possibly mRNA.  
The MEST trapping mutant was a very promising candidate as the CatNuc peptide showed the best 
detection properties (Figure 22). Its expression in liver tissue and peptide recovery during sample 
preparation was high enough to detect the CatNuc peptide and other peptides from infected liver 
tissue by LC-MS/MS. However, the CatNuc peptide was only detected without a bound substrate. 
Possible reasons are: the mutant was unable to bind the substrate (2.1), the ester bond between 
substrate and peptide was hydrolyzed during sample preparation (2.2) or because of residual 
hydrolytic activity (2.4), or the substrate was not present at the expression site (2.3). The functionality 
of trapping MEST and the stability of the peptide-substrate complex cannot be analyzed as no MEST 
substrate is known. However, a misfolded trapping mutant not able to perform the first substrate 
binding step is a likely scenario considering the non-functionality of mEH and Cif (see below) trapping 
mutants. Absence of the substrate at the expression site, in our case the liver, is unlikely as MEST is 
widely expressed throughout the body.  
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The expression of Cif HQ could be detected by LC-MS/MS but in vitro data indicated that the trapping 
mutant HQ is unable to bind its substrate (2.1). Furthermore, Cif is present in the lung after 
P. aeruginosa infection but transgene expression in the lung was not detected after AAV infection 
(Hew, 2019). During the course of this project a functional Cif E153Q trapping mutant was reported 
(Flitter et al., 2016), thus substrate trapping could possibly be performed with this trapping mutant as 
recombinant, purified enzyme by adding it to a lung homogenate. This approach would not be suitable 
for mEH or sEH as we are interested in the substrate trapped in a subcellular context but in the case of 
Cif, unknown substrates might be revealed. However, the advantage of continuous production of 
metabolites in a living system is lost when using a lung homogenate which reduces substrate 
availability. For example, reliable Cif detection required approx. 5 µg Cif which translates to 130 pmol 
enzyme. Assuming efficient trapping, a minimum of 130 pmol substrate need to be available in the 
lung homogenate to load the trapping Cif. If one lung (approximately 200 mg tissue translating to 
200 µl homogenate) was used, an overall substrate concentration of 0.65 µM would be required which 
we do not expect for epoxides, in particular because they might only be produced in a particular cell 
type constituting only a moderate fraction of the overall tissue (there are more than 30 individual cell 
types in the lung). However, in the absence of better alternatives, either the use of high lung tissue 
amounts or, possibly more promising, the expression of trapping Cif in a CFTR expressing cell line (e.g. 
lung cell line) are a worthwhile approach to find substrates for Cif.  
4.1.4. AAV-PHP.B mEH HQ trembling phenotype 
Mice injected with AAV-PHP.B mEH HQ developed a striking phenotype with severe shaking during 
movement and in rest, combined with insecure walk. In wild type mice, first signs developed 8 days 
after injection of the virus with fast progression. In contrast, mEH KO mice injected with AAV-PHP.B 
mEH HQ showed a later onset 11-12 days after the virus application and a slower progression.   
The well-studied AAVs are safe and elicit low immunogenicity (Salganik et al., 2015) and the absence 
of any phenotype after the application of AAV-PHP.B sEH HQ, AAV-PHP.B EH4 HQ, and AAV-PHP.B 
MEST HQ indicate that the phenotype is driven by trapping mEH expression and not the virus itself. 
Furthermore, no phenotype was observed when trapping mEH was expressed in the periphery using 
AAV serotype rh10, indicating that expression in the brain is causal for the phenotype.  
The hypothesis that the trapping mEH exhibits residual hydrolytic activity and is virally expressed in 
cells that lack natural mEH expression, leading to dysregulation of mEH substrates, was excluded as 
the viral expression of wild type mEH with the same virus did not lead to a phenotype.  
A possible explanation is that trapping mEH is misfolded due to the point mutation forming protein 
aggregates which lead to neurotoxicity and perhaps neurodegeneration eliciting a Parkinson’s disease-
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like pathogenesis. In Parkinson’s disease, loss of dopaminergic neurons in the substantia nigra pars 
compacta (SNpc) causes in humans the typical motor symptoms: resting tremor, bradykinesia and 
rigidity (Kalia & Lang, 2015). The dopaminergic neurons in the SNpc project to the basal ganglia and 
synapse in the striatum. Loss of these neurons leads to dopamine deficiency in the striatum responsible 
for the motor symptoms of Parkinson’s disease (Blesa & Przedborski, 2014). The observed trembling 
phenotype resembles one of the typical hallmarks of Parkinson’s disease. Furthermore, the trapping 
mEH was not able to trap a substrate in vitro and in vivo likely due to misfolding, supporting the 
hypothesis of aggregate formation.  
The hypothesis was addressed in a preliminary experiment by other members of the group with mEH 
and tyrosine hydroxylase (TH) co-staining of brain sections obtained from mEH KO mice infected with 
AAV-PHP.B mEH HQ. TH is the rate limiting enzyme in the synthesis of dopamine and a marker for 
dopaminergic neurons. AAV-PHP.B mEH HQ injected mice showed substantially reduced TH-
immunoreactivity in the SNpc compared to control mice, suggesting loss of dopaminergic neurons.  
Interestingly, mEH KO mice infected with the same virus which led to the same mEH HQ expression 
pattern in the brain showed a later onset and slower progression of the phenotype. mEH KO mice show 
no overt phenotype (Miyata et al., 1999) but when treated with the neurotoxin MPTP, they show 
significant lower TH-positive cell loss compared to wild type mice (Liu et al., 2008). MPTP, which 
commonly used to create a mouse model for Parkinson’s disease, exerts selective toxicity towards 
dopaminergic neurons and causes gradual loss of these neurons in the SNpc (Tieu, 2011). The results 
of Liu et al. suggest increased resistance of dopaminergic neurons in mEH KO mice which could explain 
the milder phenotype after injection of AAV-PHP.B mEH HQ. The increased resistance could be driven 
by increased EET levels in mEH KO mice, as EETs exert neuroprotective effects via various pathways 
(Wang et al., 2018).  
 Another, very speculative hypothesis to explain the trembling phenotype is that mEH functions as a 
receptor which is activated upon substrate binding and inactivated upon hydrolysis of the product.   
This would result in cell signal transduction as long as the enzyme-substrate complex persists. Under 
natural conditions, this complex would only exist for a short time during the first catalytic step but in 
case of the mEH trapping mutant, the complex would be stable, probably resulting in constant signal 
transduction, which could appear as trembling due to overstimulation of the brain motor system. This 
theory of mEH being a receptor would solve another mystery: mEH which contains Asp instead of Glu 
as acidic residue in the catalytic triad (E404D) shows 20-40 faster turnover than the by nature preferred 
wild type mEH (Arand et al., 1999a). The mutation causes faster hydrolysis and release of the product 
which would decrease the time the enzyme-substrate complex persists and cell signaling occurs. This 
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reduction in signaling would explain why the catalytically slower enzyme is avoided by nature. 
(Comprehensive discussion of mEH E404D in chapter 4.3.1.) 
Further experiments are required to draw conclusions on the cause of the phenotype. It would be very 
interesting whether application of L-dopa reduces the symptoms indicating that a lack of dopamine is 
responsible for the phenotype. Furthermore, application of mEH inhibitors could potentially be used 
to investigate whether the phenotype is due to a receptor function of mEH.  
4.2. Kinetic analysis of Cif 
In a substrate screening the additional Cif substrates isoleukotoxin, hepoxilin B3 and 11,12-EET were 
identified. However, the turnover rates under the used screening-conditions were below the turnover 
rates of the already reported substrates 17,18-EpETE, 19,20-EpDPA and 14,15-EET, indicating that 
these new substrates are less relevant. The best substrate in the screening, 19,20-EpDPE, was poorly 
hydrolyzed with a catalytic efficiency of kcat/Km = 1.54 x 102 s-1 x M-1 and Km >> 30 µM. In comparison, 
sEH, the main enzyme involved in epoxy-fatty acid turnover in mammals, hydrolyzes 14,15-EET with 
kcat/Km = 0.5 x 106 s-1 x M-1 and a Km = 15 µM (Decker et al., 2012), thus with several orders of magnitude 
higher efficiency. Furthermore, other microbial EHs, such as an EH from Aspergillus niger or the 
limonene-1,2-EH from Rhodococcus erythropolis, possess even higher turnover rates of their 
substrates up to 100 µmol/mg/min (van der Werf et al., 1998; Arand et al., 1999b). Taken together we 
believe that 17,18-EpETE and also the other substrates tested are not relevant Cif substrates in vivo.  
The EH activity was shown to be crucial for the effect of Cif on CFTR (Bahl et al., 2015). The current 
model proposes that Cif blocks deubiquitination by stabilizing the inhibitory effect G3BP1 on USP10 
(Bomberger et al., 2011). Whether this stabilization is direct or indirect needs to be revealed. We 
hypothesize that an endogenous Cif substrate supports (or its hydrolysis product blocks) CFTR recycling 
potentially by increasing the inhibitory effect of G3PB1 on USP10. Whether the fatty acid epoxide 
substrates identified in this and previous work are involved in CFTR recycling needs to be analyzed but 
the low hydrolysis efficiency by Cif indicates that they are likely not the relevant in vivo targets.  
Cif was shown to hydrolyze EpETEs and EpDPAs with rates that decrease from the n-3 to the n-6 
position when tested individually. Turnover rate of the two best substrates, the n-3 epoxides 17,18-
EpETE and 19,20-EpDPA was in the same range when tested individually. However, in a mixed substrate 
approach of EETs, EpETEs and EpDPAs, only EpDPAs and 14,15-EETs were hydrolyzed (Hvorecny et al., 
2017). This is in contrast with our present results. We compared the turnover of the best substrate of 
every substrate series, 14,15-EET, 17,18-EpETE and 19,20-EpDPA in a competing or individual format. 
In both formats, turnover was very similar with concentrations up to 30 µM of each substrate, which 
is also in line with the fact that we do not see any indication of substrate saturation in these assays. 
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Flitter et al. recently reported 14,15-EET turnover by Cif and connected it to a new, additional effect 
of Cif on neutrophilic inflammation in the lung. They propose that 14,15-EET produced by airway 
epithelial cells acts as a transcellular signal for neutrophils to generate the pro-resolving mediator 
15-epi LXA4. By the hydrolysis of 14,15-EET, Cif reduces the production of 15-epi LXA4. This contributes 
to a robust, damaging neutrophilic inflammation which is typical for P. aeruginosa infection in cystic 
fibrosis (Flitter et al., 2016). Our kinetic analysis showed a kcat/Km = 1.29 x 101 s-1 x M-1 for the turnover 
of 14,15-EET which is 40’000 times less efficient than sEH for the same substrate (Decker et al., 2012). 
A significant additional effect of Cif on the 14,15-EET levels therefore seems unlikely in the presence 
of sEH, which was shown to be present in Calu-3 cells, freshly isolated human PMNs (granulocytes) and 
normal human bronchial epithelial cells (NHBE) (Planagumà et al., 2010). 
Despite the unknown mechanism, Cif seems to be a promising target for antibiotic treatment of P. 
aeruginosa lung infections, which is a major problem in patients with cystic fibrosis and other airway 
diseases. Due to antibiotic resistance and biofilm formation of P. aeruginosa, treatment is very difficult 
(Parkins et al., 2018). Drugs targeting Cif might compromise the colonization of the lung by P. 
aeruginosa and reduce infections.  
4.3. The physiologic functions of EHs 
4.3.1. Three enzymes for the turnover of one substrate 
EETs, which have many beneficial effects, can be hydrolyzed by three different enzymes, sEH, mEH and 
EH3 but only sEH is generally regarded as responsible enzyme for EET metabolism by many 
researchers, due to its kinetic properties. Under same conditions, sEH is orders of magnitudes more 
efficient in hydrolyzing EETs than mEH. EH3 hydrolyzes EETs faster than sEH but at the same time shows 
a higher Km, resulting in a similar catalytic efficiency (kcat/Km) (Decker et al., 2012). However, EH3 is 
mainly expressed in skin, upper gastro-intestinal tract and lung but not in the liver (Marowsky et al., 
2017) and its contribution to EETs turnover is unknown.  
Multiple studies indicate that mEH plays a role in EETs turnover despite its kinetic disadvantage. When 
cells isolated from hippocampi of either mEH KO or sEH KO mice were incubated with AA, mEH 
accounted for 25% of the 11,12-EET, 20% of the 8,9- and 5% of the 14,15-EET turnover (Marowsky et 
al., 2009a). Furthermore, in plasma of mEH KO mice, 8,9-EET levels were lower compared to plasma 
from wild type animals (Marowsky et al., 2017). Beside the difference in subcellular localization and 
expression in different cell types, for example in the brain where mEH is expressed in neurons and sEH 
mainly present in astrocytes, there is another finding that points towards a distinct role of mEH in 
signaling molecule metabolism: An mEH variant with faster hydrolysis rate is avoided by nature. mEH 
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is the only EH found so far in vertebrate species that possesses a Glu instead of Asp as charge-relay 
acid in the catalytic triad. All other described EHs have a conserved Asp. Replacing the catalytic Glu 
with Asp (mEH E404D) increased the enzyme activity 20-24-fold for different substrates (Arand et al., 
1999a; Marowsky et al., 2016). But why would evolution favor an inefficient enzyme?  
For detoxification, the slower enzyme variant comes at a high cost: high mEH concentrations are 
required to ensure efficient detoxification. mEH expression in the liver is in the µM range (Oesch et al., 
2000) leading to the unusual situation that the substrate is similar or less concentrated than mEH and 
no enzyme saturation occurs. Below enzyme saturation, the first catalytic step determines the 
detoxification capacity which is similar for wild type mEH and mEH E404D. However, under saturating 
conditions, mEH E404D is 20-40 time faster than the wild type mEH (Arand et al., 1999a) and lower 
enzyme expression could provide similar or more efficient detoxification. But nature prefers to express 
a slower enzyme version in higher amounts to ensure efficient detoxification. One explanation for this 
could be that the slower enzyme is an advantage in the metabolism of xenobiotic compounds like B[a]p 
where mEH contributes to the production of a carcinogenic metabolite. High amounts of the slow wild 
type mEH have similar detoxification capacity than low amounts of mEH E404D but the release of the 
toxic product is slower by the wild type mEH. However, only a subset of xenobiotics is activated to 
more toxic compounds by mEH. It seems more likely that the slower wild type mEH brings an 
advantage in physiology.  
A current hypothesis is that mEH and sEH are both required to fine tune the level of EETs, for example 
in the brain. EETs were suggested to attenuate epileptic seizures in mice (Inceoglu et al., 2013) and 
specifically 11,12-EET was shown to reduced excitation in CA1 pyramidal cells by inhibiting the release 
of glutamate and opening a G protein-coupled inward rectifier potassium (GIRK) channel (Mule et al., 
2017). mEH is present in neurons and with its proximity to CYPs and high affinity but slow turnover of 
EETs, hydrolyzes low amounts of EETs efficiently, keeping the ratio of EETs and DHETs constant. Upon 
a stimulus that leads to increased EET production, the slow wild type mEH is possibly saturated and 
EETs can accumulate resulting in paracrine EET signaling which is terminated by sEH present in 
astrocytes. The fast mEH E404D would quickly hydrolyze most of the EETs produced upon a stimulus 
abolishing paracrine signaling.  
Surprisingly, in a study of Hung et al., pharmacological inhibition of sEH reduced spontaneous motor 
seizures in the pilocarpine-induced status epilepticus mouse model but sEH KO mice were more 
susceptible to seizures than WT mice (Hung et al., 2015). One could speculate that in sEH KO mice mEH 
expression in the brain is upregulated (which is the case in the liver of sEH KO mice (Marowsky et al., 
2017)) leading to a dysregulation of EETs and higher susceptibility to seizures in sEH KO mice. Another 
observation that supports the theory that mEH activity is connected to epilepsy is, that the anti-
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epileptic drugs valpromide and valproic acid inhibit mEH which might contribute to their 
pharmacologic effect (Kerr et al., 1989).  
More studies are required to understand the role of mEH in the turnover of signaling epoxides and to 
determine, whether mEH is a potential drug target, too.  
4.3.2. Potential function of EH3 in skin barrier formation 
EH3 can efficiently hydrolyze EETs but the role of this enzyme remains unknown. However, genetic 
disruption of the EPHX3 gene in mice showed no significant effects on the metabolism of EETs  in vivo 
and no other overt phenotype (Hoopes et al., 2017). A study which predicted a role of EH3 in ichthyosis 
in humans (Ala et al., 2008) and its expression pattern led to the hypothesis that EH3 is important for 
barrier formation in the skin. This hypothesis is supported by the very recent finding that EH3 
hydrolyzes an epoxy alcohol (9R,10R-trans-epoxy-13R-hydroxy-octadeca-11E-enoic acid, Figure 36) to 
a triol which is postulated to be involved in skin barrier formation (Yamanashi et al., 2018). The authors 
hypothesize that linoleic acid that is present in the linoleate ceramide ester is oxidized by 12R-LOX and 
eLOX3 resulting in the respective epoxy alcohol that is esterified to the ceramide. Hydrolyzed to the 
triol, this compound has a disruptive effect on the lipid environment, facilitating cleavage of the 
ceramide for covalent coupling to protein required for barrier formation (Chiba et al., 2016; Yamanashi 
et al., 2018). 
 
Figure 36: Free epoxy alcohol (9R,10R-trans-epoxy-13R-hydroxy-octadeca-11E-enoic acid) 
postulated to be involved in barrier formation. 
Kinetic analysis revealed that EH3 hydrolyzed this epoxy alcohol 31-fold more efficient than 14,15-EET. 
However, the study was done with the free epoxy alcohol and in the proposed model, the epoxy 
alcohol is coupled to ceramide which might affect the turnover by EH3. sEH was also capable of 
hydrolyzing the epoxy alcohol, but at a slower rate, which could explain the lack of a skin phenotype 
in the single knock-outs of sEH and EH3 (Yamanashi et al., 2018). A double-KO of sEH and EH3 could 
give more insight in the role of EHs in skin barrier formation.  
 
4.3.3. Potential function of MEST in adipose tissue expansion 
Besides the growth retardation and behavioral phenotype of MEST KO mice, MEST was also associated 
with adipose tissue expansion. In mice fed with a high energy diet, expression of MEST in adipose tissue 
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is induced and the expression levels correlated with expansion of fat mass (Nikonova et al., 2008). 
Additionally, when MEST is depleted in adipose tissue or globally, fat mass accumulation with high fat 
diet is reduced compared to WT animals (Anunciado-Koza et al., 2017). The correlation between a 
catalytic activity of MEST and adipose tissue expansion is unknown. A possible scenario could be that 
MEST modulates fatty-acid epoxides which are thought to be endogenous mediators of PPARs. Further 
studies are required to elucidate the physiologic function of MEST in development, maternal behavior 
and adipose tissue.  
4.3.4. Understanding Cif could reveal new drug targets 
Cif was shown to reduce Cl- secretion of airway epithelial cells by interfering with CFTR trafficking. It 
was proposed that Cif directly or indirectly stabilizes an inhibitory interaction between USP10 and 
G3BP1, preventing deubiquitination of incorporated CFTR. This leads to reduced apical membrane 
abundance of CFTR and reduced Cl- secretion (Bomberger et al., 2011). Cif inhibitors are a promising 
tool for the treatment of P. aeruginosa infections which would be especially beneficial for patients 
with CF where P. aeruginosa infections are the leading cause for mortality (Parkins et al., 2018). 
Additionally, increased understanding of CFTR trafficking could contribute to the development of CFTR 
correctors for CFTR modulator therapy of CF (Grasemann, 2017). CF is caused by many different 
mutations, leading to different CFTR functional defects. The most frequent mutation accounting for up 
to two thirds of all mutations is a deletion of Phe508 leading to defective CFTR protein traffic. The 
Phe508 mutated CFTR is retained at the ER from where it is rapidly sent for degradation by the 
ubiquitin-proteasome pathway (Amaral & Farinha, 2013). Small molecules which act as CFTR 
correctors to increase the abundance of CFTR on the apical plasma membrane have been developed 
and approved for treatment, but their mechanism of action is poorly understood. Identification of the 
target of Cif which we hypothesize to be an epoxide or a diol product that is involved in the ubiquitin-
proteasome pathway, could shed light on CFTR protein trafficking and could boost the development 
of CFTR correctors.   
Besides CFTR, also other members of the ABC transporter family were shown to be affected by Cif via 
the same mechanism. Cif enhanced the ubiquitination and degradation of the transporter associated 
with antigen processing-1 (TAP1) (Bomberger et al., 2014). In antigen processing, TAP1 is required for 
translocation of peptides into the ER where they bind MHC class I molecules for antigen presentation 
at the plasma membrane. CD8+ T cells recognize foreign peptides presented on MHC I which activates 
cytotoxic actions required to kill the infected cell. The downregulation of TAP1 by Cif might help P. 
aeruginosa to evade T cell response. However, further studies are needed to elucidate whether the 
interference of Cif with antigen presentation promotes P. aeruginosa infections.  
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Another ABC transporter that was shown to be affected by Cif is P-glycoprotein (P-gp), an efflux pump 
that excretes foreign substances out of cells. Cif was shown to reduce the apical membrane abundance 
of P-gp in kidney, airway, and intestinal epithelial cells (Ye et al., 2008). P-gp is often overexpressed in 
cancer cells and pumps chemotherapeutic agents out of the cell, contributing to multi drug resistance 
in cancer. Elucidation of the mechanism of Cif on P-gp trafficking or in general ABC transporter 
trafficking could reveal drug targets to inhibit P-gp expression. The downregulation of P-gp could be 
used to increase sensitivity of tumors to chemotherapeutic drugs, improving the bioavailability of P-
glycoprotein transport substrates.  
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5. OUTLOOK 
sEH is the most promising EH to continue the project, as the trapping mutant was functional. The first 
step would be to increase the CatNuc peptide recovery in the sample preparation for example by the 
addition of BSA to the peptide mixture eluted from the gel piece, or in the FASP protocol, the 
evaporation step after elution could be omitted.  
For mEH, EH3 and Cif, the next step is to produce functional trapping mutants which should be 
confirmed in vitro. Human mEH could be replaced by the rat enzyme, which had been used 
successfully. For Cif, exchange of the catalytic Glu by Gln was reported to be successful. This exchange 
is also promising for the other EHs. With in vitro trapping experiments, the sample preparation can be 
further optimized to reduce hydrolysis of the peptide-substrate complex. The functionality of EH4 and 
MEST trapping mutants cannot be tested due to the lack of known substrates, but with the experience 
gained with the other enzymes, the most promising mutants can be tested.  
For Cif and EH3, the relevant tissues need to be addressed. In a first step, trapping could be performed 
in a lung cell line with Cif and in barrier-forming keratinocytes with EH3. To target these tissues in vivo, 
other AAV serotypes or direct lung instillation should be considered.  
As soon as the substrate trapping is established, trapping could be expanded to other organs such as 
kidney and heart for sEH or adipose tissue for MEST. It is, however, important to take differences in 
the site of expression of the native enzyme and the virally expressed trapping enzyme into account 
when evaluating the results. Different promoters could be used to restrict the viral expression to cell 
types of interest. In a different set of experiments, animals could be challenged with xenobiotic 
precursors of sEH and mEH substrates to identify the extent to which these enzymes are occupied with 
detoxification in a concentration-dependent manner.  
To investigate the mechanism of the trembling phenotype developed by mice injected with AAV-PHP.B 
mEH HQ, comprehensive brain tissue analysis at different time points including quantification of TH-
positive dopaminergic neurons in the SN is required. Immunostaining with synaptic markers or other 
neuronal markers could reveal loss of synapses, dendrites or axons associated with neurodegeneration 
(Yamaguchi & Shen, 2013). Furthermore, the locomotive activity of the animals and the response to 
the administration of L-dopa should be analyzed (Tieu, 2011). If the trembling is indeed caused by loss 
of dopaminergic neurons, these mice could potentially be used as Parkinson’s disease model. 
Advantages over currently used neurotoxic animal models would be robust reproducibility, apparent 
behavioral phenotype, and easier handling compared to neurotoxins like MPTP.  
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